	Halope	ridol	Olanz	apine		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
3.4.1 short term							
Lieberman (HGDH) 2003	9	132	4	131	20.8%	2.23 [0.71 , 7.07]	
Subtotal (95% CI)		132		131	20.8%	2.23 [0.71, 7.07]	
Total events:	9		4				
Heterogeneity: Not applical	ble						
Test for overall effect: $Z = 1$	1.37 (P = 0	.17)					
3.4.2 medium term							
Kahn (EUFEST) 2005	12	103	5	105	27.2%	2.45 [0.89 , 6.70]	<b></b>
San 2012	2	21	2	25	7.9%	1.19 [0.18 , 7.74]	
Subtotal (95% CI)		124		130	35.0%	2.08 [0.86, 5.05]	
Total events:	14		7				
Heterogeneity: $Tau^2 = 0.00$	); $Chi^2 = 0$ .	44, df = 1	(P = 0.5)	1); I <sup>2</sup> = 0%	6		
Test for overall effect: $Z = 1$	1.62 (P = 0	.11)					
3.4.3 long term							
Crespo-Facorro 2006	18	56	7	55	44.2%	2.53 [1.15 , 5.56]	
Subtotal (95% CI)		56		55	44.2%	2.53 [1.15, 5.56]	
Total events:	18		7				
Heterogeneity: Not applical	ble						
Test for overall effect: $Z = 2$	2.30 (P = 0)	.02)					
Total (95% CI)		312		316	100.0%	2.30 [1.36 , 3.89]	•
Total events:	41		18				•
Heterogeneity: Tau <sup>2</sup> = 0.00	); $Chi^2 = 0$ .	55, df = 3	B (P = 0.9)	1); I <sup>2</sup> = 0%	6	0.0	1 0.1 1 10 100
Test for overall effect: $Z = 3$	3.11 (P = 0	.002)					zapine better Haloperidol wor
Test for subgroup difference	es: Chi <sup>2</sup> =	0.11, df =	= 2 (P = 0	.95), I <sup>2</sup> =	0%		

Comparison 3: COMPARISON HALOPERIDOL vs OLANZAPINE: SUBGROUP ANALYSES, Outcome 4: Leaving the study early: Adverse effects. Subgroup analyses: First episode schizophrenia

	Hal	operido	l	Ol	anzapine	•		Mean Difference	Mean Difference
StudyorSubgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
4.1.1 total - short term									
Barak 2002	4.4	0.5	10	3.8	0.9	10	7.5%	0.60 [-0.04 , 1.24]	<u> </u>
Beasley (E003) 1997	4.23	1.31	79	3.98	1.52	85	12.9%	0.25 [-0.18 , 0.68]	
Beasley (HGAD) 1996a	3.91	1.16	68	4.06	1.38	66	12.9%	-0.15 [-0.58 , 0.28]	
Bernardo (HGDD) 2001	2.8	1.1	13	3.2	1.5	14	3.6%	-0.40 [-1.39 , 0.59]	
HGCJ (Hong Kong) 1998	4.5	1.29	14	3.25	1.13	16	4.4%	1.25 [0.38 , 2.12]	
HGCU (Taiwan) 1998	4.04	1.23	28	3.88	1.3	24	6.6%	0.16 [-0.53 , 0.85]	
Lieberman (HGDH) 2003	3.18	1	127	3.01	1.09	127	21.5%	0.17 [-0.09 , 0.43]	
Tollefson (HGAJ) 1997	4.05	1.14	640	3.71	1.21	1318	30.6%	0.34 [0.23 , 0.45]	_
Subtotal (95% CI)			979			1660	100.0%	0.25 [0.05, 0.45]	
Heterogeneity: Tau <sup>2</sup> = 0.03;	Chi <sup>2</sup> = 13.18	df = 7	P = 0.07);	$l^2 = 47\%$				. , .	_
Test for overall effect: Z = 2.4			,,						
4.1.2 severity - short tern	1								
Buchanan 2003	4.6	0.9	34	4.6	1	29	53.1%	0.00 [-0.47, 0.47]	_
Taraskina 2017	4.04	1.04	30	3.5	1.1	30	46.9%	0.54 [-0.00 , 1.08]	
Subtotal (95% CI)			64			59	100.0%	0.25 [-0.27, 0.78]	
Heterogeneity: Tau <sup>2</sup> = 0.08;	$Chi^2 = 2.16,$	df = 1 (P	= 0.14); l <sup>2</sup>	= 54%					
Test for overall effect: $Z = 0.9$	94 (P = 0.35)	)							
4.1.3 severity - medium te									
Crespo-Facorro 2006	3.3	1	24	3	0.9	37	31.1%	0.30 [-0.19 , 0.79]	<del></del>
Lilly (S029) 2007	3.6	1.3	125	3.6	1.4	129	68.9%	0.00 [-0.33 , 0.33]	<b></b>
Subtotal (95% CI)			149			166	100.0%	0.09[-0.18,0.37]	<b>*</b>
Heterogeneity: $Tau^2 = 0.00$ ; Test for overall effect: $Z = 0.6$			= 0.32); l <sup>2</sup>	= 0%					
4.1.4 improvement -short				0.5			100.0-1	0.001.054.05	
Taraskina 2017	2.8	0.9	30	2.8	1.1		100.0%	0.00 [-0.51 , 0.51]	<b>—</b>
Subtotal (95% CI)			30			30	100.0%	0.00[-0.51,0.51]	
Heterogeneity: Not applicable									
Test for overall effect: $Z = 0.0$	00 (P = 1.00)	)							
4.1.5 impro vement - medi									
Lilly (S029) 2007	3.1	1.3	125	3	1.5		100.0%	0.10 [-0.24 , 0.44]	
Subtotal (95% CI)			125			129	100.0%	0.10[-0.24,0.44]	•
Heterogeneity: Not applicable									-
Test for overall effect: $Z = 0.5$	57 (P = 0.57)	)							
	Ch:2 0.00	) df 1/	D - 0 000	N1\ I2 No	,				<del></del>
Test for subgroup differences	5: Uni = 0.00	J, UI = 4 (	r < 0.000	υι), ι = υ <i>/</i>	0				-1 -0.5 0 0.5 1


Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 1: Global state: 1a. Average endpoint score (CGI, high=poor)

	Halope	ridol	Olanza	pine		Risk Ratio	Risk Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI		
4.3.1 medium term									
Lilly (S029) 2007	61	127	76	134	66.8%	0.85 [0.67, 1.07]			
Subtotal (95% CI)		127		134	66.8%	0.85 [0.67, 1.07]			
Total events:	61		76						
Heterogeneity: Not app	olicable								
Test for overall effect: 2	Z = 1.39 (P	P = 0.16)							
4.3.2 long term									
Lilly (HGGN) 2000	35	97	60	159	33.2%	0.96 [0.69 , 1.33]			
Subtotal (95% CI)		97		159	33.2%	0.96 [0.69, 1.33]			
	35		60						
Total events:	00								
Total events: Heterogeneity: Not app									
	olicable	P = 0.79)							
Heterogeneity: Not app	olicable	P = 0.79)		293	100.0%	0.88 [0.73 , 1.07]			
Heterogeneity: Not app Test for overall effect: 2	olicable	,	136	293	100.0%	0.88 [0.73 , 1.07]	•		
Heterogeneity: Not app Test for overall effect: 2 Total (95% CI)	plicable Z = 0.26 (P	224	136			0.88 [0.73 , 1.07]	0.5 0.7 1 1.5 2		


Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 3: Mental state: 1a. Overall clinically important change in overall mental state (>/= 20% reduction in PANSS endpoint score)

	Halope	eridol	Olanza	pine		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Ding 2013	8	38	11	38	6.3%	0.73 [0.33 , 1.61]	
Jiang 2009b	35	62	26	54	18.3%	1.17 [0.82 , 1.67]	<del></del>
Li 2005f	18	30	15	30	13.7%	1.20 [0.76 , 1.90]	<del>- •-</del>
Lin 2008	13	75	8	75	5.9%	1.63 [0.72 , 3.69]	
Luo 2012d	8	40	4	40	3.5%	2.00 [0.65 , 6.11]	<del></del>
Ma 2005d	9	40	6	40	4.8%	1.50 [0.59 , 3.82]	
Pan 2005	10	42	13	42	7.6%	0.77 [0.38 , 1.56]	
Qin 2006a	23	40	28	37	19.8%	0.76 [0.55 , 1.05]	<del></del>
Wang 2013az	6	32	9	32	5.0%	0.67 [0.27 , 1.66]	
Xu 2014n	7	32	9	32	5.5%	0.78 [0.33 , 1.83]	
Zhang 2010ad	11	42	9	45	6.5%	1.31 [0.60 , 2.84]	<del></del>
Zhang 2013m	11	35	3	35	3.1%	3.67 [1.12 , 12.02]	
Total (95% CI)		508		500	100.0%	1.06 [0.85 , 1.32]	
Total events:	159		141				
Heterogeneity: Tau <sup>2</sup> =	0.04; Chi <sup>2</sup>	= 14.95,	df = 11 (P	= 0.18);	$I^2 = 26\%$		0.2 0.5 1 2 5
Test for overall effect:	Z = 0.50 (F	P = 0.62					Olanzapine Haloperidol
Test for subgroup diffe	erences: No	t applical	ble				

Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 4: Mental state: 1b. Overall clinically important change in overall mental state - short term (>/= 25% reduction in PANSS endpoint score)




Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 5: Mental state: 1c. Overall clinically important change in overall mental state - short term (>/= 75% reduction in PANSS endpoint score)



Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 6: Mental state: 1d. Overall clinically important change in overall mental state - short term (>/=40% reduction in BPRS endpoint score)

	Halope	erisol	Olanza	pine		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Crespo-Facorro 2006	14	54	18	54	45.8%	0.78 [0.43 , 1.40]	
Kahn (EUFEST) 2005	18	103	43	105	54.2%	0.43 [0.26 , 0.69]	-
Total (95% CI)		157		159	100.0%	0.56 [0.31 , 1.01]	
Total events:	32		61				
Heterogeneity: $Tau^2 = 0$	).11; Chi <sup>2</sup> =	2.41, df	= 1 (P = 0	.12); I <sup>2</sup> =	59%		0.1 0.2 0.5 1 2 5 10
Test for overall effect: Z	z = 1.93 (P	= 0.05)					Olanzapine Haloperidol
Test for subgroup differ	ences: Not	applicabl	le				

Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 7: Mental state: 1e. Overall clinically important change in overall mental state- remission-medium term (PANSS score <=3 per symptom at least for 6 months)



(1) Suspicious standard deviations

## Risk of bias legend

- (A) Random sequence generation (selection bias)
- (B) Allocation concealment (selection bias)
- (C) Blinding of participants and personnel (performance bias)
- (D) Blinding of outcome assessment (detection bias)
- (E) Incomplete outcome data (attrition bias)
- (F) Selective reporting (reporting bias)
- (G) Other bias


Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 8: Mental state: 2a. Overall average endpoint score (PANSS total, high=poor)

	На	loperido	ι	Ola	anzapine	•		Mean Difference	Mean Diff erence	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI	
4.9.1 short term										
Bernardo (HGDD) 2001	34.4	11.9	13	36.6	12.5	14	3.0%	-2.20 [-11.40 , 7.00]	-	
Buchanan 2003	33.6	10.6	34	33.4	9.9	29	9.8%	0.20 [-4.87, 5.27]		
Ishigooka 2001	40.41	13.11	80	40.41	13.67	81	14.8%	0.00 [-4.14 , 4.14]		
Lahti 2007	33.2	8.1	12	33.8	6.9	17	8.0%	-0.60 [-6.24, 5.04]		
Liu 2012ao	24.35	4.45	39	22.53	5.83	37	46.1%	1.82 [-0.52 , 4.16]	<del></del>	
Subtotal (95% CI)			178			178	81.6%	0.91 [-0.85, 2.67]		
Heterogeneity: Tau <sup>2</sup> = 0.00 Test for overall effect: Z = 4.9.2 medium term			,							
Crespo-Facorro 2006	31.1	7.1	24	29.6	7.4	37	18.4%	1.50 [-2.21 , 5.21]		
Subtotal (95% CI)			24			37	18.4%			
Heterogeneity: Not applica	able									
Test for overall effect: Z = 0		3)								
Total (95% CI)			202			215	100.0%	1.02 [-0.57, 2.61]		
Heterogeneity: Tau <sup>2</sup> = 0.00	); Chi <sup>2</sup> = 1.63	, df = 5 (F	P = 0.90);	$l^2 = 0\%$						
Test for overall effect: Z =	1.26 (P = 0.2	1)							-10 -5 0 5	
Test for subgroup difference	oo Chi2 O	70 Af 1	(D 0.70	\ I2 \ \no/					Olanzapine Halope	

Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 9: Mental state: 2b. Overall -average endpoint score (BPRS total, high=poor)

	Ha	aloperido	l	0	lanzapine	<b>!</b>		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Chaudhry 2003	-36.7	28.5723	123	-44.6	28.0241	139	78.0%	7.90 [1.03 , 14.77]	
Dhar 2010	-46	15.1	20	-60	25.37	20	22.0%	14.00 [1.06 , 26.94]	<del>_</del>
Total (95% CI)			143			159	100.0%	9.24 [3.17 , 15.31]	
Heterogeneity: Tau <sup>2</sup> =	0.00; Chi <sup>2</sup>	= 0.67, df	= 1 (P = 0	.41); I <sup>2</sup> = 0	)%				
Heterogeneity: Tau <sup>2</sup> = Test for overall effect:	,	,	= 1 (P = 0	.41); l <sup>2</sup> = (	)%				-20-10 0 10 20
Test for subgroup diffe	rences: No	t applicab	le						Olanzapine Haloperio


Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 11: Mental state: 3a. Overall - average change score - short term (PANSS total, high=poor)



Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 13: Mental state: 4a. Specific - average endpoint score - depression - short term (MADRS , high=poor)

	Halope	eridol	Olanza	pine		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
4.17.1 short term							
Lindenmayer 2007	6	19	7	16	6.0%	0.72 [0.30 , 1.71]	
Subtotal (95% CI)		19		16	6.0%	0.72 [0.30 , 1.71]	
Total events:	6		7				
Heterogeneity: Not app	olicable						
Test for overall effect:	Z = 0.74 (F	P = 0.46)					
4.17.2 medium term							
Lilly (S029) 2007	68	133	81	141	94.0%	0.89 [0.72 , 1.11]	
Subtotal (95% CI)		133		141	94.0%	0.89 [0.72 , 1.11]	•
Total events:	68		81				<b>T</b>
Heterogeneity: Not app	olicable						
Test for overall effect:	Z = 1.04 (F	P = 0.30					
Total (95% CI)		152		157	100.0%	0.88 [0.71 , 1.09]	
Total events:	74		88				7
Heterogeneity: Tau <sup>2</sup> =	0.00; Chi <sup>2</sup>	= 0.21, d	f = 1 (P =	0.65); I <sup>2</sup>	= 0%		0.01 0.1 1 10 100
Test for overall effect:	Z = 1.19 (F	P = 0.23					Olanzapine Haloperidol
Test for subgroup diffe	erences: Ch	$ni^2 = 0.21$	, df = 1 (P	= 0.65),	$I^2 = 0\%$		

Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 17: Mental state: 5a. Specific - negative symptoms - clinically important change(>/=20% reduction in PANSS-N)




Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 18: Mental state: 5b. Specific - negative symptoms - clinically important change - short term (>/=40% reduction in PANSS-N)

	Ha	loperido	l	Ol	anzapine	•		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
4.19.1 short term									
Barak 2002	20.5	6.9	10	15.2	3	10	2.4%	5.30 [0.64, 9.96]	
Beasley (E003) 1997	23.08	6.13	79	21.24	8.25	85	6.6%	1.84 [-0.37 , 4.05]	<del>  -</del>
Bernardo (HGDD) 2001	18	5.6	13	17.8	5.5	14	2.8%	0.20 [-3.99 , 4.39]	
Boulay 2002	17.9	7.84	13	17.79	6.89	14	1.7%	0.11 [-5.47 , 5.69]	
HGCJ (Hong Kong) 1998	18.5	7.89	14	14.75	6.57	16	1.9%	3.75 [-1.49 , 8.99]	
HGCU (Taiwan) 1998	17.71	8.28	28	14.71	6.8	24	2.9%	3.00 [-1.10 , 7.10]	
Ishigooka 2001	22.5	7.52	78	23.42	8.41	80	5.8%	-0.92 [-3.41 , 1.57]	
Lieberman (HGDH) 2003	17.56	5.95	126	16.07	6	126	9.3%	1.49 [0.01, 2.97]	
Lindenmayer 2007	22.58	6.54	19	18.25	4.42	16	3.5%	4.33 [0.68 , 7.98]	
Luo 2012d	12.2	5	40	13.2	4.3	40	7.1%	-1.00 [-3.04 , 1.04]	
Ma 2005d	14.83	7.51	40	10.14	6.62	40	4.4%	4.69 [1.59 , 7.79]	
Qin 2006a	24.2	9.2	40	22.6	8.3	40	3.2%	1.60 [-2.24 , 5.44]	
Song 2009c	11.62	3.93	50	8.34	4.26	50	8.8%	3.28 [1.67, 4.89]	
Tollefson (HGAJ) 1997	21.29	6.87	636	19.57	6.92	1312	12.6%	1.72 [1.07 , 2.37]	
Wang 2013az	21.71	4.17	32	18.42	4.37	32	7.0%	3.29 [1.20 , 5.38]	
Xu 2014n	21.71	4.17	32	18.42	4.37	32	7.0%	3.29 [1.20 , 5.38]	
Subtotal (95% CI)			1250			1931	86.9%	2.06[1.25, 2.87]	•
Heterogeneity: Tau <sup>2</sup> = 1.00;	$Chi^2 = 28.15$	i, df = 15	(P = 0.02)	; $I^2 = 47\%$					_
Test for overall effect: $Z = 4$ .	98 (P < 0.00	001)							
4.19.2 medium term									
Lilly (S029) 2007	17.8	6.3	121	17.5	5.7	128	9.2%	0.30 [-1.20 , 1.80]	
Subtotal (95% CI)			121			128	9.2%	0.30 [-1.20, 1.80]	
Heterogeneity: Not applicab	le								
Test for overall effect: $Z = 0$ .	39 (P = 0.69	)							
4.19.3 long term									
Jones 1998 (P022)	20.65	6.21	23	15.9	5.13	21	3.9%	4.75 [1.40 , 8.10]	
Subtotal (95% CI)			23			21	3.9%	4.75[1.40,8.10]	
Heterogeneity: Not applicab	le								
Test for overall effect: $Z = 2$ .	78 (P = 0.00	6)							
Total (95% CI)			1394			2080	100.0%	2.01[1.22,2.80]	•
Heterogeneity: Tau <sup>2</sup> = 1.16;	$Chi^2 = 35.15$	6, df = 17	(P = 0.006)	6); I <sup>2</sup> = 52%					
Test for overall effect: $Z = 5$ .	02 (P < 0.00	001)							-4 -2 0 2 4
Test for subgroup difference									Olanzapine Haloperido

 $\label{lem:comparison} \begin{tabular}{ll} Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 19: Mental state: 5c. Specific - negative symptoms - average endpoint score (PANSS-N, high=poor) \\ \end{tabular}$ 

	Ha	loperido	ι	Ola	nzapine	•		Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
4.20.1 short term									
Barak 2002	20.5	6.9	10	15.2	3	10	1.6%	0.95 [0.02, 1.89]	
Beasley (E003) 1997	23.08	6.13	79	21.24	8.25	85	7.1%	0.25 [-0.06 , 0.56]	-
Bernardo (HGDD) 2001	18	5.6	13	17.8	5.5	14	2.2%	0.03 [-0.72 , 0.79]	
Boulay 2002	17.9	7.84	13	17.79	6.89	14	2.2%	0.01 [-0.74 , 0.77]	
Buchanan 2003	30.2	11.6	34	29.6	12.4	29	4.2%	0.05 [-0.45, 0.54]	
HGCJ (Hong Kong) 1998	18.5	7.89	14	14.75	6.57	16	2.4%	0.51 [-0.22 , 1.24]	
HGCU (Taiwan) 1998	17.71	8.28	28	14.71	6.8	24	3.6%	0.39 [-0.16 , 0.94]	
Ishigooka 2001	22.5	7.52	78	23.42	8.41	80	7.0%	-0.11 [-0.43, 0.20]	
Lieberman (HGDH) 2003	17.56	5.95	126	16.07	6	126	8.4%	0.25 [0.00, 0.50]	
Lindenmayer 2007	22.58	6.54	19	18.25	4.42	16	2.6%		
Luo 2012d	12.2	5	40	13.2	4.3	40	4.9%		
Ma 2005d	14.83	7.51	40	10.14	6.62	40	4.8%		
Qin 2006a	24.2	9.2	40	22.6	8.3	40	4.9%	0.18 [-0.26 , 0.62]	
Song 2009c	11.62	3.93	50	8.34	4.26	50	5.4%	0.79 [0.39 , 1.20]	
Tollefson (HGAJ) 1997	21.29	6.87	636	19.57	6.92	1312	11.6%		_
Wang 2013az	21.71	4.17	32	18.42	4.37	32	4.1%		
Xu 2014n	21.71	4.17	32	18.42	4.37	32	4.1%		
Subtotal (95% CI)			1284			1960	81.0%	0.32 [0.18, 0.46]	
Heterogeneity: $Tau^2 = 0.04$ ; Test for overall effect: $Z = 4$ .			(1 = 0.00	7),1 – 32 /	,				
4.20.2 medium term									
Crespo-Facorro 2006	4.8	5.3	24	3.5	3.8	37	4.0%		+-
Lilly (S029) 2007	17.8	6.3	121	17.5	5.7	128	8.3%		<del></del>
Subtotal (95% CI)			145			165	12.3%	0.09[-0.13, 0.32]	<b>*</b>
Heterogeneity: $Tau^2 = 0.00$ ; Test for overall effect: $Z = 0$ .		,	= 0.41); f	² = 0%					
4.20.3 long term									
Crespo-Facorro 2006	4.39	4.47	28	4.31	4.96	23	3.6%	0.02 [-0.53 , 0.57]	
Jones 1998 (P022)	20.65	6.21	23	15.9	5.13	21	3.1%	0.82 [0.20 , 1.43]	
Subtotal (95% CI)			51			44	6.7%	0.40 [-0.38, 1.19]	
Heterogeneity: $Tau^2 = 0.23$ ; Test for overall effect: $Z = 1$ .		,	= 0.06); l <sup>2</sup>	2 = 72%					
Total (95% CI)			1480			2169	100.0%	0.30[0.17,0.42]	•
Heterogeneity: Tau <sup>2</sup> = 0.03;			(P = 0.00)	5); $I^2 = 50\%$	•				
Test for overall effect: $Z = 4$ . Test for subgroup difference	•	,	(P = 0.24)	, I <sup>2</sup> = 30.7%	,				-2 -1 0 1 Olanzapine Haloperio

Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 20: Mental state: 5d. Specific - negative symptoms - average endpoint score (PANSS-N, SANS scales, SMD, high=poor)



Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 23: Mental state: 6a. Specific - positive symptoms - clinically important change - medium term (>/= 20% reduction in PANSS-P)

StudyorSubgroup	Mean	<b>CD</b>		Olanzapine					
		SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
1.24.1 short term									
Beasley (E003) 1997	18.77	8.02	79	18.08	7.76	85	3.3%	0.69 [-1.73, 3.11]	
Bernardo (HGDD) 2001	16.4	7.1	13	18.8	7.6	14	0.8%		4
Boulay 2002	12	3.74	13	15.43	6.07	14	1.6%		
Ding 2013	17.12	4.76	38	16.28	4.01	38	4.3%	0.84 [-1.14 , 2.82]	<u> </u>
HGCJ (Hong Kong) 1998	20.14	7.39	14	14.63	5.83	16	1.1%		
HGCU (Taiwan) 1998	19.46	8.22	28	16.58	7.38	24	1.3%	• •	
shigooka 2001	14.97	6.46	78	14.91	6.42	80			
_ieberman (HGDH) 2003	12.31	4.5	126	12.12	4.14	126			
_in 2008	14.8	4.3	75	11.7	3.8	75	6.6%		<u></u> _
_indenmayer 2007	14.16	4.99	19	12.06	4.07	16			
_uo 2012d	14.8	4.3	40	11.7	3.8	40		,	
Ma 2005d	10.46	6.25	40	9.88	5.87	40			
Qin 2006a	11.7	6.2	40	10.2	4.9	40			
Song 2009c	9.01	2.94	50	8.32	3.84	50			<del></del>
Follefson (HGAJ) 1997	17.75	6.93	636	16.54	7.08	1312			<del>                                      </del>
Wang 2013az	17.73	4.76	32	16.28	4.01	32		L , 1	
Wang 2013a2 Ku 2014n	16.12	4.76	32	15.28	4.01	32			<del>-   •</del>
Zhang 2010ad	5.64	1.65	42	5.23	1.26	45			<del>-   •</del>
•	11.4		36	11.7	3.5	36			<del> -</del>
Zhang 2016al		3.8							<del></del>
Zheng 2003b	11.84	3.24	34	8.75	3.51	34			
Subtotal (95% CI)	21.12 40.00		1465			2149	88.1%	1.12[0.53,1.70]	•
Heterogeneity: $Tau^2 = 0.76$ ; (Fest for overall effect: $Z = 3.7$ )			(P = 0.00	); I = 56%					
1.24.2 medium term									
_illy (S029) 2007	13	6	121	12.9	5.5	128	6.1%	0.10 [-1.33 , 1.53]	
Kianzhen 2004	10.2	6.4	60	9.3	6.2	60			
Subtotal (95% CI)	10.2	0.1	181	0.0	0.2	188		0.33 [-0.88, 1.54]	
Heterogeneity: Tau <sup>2</sup> = 0.00;	Chi² – ∩ 34	df = 1 (P		- 0%		100	3.1 /0	0.55[-0.00,1.54]	
Test for overall effect: $Z = 0.5$		,	- 0.00), 1	- 070					
1.24.3 long term									
Jones 1998 (P022)	12.78	5.11	23	12.52	5.56	21	2.2%	0.26 [-2.90 , 3.42]	
Subtotal (95% CI)	0	J	23	. 2.02	0.00	21			
Heterogeneity: Not applicable	e						/0		
Test for overall effect: $Z = 0.1$		)							
Fotal (95% CI)			1669			2358	100.0%	1.03[0.50,1.55]	
Heterogeneity: Tau <sup>2</sup> = 0.65;	Chi <sup>2</sup> = 44.70	, df = 22	(P = 0.003)	3); I <sup>2</sup> = 51%				. ,	_
Test for overall effect: $Z = 3.8$			, 2.300	,,,					-4 -2 0 2 4


Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 24: Mental state: 6b. Specific - positive symptoms - average endpoint score (PANSS-P, high=poor)

		loperido		Olanzapine		•		Std. Mean Difference	Std. Mean Diff erence
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
4.25.1 short term (PANSS-I	P, BPRS-P s	cales)							
Beasley (E003) 1997	18.77	8.02	79	18.08	7.76	85	5.9%	0.09 [-0.22, 0.39]	<b>—</b>
Bernardo (HGDD) 2001	16.4	7.1	13	18.8	7.6	14	1.8%	-0.32 [-1.08 , 0.44]	
Boulay 2002	12	3.74	13	15.43	6.07	14	1.7%	-0.65 [-1.43 , 0.12]	
Ding 2013	17.12	4.76	38	16.28	4.01	38	3.9%	0.19 [-0.26 , 0.64]	<u> </u>
HGCJ (Hong Kong) 1998	20.14	7.39	14	14.63	5.83	16	1.8%	0.81 [0.06 , 1.56]	
HGCU (Taiwan) 1998	19.46	8.22	28	16.58	7.38	24	3.0%	0.36 [-0.19 , 0.91]	<u></u>
Ishigooka 2001	14.97	6.46	78	14.91	6.42	80	5.8%	0.01 [-0.30 , 0.32]	
Lahti 2007	4.8	1.8	12	5.9	2.5	17	1.8%	-0.48 [-1.23 , 0.27]	
Lieberman (HGDH) 2003	12.31	4.5	126	12.12	4.14	126	7.0%	0.04 [-0.20 , 0.29]	
Lin 2008	14.8	4.3	75	11.7	3.8	75	5.5%	0.76 [0.43 , 1.09]	
Lindenmayer 2007	14.16	4.99	19	12.06	4.07	16	2.2%	0.45 [-0.23 , 1.12]	_ <del></del>
Luo 2012d	14.10	4.3	40	11.7	3.8	40	3.9%		<del>    -</del>
								0.76 [0.30 , 1.21]	
Ma 2005d	10.46	6.25	40	9.88	5.87	40	4.0%	0.09 [-0.34 , 0.53]	
Qin 2006a	11.7	6.2	40	10.2	4.9	40	4.0%	0.27 [-0.17 , 0.71]	+-
Song 2009c	9.01	2.94	50	8.32	3.84	50	4.6%	0.20 [-0.19 , 0.59]	+-
Tollefson (HGAJ) 1997	17.75	6.93	636	16.54	7.08	1312	10.0%	0.17 [0.08 , 0.27]	+
Wang 2013az	17.12	4.76	32	16.28	4.01	32	3.5%	0.19 [-0.30 , 0.68]	<del>    •   •   •   •   •   •   •   •   •  </del>
Xu 2014n	16.12	4.76	32	15.28	4.01	32	3.5%	0.19 [-0.30 , 0.68]	<del></del>
Zhang 2010ad	5.64	1.65	42	5.23	1.26	45	4.2%	0.28 [-0.14 , 0.70]	<del>  -</del>
Zhang 2016al	11.4	3.8	36	11.7	3.5	36	3.8%	-0.08 [-0.54 , 0.38]	<del></del>
Zheng 2003b	11.84	3.24	34	8.75	3.51	34	3.4%	0.90 [0.40 , 1.40]	
Subtotal (95% CI)			1477			2166	85.3%	0.22[0.10,0.35]	•
Heterogeneity: $Tau^2 = 0.04$ ;	$Chi^2 = 42.93$	3, df = 20	(P = 0.002)	2); $I^2 = 53\%$					•
Test for overall effect: $Z = 3.4$	14 (P = 0.00)	06)							
4.25.2 medium term (PANS	S-Ponly)								
Lilly (S029) 2007	13	6	121	12.9	5.5	128	7.0%	0.02 [-0.23 , 0.27]	
Xianzhen 2004	10.2	6.4	60	9.3	6.2	60	5.1%	0.14 [-0.22 , 0.50]	
Subtotal (95% CI)	10.2	0.4	181	5.5	0.2	188	12.1%	0.06[-0.15, 0.26]	
Heterogeneity: Tau <sup>2</sup> = 0.00;	^hi² ∩ 21	df 1 /D		00/		100	12.170	0.06[-0.15, 0.26]	•
Test for overall effect: Z = 0.5		,	= 0.56), 1	= 0%					
	,	')							
4.25.3 long term (PANSS-P	• •								
Jones 1998 (P022)	12.78	5.11	23	12.52	5.56	21	2.7%	0.05 [-0.54 , 0.64]	
Subtotal (95% CI)			23			21	2.7%	0.05[-0.54, 0.64]	
Heterogeneity: Not applicable	е								T
Test for overall effect: $Z = 0.1$	6 (P = 0.87	<b>'</b> )							
Total (95% CI)			1681			2375	100.0%	0.20[0.09,0.31]	_
Heterogeneity: Tau <sup>2</sup> = 0.03;	Chi <sup>2</sup> = 45 03	3. df = 23		4):   <sup>2</sup> = 49%	,		200.070	,,	▼
			,. – 0.00	.,, 1 = 1070					
Test for overall effect: $Z = 3.5$									-2 -1 0 1

Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 25: Mental state: 6c. Specific - positive symptoms - average endpoint score (PANSS-P, BPRS-P, SMD, high=poor)

	Ha	loperido	l	Ola	nzapine	•		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
4.28.1 short term									
Avasthi 2001	26.57	8.73	7	25.12	5.25	16	1.5%	1.45 [-5.51 , 8.41]	
Barak 2002	36.5	7	10	34.5	10.6	10	1.2%	2.00 [-5.87 , 9.87]	
Boulay 2002	26.2	4.96	13	28.79	5.07	14	4.1%	-2.59 [-6.37 , 1.19]	
Ding 2013	29.51	5.43	38	25.97	5.94	38	6.6%	3.54 [0.98, 6.10]	
Lieberman (HGDH) 2003	29.48	8.34	130	27.66	8.09	132	8.2%	1.82 [-0.17, 3.81]	
Lin 2008	21.8	3.9	75	21.6	4	75	10.6%	0.20 [-1.06 , 1.46]	
Lindenmayer 2007	30.89	8.9	19	26.75	5.29	16	2.9%	4.14 [-0.63 , 8.91]	
Luo 2012d	21.8	3.9	40	21.6	4	40	9.0%	0.20 [-1.53 , 1.93]	
Ma 2005d	15.61	5.76	40	12.32	7.7	40	5.6%	3.29 [0.31, 6.27]	
Song 2009c	21.91	4.23	50	20.6	4.11	50	9.4%	1.31 [-0.32 , 2.94]	<u> </u>
Tollefson (HGAJ) 1997	39.69	12.16	636	36.31	12.2	1312	11.0%	3.38 [2.23 , 4.53]	
Wang 2013az	29.51	5.43	32	25.97	5.94	32	6.0%	3.54 [0.75 , 6.33]	
Xu 2014n	29.51	5.43	32	25.97	5.94	32	6.0%	3.54 [0.75 , 6.33]	
Zhang 2016al	22.3	5.5	36	23	5.7	36	6.5%	-0.70 [-3.29 , 1.89]	
Subtotal (95% CI)			1158			1843	88.6%	1.74 [0.73, 2.75]	•
Heterogeneity: Tau <sup>2</sup> = 1.85;	Chi <sup>2</sup> = 32.35	5, df = 13	(P = 0.002)	2); I <sup>2</sup> = 60%					_
Test for overall effect: $Z = 3$ .	38 (P = 0.00	07)							
4.28.2 medium term									
Lilly (S029) 2007	31.6	10.7	122	31.7	11.1	127	6.2%	-0.10 [-2.81 , 2.61]	
Xianzhen 2004	31.6	8.9	60	30.4	8.6	60			<del></del>
Subtotal (95% CI)	31.0	0.9	182	30.4	0.0	187		0.46 [-1.59, 2.50]	
Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.00;	Chi <sup>2</sup> 0.20	df 1/D		00/		187	11.4%	0.40[-1.39,2.50]	<b>—</b>
Test for overall effect: Z = 0.			= 0.54); [	= 076					
restror overall effect. Z = 0.	44 (F = U.00	)							
Total (95% CI)			1340			2030	100.0%	1.59[0.67,2.52]	•
Heterogeneity: $Tau^2 = 1.67$ ;	$Chi^2 = 34.11$	, $df = 15$	(P = 0.003)	$(3); I^2 = 56\%$					
Test for overall effect: $Z = 3$ .	39 (P = 0.00)	07)							-10 -5 0 5


Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 28: Mental state: 7. Specific - psychopathology, general - average endpoint score (PANSS psychopathology, high=poor)




Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 29: Mental state: 8. Specific - various - average endpoint score - short term (PANSS subscales, high=poor)

	Exp	erimenta	al	(	Control			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Ma 2005d	16.5	5.4	40	15.4	4.7	40	73.8%	1.10 [-1.12 , 3.32]	
Qin 2006a	20.2	13.6	40	20.7	10.2	40	13.1%	-0.50 [-5.77 , 4.77]	
Zhang 2010ae	20.2	13.6	40	20.7	10.2	40	13.1%	-0.50 [-5.77 , 4.77]	
Total (95% CI)			120			120	100.0%	0.68 [-1.23 , 2.59]	
Heterogeneity: Tau <sup>2</sup> =	0.00; Chi <sup>2</sup> =	0.52, df	= 2 (P = 0)	$(0.77); I^2 = 0$	%				
Test for overall effect:	Z = 0.70 (P	= 0.48)							-4 -2 0 2 4
Test for subgroup diffe	erences: Not	applicab	le						Olanzapine Haloperidol

Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 30: Mental state: 9. Specific - time to onset of effect - short term



Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 31: Mental state: 10. Specific - Needing additional benzodiazepines



Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 32: Functioning: 1a. General -average endpoint score - short term (GAF, high=good)

nalysis 4.34													
	На	loperido	ι	ol	anzapine	•		Mean Difference		Mean D	iff eren	ce	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	ľ	V, Rando	m, 95%	CI	
Lilly (S029) 2007	6.9	4.7	118	6.3	4.8	122	100.0%	0.60 [-0.60 , 1.80]					_
Total (95% CI) Heterogeneity: Not app	plicable		118			122	100.0%	0.60 [-0.60,1.80]		-		<u> </u>	-
Test for overall effect:	Z = 0.98 (P	= 0.33)							-2	-1	0	1	<del>-</del>
Test for subgroup diffe	rences: Not	applicab	le						Olan	zapine	Hale	operido	A .

Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 34: Functioning: 2a. Specific - cognition- average endpoint score - long term (SCD, high=poor)

Study or Subgroup	Halo Mean	operidol SD To	tal	Ola Mean	nzapine SD		Weight	Mean Difference IV, Random, 95% CI	Mean Difference IV, Random, 95% CI
	- ""								
.35.1 neuro-cognitio				-		40	400.00/	100[101 11 11]	
Sergi 2007	51	12.6	20	46.4	11.1		100.0%	4.60 [-1.91 , 11.11]	<b>—</b>
Subtotal (95% CI)			20			40	100.0%	4.60 [-1.91 , 11.11]	•
Heterogeneity: Not applicate	able								
Test for overall effect: Z =	1.39 (P = 0	0.17)							
.35.2 neuro-cognitio	n - Contro	olled Oral V	Vord As	ssociation	Test				
Sergi 2007	52.7	12.8	20	45.5	11.4	40	100.0%	7.20 [0.57 , 13.83]	-
Subtotal (95% CI)			20			40	100.0%	7.20 [0.57 , 13.83]	
Heterogeneity: Not applica	able							. , .	•
est for overall effect: Z =		0.03)							
.35.3 neuro-cognitio	n - Degrac	led Stimul	us Con	tinuous F	erform	ance Tes	st		
Sergi 2007	0.86	0.08	20	0.81	0.15		100.0%	0.05 [-0.01 , 0.11]	•
Subtotal (95% CI)			20				100.0%	0.05 [-0.01, 0.11]	<b></b>
	ablo		20			40	100.070	0.03 [-0.01, 0.11]	
Heterogeneity: Not application   Test for overall effect: Z =		0.09)							
1 25 4 nouve cognitie	n Digit C	vmbal sad	ina						
1.35.4 neuro-cognitio Gergi 2007	51.3	11.8	111g 20	48.7	13.3	<b>4</b> 0	100.0%	2.60 [-4.01 , 9.21]	<u> </u>
=	51.5			70.7	10.0			= = =	<b></b>
Subtotal (95% CI)	ماطم		20			40	100.0%	2.60 [-4.01, 9.21]	<b>~</b>
Heterogeneity: Not applicates for overall effect: $Z =$		0.44)							
.35.5 neuro-cognitio	n - Groov	ed Peghosi	rd Test						
•		_			70.4	40	100.00/	14 90 [ 40 96 40 70]	
Sergi 2007	202.8	35.5	20	217.6	73.4		100.0%		
Subtotal (95% CI)			20			40	100.0%	-14.80 [-42.36, 12.76]	
Heterogeneity: Not applica Fest for overall effect: Z =		0.29)							
35.6 neuro-cognitio				47.0	0.5	40	100.00/	0.00 [0.05 5.05]	
Sergi 2007	20.7	5	20	17.9	3.5	40		2.80 [0.35 , 5.25]	
Subtotal (95% CI)			20			40	100.0%	2.80 [0.35 , 5.25]	•
Heterogeneity: Not applica	able								<b>,</b>
Test for overall effect: Z =	2.24 (P = 0	0.02)							
.35.7 neuro-cognitio	n - Wiscon	sin Card S	orting	Test					
Sergi 2007	2.4	1.7	20	1.6	1.9	40	100.0%	0.80 [-0.15 , 1.75]	•
Subtotal (95% CI)			20			40	100.0%	0.80 [-0.15 , 1.75]	<del>T</del>
Heterogeneity: Not applica	ahla							0.00 [ 0.20 , 20]	
Test for overall effect: $Z =$		0.10)							
.35.8 social cognition	ı - Facial E	motion Id	entific	cation Tes	t				
Gergi 2007	10.6	3.1	20	11.1	2.8	40	100.0%	-0.50 [-2.11 , 1.11]	•
Subtotal (95% CI)			20			40	100.0%	-0.50 [-2.11 , 1.11]	<b>T</b>
leterogeneity: Not applica	able					_		,,	Ť
Test for overall effect: Z =		0.54)							
3.35.9 social cognition	ı - Half Pr	ofile of No	nverba	al Sensitiv	ity				
Sergi 2007	79.8	8.5	20	78	8	40	100.0%	1.80 [-2.67, 6.27]	<b></b>
Subtotal (95% CI)			20			40	100.0%	1.80 [-2.67, 6.27]	<b>T</b>
						.0		,	
Heterogeneity: Not applica	0.79 (P = 0)	0.43)							
Test for overall effect: Z =				on Task					
est for overall effect: Z =					1.8	40	100.0%	0.80 [-0.03 , 1.63]	
est for overall effect: Z = 4.35.10 social cognitic Gergi 2007	on - Interp 9.2	ersonal Pe 1.4	20	8.4	1.0				
est for overall effect: Z =				8.4	1.0		100.0%	0.80 [-0.03,1.63]	<del>-</del>
est for overall effect: Z = 4.35.10 social cognitic Gergi 2007	9.2		20	8.4	1.0		100.0%	0.80 [-0.03, 1.63]	T
est for overall effect: Z = 1.35.10 social cognition Sergi 2007 Subtotal (95% CI)	9.2 able	1.4	20	8.4	1.0		100.0%	0.80 [-0.03,1.63]	
Test for overall effect: Z = 1.35.10 social cognition of the cognition of	9.2 able 1.89 (P = 0	1.4	20 <b>20</b>				100.0%	0.80 [-0.03,1.63]	
Test for overall effect: Z = 1.35.10 social cognition of the cognition of	9.2 able 1.89 (P = 0	1.4	20 <b>20</b>			40	100.0%		
Fest for overall effect: Z = 1.35.10 social cognition of the cognition of	9.2 able 1.89 (P = 0 on - Voice	1.4 0.06) <b>Emotion I</b>	20 20 20 dentifi	cation Te	st	<b>40</b>	100.0%	0.20 [-1.76 , 2.16]	
Fest for overall effect: Z = 1.35.10 social cognition of the cognition of	9.2 able 1.89 (P = 0 on - Voice 10.6	1.4 0.06) <b>Emotion I</b>	20 <b>20</b> dentifi	cation Te	st	<b>40</b>			•
Fest for overall effect: Z = 1.35.10 social cognition of the cognition of	9.2  able 1.89 (P = 0)  on - Voice 10.6	1.4 0.06) Emotion to 3.9	20 20 20 dentifi	cation Te	st	<b>40</b>	100.0%	0.20 [-1.76 , 2.16]	•
Fest for overall effect: Z = 4.35.10 social cognition of the cognition of	9.2  able 1.89 (P = 0  on - Voice 10.6  able 0.20 (P = 0	1.4 0.06) Emotion to 3.9	20 20 dentifi 20 20	cation Te 10.4	s <b>t</b> 3.1	<b>40</b>	100.0%	0.20 [-1.76 , 2.16]	•


Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 35: Functioning: 2b. Specific - cognition - average endpoint scores - short term (various domains, high=good)

		aloperidol			anzapine			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
.36.1 attention									
Crespo-Facorro 2006	73.31	9.94	13	75.09	12.49	11	100.0%	-1.78 [-10.93 , 7.37]	_
Subtotal (95% CI)	70.01	0.01	13	70.00	12.10		100.0%	-1.78 [-10.93,7.37]	
•	hlo		13			11	100.070	-1.10[-10.55,1.51]	
Heterogeneity: Not applica		2.70\							
Test for overall effect: $Z = 0$	).38 (P = 0	).70)							
4.36.2 functions - execu	utive								
Crespo-Facorro 2006	83.47	57.7	15	65.38	25.9	13	100.0%	18.09 [-14.33, 50.51]	
Subtotal (95% CI)			15			13	100.0%	18.09 [-14.33,50.51]	
Heterogeneity: Not applica	ble							. , .	
Test for overall effect: Z =		).27)							
	_								
4.36.3 processing speed									<u>l</u>
Crespo-Facorro 2006	9.67	4.05	15	9.46	2.15	13	100.0%	0.21 [-2.15 , 2.57]	-
Subtotal (95% CI)			15			13	100.0%	0.21 [-2.15, 2.57]	•
Heterogeneity: Not applica	ble								Ţ
Test for overall effect: $Z = 0$	).17 (P = 0	).86)							
1 36 4 memory view-l									
4.36.4 memory - visual	04.57	0.4	4.4	01.15	0.07	40	100.00/	2 40 [ 2 0 7 40 441	
Crespo-Facorro 2006	24.57	8.4	14	21.15	9.27		100.0%	3.42 [-3.27 , 10.11]	<del></del>
Subtotal (95% CI)			14			13	100.0%	3.42 [-3.27, 10.11]	
Heterogeneity: Not applica									
Test for overall effect: Z = -	.00 (P = 0	).32)							
4.36.5 memory - workin	ıg								
Crespo-Facorro 2006	5.4	1.92	15	6	1.47	13	100.0%	-0.60 [-1.86 , 0.66]	<u> </u>
Subtotal (95% CI)	J		15	3	,		100.0%	-0.60 [-1.86, 0.66]	<b>T</b>
Heterogeneity: Not applica	hla						200.0 /0	0.00[ 1.00,0.00]	₹
Test for overall effect: $Z = 0$		).35)							
	_								
<b>4.36.6 neuro-cognitio</b> r Crespo-Facorro 2006	1 <b>- Groove</b> 63.82	ed Pegboa 12.04	rd Test 28	59.45	7.14	20	100.0%	1271100 0021	_
·	03.02	12.04		33.43	7.14			4.37 [-1.08 , 9.82]	<b>†</b> ■
Subtotal (95% CI)			28			20	100.0%	4.37 [-1.08, 9.82]	
Heterogeneity: Not applicates $Z = \frac{1}{2}$		1 12)							
rest for overall effect. Z =	1.57 (1 = 0	7.12)							
4.36.7 neuro-cognition	- Rey Aud	ditory Verl	bal Learı	ning					
Crespo-Facorro 2006	45.5	10.82	34	48.59	12.01	27	100.0%	-3.09 [-8.90 , 2.72]	— <del>—</del>
Subtotal (95% CI)			34			27	100.0%	-3.09 [-8.90,2.72]	
Heterogeneity: Not applica	ble								
Test for overall effect: $Z = \frac{1}{2}$		).30)							
1 26 9 noure cognitica	-Brick Ta	nc+ of A++-	ntion						
<b>1.36.8 neuro-cognitior</b> Crespo-Facorro 2006	15.74	3.02	27	16.5	2.98	၁၁	100.0%	-0.76 [-2.45 , 0.93]	
	15.74	3.02		10.5	2.90				
Subtotal (95% CI)	blo		27			22	100.0%	-0.76 [-2.45,0.93]	lacksquare
Heterogeneity: Not applica Fest for overall effect: $Z = 0$		0.38)							
. 35.161 5761411 611661. 2 - (	(1 – 0								
4.36.9 neuro-cognition	_								
Crespo-Facorro 2006	50.07	9.91	28	49.8	8.4		100.0%	0.27 [-5.00 , 5.54]	<b>—</b>
Subtotal (95% CI)			28			19	100.0%	0.27 [-5.00,5.54]	
Heterogeneity: Not applica	ble								$\top$
Test for overall effect: $Z = 0$	).10 (P = 0	).92)							
	n -EAS va	rhal flucs	cytest						
1 36 10 neuro-cognitio			-	27.02	10.24	20	100.00/	506[1104 040]	
4.36.10 neuro-cognitio	32.06	10.89	34	37.92	10.24		100.0%	-5.86 [-11.24 , -0.48]	<del>-</del>
Crespo-Facorro 2006			34			26	100.0%	-5.86 [-11.24,-0.48]	
Crespo-Facorro 2006 Subtotal (95% CI)									•
Crespo-Facorro 2006 Subtotal (95% CI) Heterogeneity: Not applica									
Crespo-Facorro 2006 Subtotal (95% CI)		).03)							
Crespo-Facorro 2006 Subtotal (95% CI) Heterogeneity: Not applica	2.14 (P = 0			)0001) l² –	0%				-20 -10 0 10 2

 $\label{lem:comparison} \begin{tabular}{ll} Comparison 4: COMPARISON HALOPERIDOL\ vs\ OLANZAPINE: SECONDARY\ OUTCOMES,\ Outcome\ 36:\ Functioning:\ 2c.\ Specific\ -cognition\ -\ average\ endpoint\ scores\ -\ medium\ term\ (various\ domains,\ high=good) \end{tabular}$ 

	Halope	eridol	Olanza	apine		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Ishigooka 2001	61	89	58	93	100.0%	1.10 [0.89 , 1.36]	•
Total (95% CI)		89		93	100.0%	1.10 [0.89 , 1.36]	
Total events:	61		58				
Heterogeneity: Not ap	plicable						0.2 0.5 1 2 5
Test for overall effect:	Z = 0.87 (F	P = 0.38					Olanzapine Haloperidol
Test for subgroup diff	erences: No	ot applica	ble				


Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 38: Adverse effects/events: 1a. General - at least one event or effect - short term (various scales)




Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 39: Adverse effects/events: 1b. General - severe enough to cause withdrawal from study

	Halope	ridol	Olanza	pine		Risk Ratio	Risk	Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	IV, Random, 95% CI	IV, Rando	om, 95% CI
4.40.1 needing some antic	holinergic	drugs						
Beasley (E003) 1997	39	81	29	350	17.6%	5.81 [3.84, 8.80]		-
Beasley (HGAD) 1996a	47	69	36	198	19.5%	3.75 [2.68 , 5.25]		-
Chaudhry 2003	40	124	24	139	16.9%	1.87 [1.20 , 2.91]		-
Crespo-Facorro 2006	35	52	2	54	4.7%	18.17 [4.60 , 71.74]		
Lieberman (HGDH) 2003	68	131	23	132	17.8%	2.98 [1.98 , 4.47]		-
Tollefson (HGAJ) 1997	315	660	228	1336	23.4%	2.80 [2.42 , 3.23]		
Subtotal (95% CI)		1117		2209	100.0%	3.47 [2.50 , 4.83]		•
Total events:	544		342					_
Heterogeneity: Tau <sup>2</sup> = 0.12	; Chi <sup>2</sup> = 23.	27, df = 5	5 (P = 0.00)	003); I <sup>2</sup> =	79%			
Test for overall effect: $Z = 7$	.39 (P < 0.0	00001)	`	,.				
4.40.2 needing benzodiaze	anines							
Chaudhry 2003	57	124	59	139	6.1%	1.08 [0.83 , 1.42]		
Crespo-Facorro 2006	11	52	8	54		1.43 [0.62 , 3.27]		Ť
Lahti 2007	1	12	1	17		1.42 [0.10 , 20.49]		<del> </del>
Tollefson (HGAJ) 1997	437	660	808	1336	93.2%	1.09 [1.02 , 1.17]		
Subtotal (95% CI)	407	848	000	1546		1.10 [1.02 , 1.17]		
Total events:	506	040	876	1340	100.0%	1.10 [1.02 , 1.17]		1
Heterogeneity: Tau <sup>2</sup> = 0.00		1 df _ 3		.· I <sup>2</sup> _ ∩º/.				
Test for overall effect: $Z = 2$			(1 = 0.93)	1, 1 = 0 /0				
4 40 2	. 1							
4.40.3 needing propranolo		101	0	100	100.00/	0.06 [0.40, 00.40]		
Lieberman (HGDH) 2003	24	131	3		100.0%	8.06 [2.49 , 26.12]		
Subtotal (95% CI)	0.4	131	•	132	100.0%	8.06 [2.49 , 26.12]		
Total events:	24		3					
Heterogeneity: Not applicat		2005)						
Test for overall effect: $Z = 3$	6.48 (P = 0.0	JUU5)						
Test for subgroup difference	es: Chi² = 0	.00, df =	2 (P < 0.0	00001), I <sup>2</sup>	= 0%		0.01 0.1	1 10 100
							Olanzapine	Haloperidol

Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 40: Adverse effects/events: 2a. General - needing additional medication - short term



Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 41: Adverse effects/events: 2b. General - needing additional medication - medium term



Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 42: Adverse effects/events: 2c General - needing additional medication - long term

Analysis 4.43	

Study or Subgroup	=	idol	Olanza	•		Risk Ratio	Risk Ratio
	Events	Total	Events	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
4 42 1 ahmanni - 1 - : "							
4.43.1 abnormal gait	17	00	0	00	100.00/	0.00 [0.11 07.04]	_
Ishigooka 2001	17	89	2		100.0%		
Subtotal (95% CI)	47	89	0	93	100.0%	8.88 [2.11 , 37.34]	
Total events:	. 17		2				
Heterogeneity: Not applicat Test for overall effect: Z = 2		03)					
1.43.2 akathisia							
Avasthi 2001	5	10	2	17	1.5%	4.25 [1.01 , 17.97]	
Beasley (E003) 1997	12	81	4	350	2.6%	•	
Beasley (HGAD) 1996a	11	69	12	198	5.3%	•	
Bernardo (HGDD) 2001	4	13	1	14	0.7%		<del></del>
Chaudhry 2003	6	124	3	139	1.7%	2.24 [0.57 , 8.78]	<del>                                     </del>
Ding 2013	10	38	0	38		21.00 [1.27 , 346.06]	<del>                                     </del>
HGCU (Taiwan) 1998	5	28	0	26		10.24 [0.59 , 176.56]	
Ishigooka 2001	30	89	10	93			-
	19	62	3	54			
Jiang 2009b Li 2005f	9	30	2	30	1.5%	. , .	<del></del>
Lieberman (HGDH) 2003	67	131	16	132			-
Liu 2012ao Mayaayi 2012	9	39	1	37	0.8%	•	-
Mousavi 2013	2	10	0	10	0.4%	•	-
Qin 2006a	8	40	4	40		• •	+-
Song 2009c	10	50	1	50	0.8%		<del></del>
Tollefson (HGAJ) 1997	149	660	104	1336	58.5%		
Subtotal (95% CI)		1474		2564	100.0%	3.33 [2.79 , 3.98]	♦
Total events:	356		163				
Heterogeneity: $Tau^2 = 0.00$ Test for overall effect: $Z = 1$			5 (P = 0.4	$.5$ ); $I^2 = 0$	1%		
	•	·					
4.43.3 bradykinesia	<b>.</b> -		_		100.00	0.00.00.44 07.04	
Ishigooka 2001	17	89	2		100.0%	•	
Subtotal (95% CI)		89		93	100.0%	8.88 [2.11 , 37.34]	
Total events: Heterogeneity: Not applicat	. 17		2				
<b>4.43.4 dyskinetic moveme</b> Beasley (E003) 1997 Tollefson (HGAJ) 1997	nts 5 15	81 660	2 26	350 1336	26.2% 42.7%	10.80 [2.13 , 54.69] 1.17 [0.62 , 2.19]	
Beasley (E003) 1997	5				42.7%	1.17 [0.62 , 2.19]	
Beasley (E003) 1997 Tollefson (HGAJ) 1997	5 15	660	26	1336	42.7% 31.1%	1.17 [0.62 , 2.19]	+
Beasley (E003) 1997 Tollefson (HGAJ) 1997 Zubair 2020 Subtotal (95% CI)	5 15	660 175	26	1336 175	42.7% 31.1%	1.17 [0.62 , 2.19] 2.67 [0.72 , 9.89]	•
Beasley (E003) 1997 Tollefson (HGAJ) 1997 Zubair 2020 Subtotal (95% CI) Total events: Heterogeneity: Tau <sup>2</sup> = 0.82	5 15 8 28 ; Chi2 = 6.82	660 175 <b>916</b> 2, df = 2	26 3	1336 175 <b>1861</b>	42.7% 31.1% <b>100.0%</b>	1.17 [0.62 , 2.19] 2.67 [0.72 , 9.89]	•
Beasley (E003) 1997 Tollefson (HGAJ) 1997 Zubair 2020	5 15 8 28 ; Chi2 = 6.82	660 175 <b>916</b> 2, df = 2	26 3	1336 175 <b>1861</b>	42.7% 31.1% <b>100.0%</b>	1.17 [0.62 , 2.19] 2.67 [0.72 , 9.89] <b>2.71 [0.79 , 9.28]</b>	•
Beasley (E003) 1997 Tollefson (HGAJ) 1997 Zubair 2020 Subtotal (95% CI) Total events: Heterogeneity: Tau <sup>2</sup> = 0.82 Test for overall effect: Z = 1 4.43.5 dystonia, acute Avasthi 2001	5 15 8 28 ; Chi2 = 6.82	660 175 <b>916</b> 2, df = 2	26 3	1336 175 <b>1861</b>	42.7% 31.1% <b>100.0%</b> 6	1.17 [0.62 , 2.19] 2.67 [0.72 , 9.89] <b>2.71 [0.79 , 9.28]</b> 6.80 [0.88 , 52.68]	•
Beasley (E003) 1997 Tollefson (HGAJ) 1997 Zubair 2020 Subtotal (95% CI) Total events: Heterogeneity: Tau <sup>2</sup> = 0.82 Test for overall effect: Z = 1 4.43.5 dystonia, acute Avasthi 2001	5 15 8 28 ; Chi <sup>2</sup> = 6.82 .58 (P = 0.1	660 175 <b>916</b> 2, df = 2	26 3 31 (P = 0.03)	1336 175 <b>1861</b> ; I <sup>2</sup> = 71%	42.7% 31.1% <b>100.0%</b> 6	1.17 [0.62 , 2.19] 2.67 [0.72 , 9.89] <b>2.71 [0.79 , 9.28]</b>	•
Beasley (E003) 1997 Tollefson (HGAJ) 1997 Zubair 2020 Subtotal (95% CI) Total events: Heterogeneity: Tau <sup>2</sup> = 0.82 Test for overall effect: Z = 1 4.43.5 dystonia, acute Avasthi 2001 Beasley (E003) 1997	5 15 8 28 ; Chi <sup>2</sup> = 6.82 .58 (P = 0.1	660 175 <b>916</b> 2, df = 2 1)	26 3 31 (P = 0.03)	1336 175 <b>1861</b> ; $I^2 = 719$	42.7% 31.1% <b>100.0%</b> 6 13.4% 7.5%	1.17 [0.62 , 2.19] 2.67 [0.72 , 9.89] <b>2.71 [0.79 , 9.28]</b> 6.80 [0.88 , 52.68]	•
Beasley (E003) 1997 Tollefson (HGAJ) 1997 Zubair 2020 Subtotal (95% CI) Total events: Heterogeneity: Tau² = 0.82 Test for overall effect: Z = 1 4.43.5 dystonia, acute Avasthi 2001 Beasley (E003) 1997 Beasley (HGAD) 1996a	5 15 8 28 ; Chi <sup>2</sup> = 6.82 .58 (P = 0.1	660 175 <b>916</b> 2, df = 2 1)	26 3 31 (P = 0.03):	1336 175 <b>1861</b> ; I <sup>2</sup> = 719	42.7% 31.1% <b>100.0%</b> % 13.4% 7.5% 7.8%	1.17 [0.62 , 2.19] 2.67 [0.72 , 9.89] <b>2.71 [0.79 , 9.28]</b> 6.80 [0.88 , 52.68] 38.52 [2.09 , 708.48]	
Beasley (E003) 1997 Tollefson (HGAJ) 1997 Zubair 2020 Subtotal (95% CI) Total events: Heterogeneity: Tau² = 0.82 Test for overall effect: Z = 1 4.43.5 dystonia, acute Avasthi 2001 Beasley (E003) 1997 Beasley (HGAD) 1996a Chaudhry 2003	5 15 8 28 ; Chi <sup>2</sup> = 6.82 .58 (P = 0.1	660 175 <b>916</b> 2, df = 2 1)	26 3 31 (P = 0.03):	1336 175 <b>1861</b> ; $ ^2 = 71^\circ$ 17 350 198	42.7% 31.1% <b>100.0%</b> % 13.4% 7.5% 7.8% 7.7%	1.17 [0.62 , 2.19] 2.67 [0.72 , 9.89] <b>2.71 [0.79 , 9.28]</b> 6.80 [0.88 , 52.68] 38.52 [2.09 , 708.48] 54.01 [3.19 , 915.98]	
Beasley (E003) 1997 Tollefson (HGAJ) 1997 Zubair 2020 Subtotal (95% CI) Total events: Heterogeneity: Tau² = 0.82 Test for overall effect: Z = 1 4.43.5 dystonia, acute Avasthi 2001 Beasley (E003) 1997 Beasley (HGAD) 1996a Chaudhry 2003 Ding 2013	5 15 8 28 ; Chi <sup>2</sup> = 6.82 .58 (P = 0.1	660 175 <b>916</b> 2, df = 2 1) 10 81 69 124	26 3 31 (P = 0.03): 1 0 0	1336 175 <b>1861</b> ;   <sup>2</sup> = 71% 17 350 198 139	42.7% 31.1% <b>100.0%</b> 6 13.4% 7.5% 7.8% 7.7% 8.0%	1.17 [0.62 , 2.19] 2.67 [0.72 , 9.89] <b>2.71 [0.79 , 9.28]</b> 6.80 [0.88 , 52.68] 38.52 [2.09 , 708.48] 54.01 [3.19 , 915.98] 14.56 [0.83 , 255.85]	
Beasley (E003) 1997 Tollefson (HGAJ) 1997 Zubair 2020 Subtotal (95% CI) Total events: Heterogeneity: Tau² = 0.82 Test for overall effect: Z = 1 4.43.5 dystonia, acute Avasthi 2001 Beasley (E003) 1997 Beasley (HGAD) 1996a Chaudhry 2003 Ding 2013 Kinon 2004	5 15 8 28 ; Chi <sup>2</sup> = 6.82 .58 (P = 0.1	660 175 <b>916</b> 2, df = 2 1) 10 81 69 124 38	26 3 31 (P = 0.03): 1 0 0 0	1336 175 <b>1861</b> ;   <sup>2</sup> = 719 17 350 198 139 38	42.7% 31.1% <b>100.0%</b> 6 13.4% 7.5% 7.8% 7.7% 8.0% 7.5%	1.17 [0.62 , 2.19] 2.67 [0.72 , 9.89] <b>2.71 [0.79 , 9.28]</b> 6.80 [0.88 , 52.68] 38.52 [2.09 , 708.48] 54.01 [3.19 , 915.98] 14.56 [0.83 , 255.85] 25.00 [1.53 , 407.69] 9.73 [0.54 , 176.18]	
Beasley (E003) 1997 Tollefson (HGAJ) 1997 Zubair 2020 Subtotal (95% CI) Total events: Heterogeneity: Tau <sup>2</sup> = 0.82 Test for overall effect: Z = 1	5 15 8 28 ; Chi <sup>2</sup> = 6.82 .58 (P = 0.1	660 175 <b>916</b> 2, df = 2 1) 10 81 69 124 38 48	26 3 31 (P = 0.03): 1 0 0 0	1336 175 <b>1861</b> ;   <sup>2</sup> = 719 17 350 198 139 38 52	42.7% 31.1% <b>100.0%</b> 6 13.4% 7.5% 7.8% 7.7% 8.0% 7.5% 48.1%	1.17 [0.62 , 2.19] 2.67 [0.72 , 9.89] 2.71 [0.79 , 9.28] 6.80 [0.88 , 52.68] 38.52 [2.09 , 708.48] 54.01 [3.19 , 915.98] 14.56 [0.83 , 255.85] 25.00 [1.53 , 407.69] 9.73 [0.54 , 176.18] 3.73 [2.15 , 6.47]	*
Beasley (E003) 1997 Tollefson (HGAJ) 1997 Zubair 2020 <b>Subtotal (95% CI)</b> Total events: Heterogeneity: Tau² = 0.82 Test for overall effect: Z = 1 <b>4.43.5 dystonia, acute</b> Avasthi 2001 Beasley (E003) 1997 Beasley (HGAD) 1996a Chaudhry 2003 Ding 2013 Kinon 2004 Tollefson (HGAJ) 1997	5 15 8 28 ; Chi <sup>2</sup> = 6.82 .58 (P = 0.1	660 175 <b>916</b> 2, df = 2 1) 10 81 69 124 38 48 660	26 3 31 (P = 0.03): 1 0 0 0	1336 175 <b>1861</b> ;   <sup>2</sup> = 71°, 17 350 198 139 38 52 1336	42.7% 31.1% <b>100.0%</b> 6 13.4% 7.5% 7.8% 7.7% 8.0% 7.5% 48.1%	1.17 [0.62 , 2.19] 2.67 [0.72 , 9.89] 2.71 [0.79 , 9.28] 6.80 [0.88 , 52.68] 38.52 [2.09 , 708.48] 54.01 [3.19 , 915.98] 14.56 [0.83 , 255.85] 25.00 [1.53 , 407.69] 9.73 [0.54 , 176.18] 3.73 [2.15 , 6.47]	**************************************
Beasley (E003) 1997 Tollefson (HGAJ) 1997 Zubair 2020 Subtotal (95% CI) Total events: Heterogeneity: Tau² = 0.82 Test for overall effect: Z = 1  4.43.5 dystonia, acute Avasthi 2001 Beasley (E003) 1997 Beasley (HGAD) 1996a Chaudhry 2003 Ding 2013 Kinon 2004 Tollefson (HGAJ) 1997 Subtotal (95% CI) Total events: Heterogeneity: Tau² = 0.31	$5$ $15$ $8$ $28$ $; Chi^2 = 6.82$ $.58 (P = 0.1)$ $4$ $4$ $9$ $6$ $12$ $4$ $35$ $74$ $; Chi^2 = 7.79$	660 175 <b>916</b> 2, df = 2 1) 10 81 69 124 38 48 660 <b>1030</b> 0, df = 6	26 3 31 (P = 0.03): 1 0 0 0 0 0 19	1336 175 <b>1861</b> ;   <sup>2</sup> = 71°, 17 350 198 139 38 52 1336 <b>2130</b>	42.7% 31.1% 100.0% 6 13.4% 7.5% 7.8% 7.7% 8.0% 7.5% 48.1% 100.0%	1.17 [0.62 , 2.19] 2.67 [0.72 , 9.89] 2.71 [0.79 , 9.28] 6.80 [0.88 , 52.68] 38.52 [2.09 , 708.48] 54.01 [3.19 , 915.98] 14.56 [0.83 , 255.85] 25.00 [1.53 , 407.69] 9.73 [0.54 , 176.18] 3.73 [2.15 , 6.47]	**************************************
Beasley (E003) 1997 Tollefson (HGAJ) 1997 Zubair 2020 Subtotal (95% CI) Total events: Heterogeneity: Tau² = 0.82 Test for overall effect: Z = 1  4.43.5 dystonia, acute Avasthi 2001 Beasley (E003) 1997 Beasley (HGAD) 1996a Chaudhry 2003 Ding 2013 Kinon 2004 Tollefson (HGAJ) 1997 Subtotal (95% CI) Total events:	$5$ $15$ $8$ $28$ $; Chi^2 = 6.82$ $.58 (P = 0.1)$ $4$ $4$ $9$ $6$ $12$ $4$ $35$ $74$ $; Chi^2 = 7.79$	660 175 <b>916</b> 2, df = 2 1) 10 81 69 124 38 48 660 <b>1030</b> 0, df = 6	26 3 31 (P = 0.03): 1 0 0 0 0 0 19	1336 175 <b>1861</b> ;   <sup>2</sup> = 71°, 17 350 198 139 38 52 1336 <b>2130</b>	42.7% 31.1% 100.0% 6 13.4% 7.5% 7.8% 7.7% 8.0% 7.5% 48.1% 100.0%	1.17 [0.62 , 2.19] 2.67 [0.72 , 9.89] 2.71 [0.79 , 9.28] 6.80 [0.88 , 52.68] 38.52 [2.09 , 708.48] 54.01 [3.19 , 915.98] 14.56 [0.83 , 255.85] 25.00 [1.53 , 407.69] 9.73 [0.54 , 176.18] 3.73 [2.15 , 6.47]	
Beasley (E003) 1997 Tollefson (HGAJ) 1997 Zubair 2020 Subtotal (95% CI) Total events: Heterogeneity: Tau² = 0.82 Test for overall effect: Z = 1 4.43.5 dystonia, acute Avasthi 2001 Beasley (E003) 1997 Beasley (HGAD) 1996a Chaudhry 2003 Ding 2013 Kinon 2004 Tollefson (HGAJ) 1997 Subtotal (95% CI) Total events: Heterogeneity: Tau² = 0.31 Test for overall effect: Z = 4	$5$ $15$ $8$ $28$ $; Chi^2 = 6.82$ $.58 (P = 0.1)$ $4$ $4$ $9$ $6$ $12$ $4$ $35$ $74$ $; Chi^2 = 7.79$	660 175 <b>916</b> 2, df = 2 1) 10 81 69 124 38 48 660 <b>1030</b> 0, df = 6	26 3 31 (P = 0.03): 1 0 0 0 0 0 19	1336 175 <b>1861</b> ;   <sup>2</sup> = 71°, 17 350 198 139 38 52 1336 <b>2130</b>	42.7% 31.1% 100.0% 6 13.4% 7.5% 7.8% 7.7% 8.0% 7.5% 48.1% 100.0%	1.17 [0.62 , 2.19] 2.67 [0.72 , 9.89] 2.71 [0.79 , 9.28] 6.80 [0.88 , 52.68] 38.52 [2.09 , 708.48] 54.01 [3.19 , 915.98] 14.56 [0.83 , 255.85] 25.00 [1.53 , 407.69] 9.73 [0.54 , 176.18] 3.73 [2.15 , 6.47]	*
Beasley (E003) 1997 Tollefson (HGAJ) 1997 Zubair 2020 Subtotal (95% CI) Total events: Heterogeneity: Tau² = 0.82 Test for overall effect: Z = 1 4.43.5 dystonia, acute Avasthi 2001 Beasley (E003) 1997 Beasley (HGAD) 1996a Chaudhry 2003 Ding 2013 Kinon 2004 Tollefson (HGAJ) 1997 Subtotal (95% CI) Total events: Heterogeneity: Tau² = 0.31 Test for overall effect: Z = 4	$5$ $15$ $8$ $28$ $; Chi^2 = 6.82$ $.58 (P = 0.1)$ $4$ $4$ $9$ $6$ $12$ $4$ $35$ $74$ $; Chi^2 = 7.79$	660 175 <b>916</b> 2, df = 2 1) 10 81 69 124 38 48 660 <b>1030</b> 0, df = 6	26 3 31 (P = 0.03): 1 0 0 0 0 0 19	1336 175 <b>1861</b> ;   <sup>2</sup> = 71°, 17 350 198 139 38 52 1336 <b>2130</b>	42.7% 31.1% 100.0% 6 13.4% 7.5% 7.7% 8.0% 7.5% 48.1% 100.0%	1.17 [0.62 , 2.19] 2.67 [0.72 , 9.89] 2.71 [0.79 , 9.28] 6.80 [0.88 , 52.68] 38.52 [2.09 , 708.48] 54.01 [3.19 , 915.98] 14.56 [0.83 , 255.85] 25.00 [1.53 , 407.69] 9.73 [0.54 , 176.18] 3.73 [2.15 , 6.47] 8.25 [3.53 , 19.29]	*
Beasley (E003) 1997 Tollefson (HGAJ) 1997 Zubair 2020 Subtotal (95% CI) Total events: Heterogeneity: Tau² = 0.82 Test for overall effect: Z = 1  4.43.5 dystonia, acute Avasthi 2001 Beasley (E003) 1997 Beasley (HGAD) 1996a Chaudhry 2003 Ding 2013 Kinon 2004 Tollefson (HGAJ) 1997 Subtotal (95% CI) Total events: Heterogeneity: Tau² = 0.31	5 15 8 28 ; Chi <sup>2</sup> = 6.82 .58 (P = 0.1 4 4 9 6 12 4 35 74 ; Chi <sup>2</sup> = 7.79 .87 (P < 0.0	660 175 <b>916</b> 2, df = 2 1) 10 81 69 124 38 48 660 <b>1030</b> 0, df = 6	26 3 31 (P = 0.03); 1 0 0 0 0 0 19 20 (P = 0.25);	1336 175 <b>1861</b> ;   <sup>2</sup> = 719 17 350 198 139 38 52 1336 <b>2130</b> ;   <sup>2</sup> = 239	42.7% 31.1% 100.0% 6 13.4% 7.5% 7.7% 8.0% 7.5% 48.1% 100.0%	1.17 [0.62 , 2.19] 2.67 [0.72 , 9.89] 2.71 [0.79 , 9.28] 6.80 [0.88 , 52.68] 38.52 [2.09 , 708.48] 54.01 [3.19 , 915.98] 14.56 [0.83 , 255.85] 25.00 [1.53 , 407.69] 9.73 [0.54 , 176.18] 3.73 [2.15 , 6.47] 8.25 [3.53 , 19.29]	
Beasley (E003) 1997 Tollefson (HGAJ) 1997 Zubair 2020 Subtotal (95% CI) Total events: Heterogeneity: Tau² = 0.82 Test for overall effect: Z = 1 4.43.5 dystonia, acute Avasthi 2001 Beasley (E003) 1997 Beasley (HGAD) 1996a Chaudhry 2003 Ding 2013 Kinon 2004 Tollefson (HGAJ) 1997 Subtotal (95% CI) Total events: Heterogeneity: Tau² = 0.31 Test for overall effect: Z = 4 4.43.6 hypertonia Beasley (E003) 1997 Beasley (HGAD) 1996a	5 15 8 28 ; Chi <sup>2</sup> = 6.82 .58 (P = 0.1 4 4 9 6 12 4 35 74 ; Chi <sup>2</sup> = 7.79 .87 (P < 0.0	660 175 <b>916</b> 2, df = 2 1) 10 81 69 124 38 48 660 <b>1030</b> 0, df = 6 0001)	26 3 31 (P = 0.03); 1 0 0 0 0 0 19 20 (P = 0.25);	1336 175 <b>1861</b> 177 1861 177 350 198 139 38 52 1336 <b>2130</b> 12 = 239	42.7% 31.1% 100.0% 6 13.4% 7.5% 7.7% 8.0% 7.5% 48.1% 100.0%	1.17 [0.62 , 2.19] 2.67 [0.72 , 9.89] 2.71 [0.79 , 9.28] 6.80 [0.88 , 52.68] 38.52 [2.09 , 708.48] 54.01 [3.19 , 915.98] 14.56 [0.83 , 255.85] 25.00 [1.53 , 407.69] 9.73 [0.54 , 176.18] 3.73 [2.15 , 6.47] 8.25 [3.53 , 19.29]	*
Beasley (E003) 1997 Tollefson (HGAJ) 1997 Zubair 2020 Subtotal (95% CI) Total events: Heterogeneity: Tau² = 0.82 Test for overall effect: Z = 1 4.43.5 dystonia, acute Avasthi 2001 Beasley (E003) 1997 Beasley (HGAD) 1996a Chaudhry 2003 Ding 2013 Kinon 2004 Tollefson (HGAJ) 1997 Subtotal (95% CI) Total events: Heterogeneity: Tau² = 0.31 Test for overall effect: Z = 4 4.43.6 hypertonia Beasley (E003) 1997	5 15 8 28 ; Chi <sup>2</sup> = 6.82 .58 (P = 0.1 4 4 9 6 12 4 35 74 ; Chi <sup>2</sup> = 7.79 .87 (P < 0.0	660 175 <b>916</b> 2, df = 2 1) 10 81 69 124 38 48 660 <b>1030</b> 0, df = 6 0001)	26 3 31 (P = 0.03); 1 0 0 0 0 0 19 20 (P = 0.25);	1336 175 <b>1861</b> 177 1861 177 350 198 139 38 52 1336 <b>2130</b> 18 18 2130	42.7% 31.1% 100.0% 6 13.4% 7.5% 7.8% 7.7% 8.0% 7.5% 48.1% 100.0% 6	1.17 [0.62 , 2.19] 2.67 [0.72 , 9.89] 2.71 [0.79 , 9.28] 6.80 [0.88 , 52.68] 38.52 [2.09 , 708.48] 54.01 [3.19 , 915.98] 14.56 [0.83 , 255.85] 25.00 [1.53 , 407.69] 9.73 [0.54 , 176.18] 3.73 [2.15 , 6.47] 8.25 [3.53 , 19.29] 11.52 [3.13 , 42.48] 4.43 [2.19 , 8.99] 6.50 [0.86 , 49.30]	*
Beasley (E003) 1997 Tollefson (HGAJ) 1997 Zubair 2020 Subtotal (95% CI) Total events: Heterogeneity: Tau² = 0.82 Test for overall effect: Z = 1 4.43.5 dystonia, acute Avasthi 2001 Beasley (E003) 1997 Beasley (HGAD) 1996a Chaudhry 2003 Ding 2013 Kinon 2004 Tollefson (HGAJ) 1997 Subtotal (95% CI) Total events: Heterogeneity: Tau² = 0.31 Test for overall effect: Z = 4 4.43.6 hypertonia Beasley (E003) 1997 Beasley (HGAD) 1996a HGCU (Taiwan) 1998 Kinon 2004	5 15 8 28 ; Chi <sup>2</sup> = 6.82 .58 (P = 0.1 4 4 9 6 12 4 35 74 ; Chi <sup>2</sup> = 7.79 .87 (P < 0.0	660 175 <b>916</b> 2, df = 2 1) 10 81 69 124 38 48 660 <b>1030</b> 0, df = 6 0001)	26 3 31 (P = 0.03); 1 0 0 0 0 0 19 20 (P = 0.25); 3 11 1	1336 175 1861 175 1861 177 350 198 139 38 52 1336 2130 192 239 350 198 26 52	42.7% 31.1% 100.0% 6 13.4% 7.5% 7.7% 8.0% 7.5% 48.1% 100.0% 6	1.17 [0.62 , 2.19] 2.67 [0.72 , 9.89] 2.71 [0.79 , 9.28] 6.80 [0.88 , 52.68] 38.52 [2.09 , 708.48] 54.01 [3.19 , 915.98] 14.56 [0.83 , 255.85] 25.00 [1.53 , 407.69] 9.73 [0.54 , 176.18] 3.73 [2.15 , 6.47] 8.25 [3.53 , 19.29] 11.52 [3.13 , 42.48] 4.43 [2.19 , 8.99] 6.50 [0.86 , 49.30] 9.73 [0.54 , 176.18]	*
Beasley (E003) 1997 Tollefson (HGAJ) 1997 Zubair 2020 Subtotal (95% CI) Total events: Heterogeneity: Tau² = 0.82 Test for overall effect: Z = 1 4.43.5 dystonia, acute Avasthi 2001 Beasley (E003) 1997 Beasley (HGAD) 1996a Chaudhry 2003 Ding 2013 Kinon 2004 Tollefson (HGAJ) 1997 Subtotal (95% CI) Total events: Heterogeneity: Tau² = 0.31 Test for overall effect: Z = 4 4.43.6 hypertonia Beasley (E003) 1997 Beasley (HGAD) 1996a HGCU (Taiwan) 1998 Kinon 2004 Song 2009c	5 15 8 28 ; Chi <sup>2</sup> = 6.82 .58 (P = 0.1 4 4 9 6 12 4 35 74 ; Chi <sup>2</sup> = 7.79 8.87 (P < 0.0	660 175 <b>916</b> 2, df = 2 1) 10 81 69 124 38 48 660 <b>1030</b> 0, df = 6 0001)	26 3 31 (P = 0.03); 1 0 0 0 0 0 19 20 (P = 0.25); 3 11 1 0 0	1336 175 <b>1861</b> 177 1861 177 350 198 139 38 52 1336 <b>2130</b> 198 219 350 198 26 52 50	42.7% 31.1% 100.0% 6 13.4% 7.5% 7.8% 7.7% 8.0% 7.5% 48.1% 100.0% 6	1.17 [0.62 , 2.19] 2.67 [0.72 , 9.89] 2.71 [0.79 , 9.28] 6.80 [0.88 , 52.68] 38.52 [2.09 , 708.48] 54.01 [3.19 , 915.98] 14.56 [0.83 , 255.85] 25.00 [1.53 , 407.69] 9.73 [0.54 , 176.18] 3.73 [2.15 , 6.47] 8.25 [3.53 , 19.29] 11.52 [3.13 , 42.48] 4.43 [2.19 , 8.99] 6.50 [0.86 , 49.30] 9.73 [0.54 , 176.18] 11.00 [0.62 , 193.80]	
Beasley (E003) 1997 Tollefson (HGAJ) 1997 Zubair 2020 Subtotal (95% CI) Total events: Heterogeneity: Tau² = 0.82 Test for overall effect: Z = 1 4.43.5 dystonia, acute Avasthi 2001 Beasley (E003) 1997 Beasley (HGAD) 1996a Chaudhry 2003 Ding 2013 Kinon 2004 Tollefson (HGAJ) 1997 Subtotal (95% CI) Total events: Heterogeneity: Tau² = 0.31 Test for overall effect: Z = 4 4.43.6 hypertonia Beasley (E003) 1997 Beasley (HGAD) 1996a HGCU (Taiwan) 1998 Kinon 2004 Song 2009c Tollefson (HGAJ) 1997	5 15 8 28 ; Chi <sup>2</sup> = 6.82 .58 (P = 0.1 4 4 9 6 12 4 35 74 ; Chi <sup>2</sup> = 7.79 .87 (P < 0.0	660 175 <b>916</b> 2, df = 2 1) 10 81 69 124 38 48 660 <b>1030</b> 0, df = 6 0001)	26 3 31 (P = 0.03); 1 0 0 0 0 0 19 20 (P = 0.25); 3 11 1	1336 175 1861 177 1861 177 350 198 139 38 52 1336 2130 198 2130 198 2130 198 2130 198 2130 198 2130 198 2130 213	42.7% 31.1% 100.0% 6 13.4% 7.5% 7.8% 7.7% 8.0% 7.5% 48.1% 100.0% 6 15.8% 27.6% 8.5% 4.7% 4.7% 38.6%	1.17 [0.62 , 2.19] 2.67 [0.72 , 9.89] 2.71 [0.79 , 9.28] 6.80 [0.88 , 52.68] 38.52 [2.09 , 708.48] 54.01 [3.19 , 915.98] 14.56 [0.83 , 255.85] 25.00 [1.53 , 407.69] 9.73 [0.54 , 176.18] 3.73 [2.15 , 6.47] 8.25 [3.53 , 19.29] 11.52 [3.13 , 42.48] 4.43 [2.19 , 8.99] 6.50 [0.86 , 49.30] 9.73 [0.54 , 176.18] 11.00 [0.62 , 193.80] 2.28 [1.86 , 2.81]	
Beasley (E003) 1997 Tollefson (HGAJ) 1997 Zubair 2020 Subtotal (95% CI) Total events: Heterogeneity: Tau² = 0.82 Test for overall effect: Z = 1 4.43.5 dystonia, acute Avasthi 2001 Beasley (E003) 1997 Beasley (HGAD) 1996a Chaudhry 2003 Ding 2013 Kinon 2004 Tollefson (HGAJ) 1997 Subtotal (95% CI) Total events: Heterogeneity: Tau² = 0.31 Test for overall effect: Z = 4 4.43.6 hypertonia Beasley (E003) 1997 Beasley (HGAD) 1996a HGCU (Taiwan) 1998 Kinon 2004 Song 2009c Tollefson (HGAJ) 1997 Subtotal (95% CI)	5 15 8 28 ; Chi <sup>2</sup> = 6.82 .58 (P = 0.1 4 4 9 6 12 4 35 74 ; Chi <sup>2</sup> = 7.79 8.87 (P < 0.0	660 175 <b>916</b> 2, df = 2 1) 10 81 69 124 38 48 660 <b>1030</b> 0, df = 6 0001)	26 3 31 (P = 0.03); 1 0 0 0 0 0 19 20 (P = 0.25); 3 11 1 0 0	1336 175 <b>1861</b> 177 1861 177 350 198 139 38 52 1336 <b>2130</b> 198 219 350 198 26 52 50	42.7% 31.1% 100.0% 6 13.4% 7.5% 7.8% 7.7% 8.0% 7.5% 48.1% 100.0% 6 15.8% 27.6% 8.5% 4.7% 4.7% 38.6%	1.17 [0.62 , 2.19] 2.67 [0.72 , 9.89] 2.71 [0.79 , 9.28] 6.80 [0.88 , 52.68] 38.52 [2.09 , 708.48] 54.01 [3.19 , 915.98] 14.56 [0.83 , 255.85] 25.00 [1.53 , 407.69] 9.73 [0.54 , 176.18] 3.73 [2.15 , 6.47] 8.25 [3.53 , 19.29] 11.52 [3.13 , 42.48] 4.43 [2.19 , 8.99] 6.50 [0.86 , 49.30] 9.73 [0.54 , 176.18] 11.00 [0.62 , 193.80] 2.28 [1.86 , 2.81]	*
Beasley (E003) 1997 Tollefson (HGAJ) 1997 Zubair 2020 Subtotal (95% CI) Total events: Heterogeneity: Tau² = 0.82 Test for overall effect: Z = 1 4.43.5 dystonia, acute Avasthi 2001 Beasley (E003) 1997 Beasley (HGAD) 1996a Chaudhry 2003 Ding 2013 Kinon 2004 Tollefson (HGAJ) 1997 Subtotal (95% CI) Total events: Heterogeneity: Tau² = 0.31 Test for overall effect: Z = 4 4.43.6 hypertonia Beasley (E003) 1997 Beasley (HGAD) 1996a HGCU (Taiwan) 1998 Kinon 2004 Song 2009c Tollefson (HGAJ) 1997 Subtotal (95% CI) Total events:	5 15 8 28 ; Chi <sup>2</sup> = 6.82 .58 (P = 0.1 4 4 9 6 12 4 35 74 ; Chi <sup>2</sup> = 7.79 .87 (P < 0.0	660 175 <b>916</b> 2, df = 2 1) 10 81 69 124 38 48 660 <b>1030</b> 0, df = 6 0001) 81 69 28 48 50 660 <b>936</b>	26 3 31 (P = 0.03); 1 0 0 0 0 0 19 20 (P = 0.25); 3 11 1 0 0 140	1336 175 1861 175 1861 177 350 198 139 38 52 1336 2130 198 26 52 50 1336 2012	42.7% 31.1% 100.0%  13.4% 7.5% 7.8% 7.7% 8.0% 7.5% 48.1% 100.0%  6  15.8% 27.6% 8.5% 4.7% 38.6% 100.0%	1.17 [0.62 , 2.19] 2.67 [0.72 , 9.89] 2.71 [0.79 , 9.28] 6.80 [0.88 , 52.68] 38.52 [2.09 , 708.48] 54.01 [3.19 , 915.98] 14.56 [0.83 , 255.85] 25.00 [1.53 , 407.69] 9.73 [0.54 , 176.18] 3.73 [2.15 , 6.47] 8.25 [3.53 , 19.29] 11.52 [3.13 , 42.48] 4.43 [2.19 , 8.99] 6.50 [0.86 , 49.30] 9.73 [0.54 , 176.18] 11.00 [0.62 , 193.80] 2.28 [1.86 , 2.81]	*
Beasley (E003) 1997 Tollefson (HGAJ) 1997 Zubair 2020 Subtotal (95% CI) Total events: Heterogeneity: Tau² = 0.82 Test for overall effect: Z = 1 4.43.5 dystonia, acute Avasthi 2001 Beasley (E003) 1997 Beasley (HGAD) 1996a Chaudhry 2003 Ding 2013 Kinon 2004 Tollefson (HGAJ) 1997 Subtotal (95% CI) Total events: Heterogeneity: Tau² = 0.31 Test for overall effect: Z = 4 4.43.6 hypertonia Beasley (E003) 1997 Beasley (HGAD) 1996a HGCU (Taiwan) 1998	5 15 8 28 ; Chi <sup>2</sup> = 6.82 .58 (P = 0.1 4 4 9 6 12 4 35 74 ; Chi <sup>2</sup> = 7.79 8.87 (P < 0.0	660 175 916 2, df = 2 1) 10 81 69 124 38 48 660 1030 0, df = 6 0001) 81 69 28 48 50 660 936	26 3 31 (P = 0.03); 1 0 0 0 0 0 19 20 (P = 0.25); 3 11 1 0 0 140	1336 175 1861 175 1861 177 350 198 139 38 52 1336 2130 198 26 52 50 1336 2012	42.7% 31.1% 100.0%  13.4% 7.5% 7.8% 7.7% 8.0% 7.5% 48.1% 100.0%  6  15.8% 27.6% 8.5% 4.7% 38.6% 100.0%	1.17 [0.62 , 2.19] 2.67 [0.72 , 9.89] 2.71 [0.79 , 9.28] 6.80 [0.88 , 52.68] 38.52 [2.09 , 708.48] 54.01 [3.19 , 915.98] 14.56 [0.83 , 255.85] 25.00 [1.53 , 407.69] 9.73 [0.54 , 176.18] 3.73 [2.15 , 6.47] 8.25 [3.53 , 19.29] 11.52 [3.13 , 42.48] 4.43 [2.19 , 8.99] 6.50 [0.86 , 49.30] 9.73 [0.54 , 176.18] 11.00 [0.62 , 193.80] 2.28 [1.86 , 2.81]	

vasthi 2001 ollefson (HGAJ) 1997	5 110	10 660	2 97	17 1336	3.1% 96.9%	4.25 [1.01 , 17.97] 2.30 [1.78 , 2.97]		_
ubtotal (95% CI)	110	670	97	1353	100.0%			
otal events:	115	670	99	1333	100.0%	2.34 [1.82 , 3.01]		♥
leterogeneity: Tau <sup>2</sup> = 0.00; 0		df – 1 (P		I <sup>2</sup> – 0%				
est for overall effect: $Z = 6.5$			- 0.41),	1 - 070				
.43.8 myotonia								
iang 2009b	27	62	5	54	67.8%	4.70 [1.95 , 11.36]		_
i 2005f	13	30	2	30	26.9%	6.50 [1.60 , 26.36]		
in 2006a	1	40	0	40	5.2%	3.00 [0.13 , 71.51]		
ubtotal (95% CI)		132		124	100.0%	5.01 [2.42, 10.36]		•
otal events:	41		7					_
leterogeneity: $Tau^2 = 0.00$ ; Coest for overall effect: $Z = 4.3$			= 0.88);	I <sup>2</sup> = 0%				
.43.9 parkinsonism	0	10	4	4.4	1 50/	0.40 [0.00 40.70]		
ernardo (HGDD) 2001	6 72	13 131	1 34	14	1.5%	6.46 [0.89 , 46.70]		<u> </u>
ieberman (HGDH) 2003	72 177	660	34 128	132	36.6%	2.13 [1.54 , 2.96]		<del>*</del> _
ollefson (HGAJ) 1997 ubtotal (95% CI)	177	804	120	1336	62.0% <b>100.0%</b>	2.80 [2.27 , 3.44]		
otal events:	255	004	163	1402	100.0%	2.57 [2.02 , 3.26]		♥
otar events. leterogeneity: Tau² = 0.01; (		df _ 2 (D		12 _ 26%				
est for overall effect: $Z = 7.6$			,,					
.43.10 rigidity								
vasthi 2001	8	10	2	17	100.0%	6.80 [1.78 , 25.92]		
ubtotal (95% CI)		10		17	100.0%	6.80 [1.78 , 25.92]		
otal events:	8		2					
leterogeneity: Not applicable $f$ est for overall effect: $Z = 2.8$		05)						
		05)						
est for overall effect: Z = 2.8		10	6	17	12.5%	1.98 [0.93 , 4.24]		
est for overall effect: $Z = 2.8$ <b>.43.11 tremor</b>	31 (P = 0.00	·	6 2	17 350	12.5% 5.3%	1.98 [0.93 , 4.24] 19.44 [4.28 , 88.28]		
est for overall effect: Z = 2.8  .43.11 tremor  .vasthi 2001	31 (P = 0.00 7	10						-
est for overall effect: Z = 2.8  .43.11 tremor  .vasthi 2001  easley (E003) 1997	7 9	10 81	2	350	5.3%	19.44 [4.28 , 88.28]		- <u>-</u> -
est for overall effect: Z = 2.8  43.11 tremor  vasthi 2001  easley (E003) 1997  easley (HGAD) 1996a	7 9 10	10 81 69	2 7	350 198	5.3% 10.3% 11.9%	19.44 [4.28 , 88.28] 4.10 [1.62 , 10.35]		   
est for overall effect: Z = 2.8  43.11 tremor  vasthi 2001  easley (E003) 1997  easley (HGAD) 1996a  chaudhry 2003	7 9 10 17	10 81 69 124	2 7 8	350 198 139	5.3% 10.3% 11.9%	19.44 [4.28 , 88.28] 4.10 [1.62 , 10.35] 2.38 [1.07 , 5.33]		
est for overall effect: Z = 2.8  43.11 tremor  vasthi 2001  leasley (E003) 1997  leasley (HGAD) 1996a  chaudhry 2003  ling 2013	7 9 10 17 13	10 81 69 124 38 28	2 7 8 0	350 198 139 38	5.3% 10.3% 11.9% 1.9%	19.44 [4.28 , 88.28] 4.10 [1.62 , 10.35] 2.38 [1.07 , 5.33] 27.00 [1.66 , 438.51]	-	- - - - - - -
est for overall effect: Z = 2.8  43.11 tremor  vasthi 2001  leasley (E003) 1997  leasley (HGAD) 1996a  chaudhry 2003  bing 2013  IGCU (Taiwan) 1998  shigooka 2001  liang 2009b	7 9 10 17 13 5 27 20	10 81 69 124 38 28 89 62	2 7 8 0 1	350 198 139 38 26 93 54	5.3% 10.3% 11.9% 1.9% 3.2% 11.4% 6.0%	19.44 [4.28 , 88.28] 4.10 [1.62 , 10.35] 2.38 [1.07 , 5.33] 27.00 [1.66 , 438.51] 4.64 [0.58 , 37.15] 4.70 [2.04 , 10.84] 8.71 [2.13 , 35.57]	_	
est for overall effect: Z = 2.8  43.11 tremor  vasthi 2001  leasley (E003) 1997  leasley (HGAD) 1996a  chaudhry 2003  bing 2013  IGCU (Taiwan) 1998  shigooka 2001  liang 2009b  i 2005f	7 9 10 17 13 5 27 20 10	10 81 69 124 38 28	2 7 8 0 1 6	350 198 139 38 26 93	5.3% 10.3% 11.9% 1.9% 3.2% 11.4%	19.44 [4.28 , 88.28] 4.10 [1.62 , 10.35] 2.38 [1.07 , 5.33] 27.00 [1.66 , 438.51] 4.64 [0.58 , 37.15] 4.70 [2.04 , 10.84] 8.71 [2.13 , 35.57] 10.00 [1.36 , 73.33]	_	
est for overall effect: Z = 2.8  .43.11 tremor  .vasthi 2001  .easley (E003) 1997  .easley (HGAD) 1996a  .chaudhry 2003  .chaudhry 2003  .chaudhry 2013  .chaudhry 2013  .chaudhry 2001  .chaudhry 2009b  .chaudhry 2009b  .chaudhry 2006a	7 9 10 17 13 5 27 20	10 81 69 124 38 28 89 62	2 7 8 0 1 6 2	350 198 139 38 26 93 54	5.3% 10.3% 11.9% 1.9% 3.2% 11.4% 6.0% 3.4% 1.6%	19.44 [4.28 , 88.28] 4.10 [1.62 , 10.35] 2.38 [1.07 , 5.33] 27.00 [1.66 , 438.51] 4.64 [0.58 , 37.15] 4.70 [2.04 , 10.84] 8.71 [2.13 , 35.57] 10.00 [1.36 , 73.33] 5.00 [0.25 , 100.97]	_	
est for overall effect: Z = 2.8  43.11 tremor  vasthi 2001  leasley (E003) 1997  leasley (HGAD) 1996a  chaudhry 2003  bing 2013  IGCU (Taiwan) 1998  shigooka 2001  liang 2009b  i 2005f	7 9 10 17 13 5 27 20 10 2 11	10 81 69 124 38 28 89 62 30	2 7 8 0 1 6 2	350 198 139 38 26 93 54 30	5.3% 10.3% 11.9% 1.9% 3.2% 11.4% 6.0% 3.4% 1.6%	19.44 [4.28 , 88.28] 4.10 [1.62 , 10.35] 2.38 [1.07 , 5.33] 27.00 [1.66 , 438.51] 4.64 [0.58 , 37.15] 4.70 [2.04 , 10.84] 8.71 [2.13 , 35.57] 10.00 [1.36 , 73.33] 5.00 [0.25 , 100.97] 23.00 [1.39 , 380.01]	_	
est for overall effect: Z = 2.8  .43.11 tremor  .vasthi 2001  .easley (E003) 1997  .easley (HGAD) 1996a  .chaudhry 2003  .chaudhry 2003  .chaudhry 2013  .chaudhry 2013  .chaudhry 2001  .chaudhry 2009b  .chaudhry 2009b  .chaudhry 2006a	7 9 10 17 13 5 27 20 10 2	10 81 69 124 38 28 89 62 30 40 50 660	2 7 8 0 1 6 2 1	350 198 139 38 26 93 54 30 40	5.3% 10.3% 11.9% 1.9% 3.2% 11.4% 6.0% 3.4% 1.6%	19.44 [4.28 , 88.28] 4.10 [1.62 , 10.35] 2.38 [1.07 , 5.33] 27.00 [1.66 , 438.51] 4.64 [0.58 , 37.15] 4.70 [2.04 , 10.84] 8.71 [2.13 , 35.57] 10.00 [1.36 , 73.33] 5.00 [0.25 , 100.97] 23.00 [1.39 , 380.01] 3.50 [2.48 , 4.93]	_	
est for overall effect: Z = 2.8  .43.11 tremor  .vasthi 2001 leasley (E003) 1997 leasley (HGAD) 1996a chaudhry 2003 ling 2013 IGCU (Taiwan) 1998 chigooka 2001 liang 2009b ii 2005f lin 2006a long 2009c ollefson (HGAJ) 1997 ubair 2020	7 9 10 17 13 5 27 20 10 2 11	10 81 69 124 38 28 89 62 30 40 50 660 175	2 7 8 0 1 6 2 1 0	350 198 139 38 26 93 54 30 40 50	5.3% 10.3% 11.9% 1.9% 3.2% 11.4% 6.0% 3.4% 1.6% 1.9%	19.44 [4.28 , 88.28] 4.10 [1.62 , 10.35] 2.38 [1.07 , 5.33] 27.00 [1.66 , 438.51] 4.64 [0.58 , 37.15] 4.70 [2.04 , 10.84] 8.71 [2.13 , 35.57] 10.00 [1.36 , 73.33] 5.00 [0.25 , 100.97] 23.00 [1.39 , 380.01]	_	
est for overall effect: Z = 2.8  .43.11 tremor  .vasthi 2001 leasley (E003) 1997 leasley (HGAD) 1996a chaudhry 2003 ling 2013 IGCU (Taiwan) 1998 chigooka 2001 liang 2009b ii 2005f lin 2006a long 2009c ollefson (HGAJ) 1997	7 9 10 17 13 5 27 20 10 2 11 83 11	10 81 69 124 38 28 89 62 30 40 50 660	2 7 8 0 1 6 2 1 0 0 48	350 198 139 38 26 93 54 30 40 50	5.3% 10.3% 11.9% 1.9% 3.2% 11.4% 6.0% 3.4% 1.6% 1.9% 19.5%	19.44 [4.28 , 88.28] 4.10 [1.62 , 10.35] 2.38 [1.07 , 5.33] 27.00 [1.66 , 438.51] 4.64 [0.58 , 37.15] 4.70 [2.04 , 10.84] 8.71 [2.13 , 35.57] 10.00 [1.36 , 73.33] 5.00 [0.25 , 100.97] 23.00 [1.39 , 380.01] 3.50 [2.48 , 4.93]		
dest for overall effect: Z = 2.8  43.11 tremor  Evasthi 2001  Evasley (E003) 1997  Evasley (HGAD) 1996a  Ehaudhry 2003  Ehaudhry 2003  Eling 2013  EGCU (Taiwan) 1998  Ehigooka 2001  Eiang 2009b  Ei 2005f  Ein 2006a  Eong 2009c  Collefson (HGAJ) 1997  Eubair 2020  Eubtotal (95% CI)  Eiototal events:	7 9 10 17 13 5 27 20 10 2 11 83 11 225	10 81 69 124 38 28 89 62 30 40 50 660 175 <b>1456</b>	2 7 8 0 1 6 2 1 0 0 48 9	350 198 139 38 26 93 54 30 40 50 1336 175 <b>2546</b>	5.3% 10.3% 11.9% 1.9% 3.2% 11.4% 6.0% 3.4% 1.6% 19.5% 11.2% 100.0%	19.44 [4.28 , 88.28] 4.10 [1.62 , 10.35] 2.38 [1.07 , 5.33] 27.00 [1.66 , 438.51] 4.64 [0.58 , 37.15] 4.70 [2.04 , 10.84] 8.71 [2.13 , 35.57] 10.00 [1.36 , 73.33] 5.00 [0.25 , 100.97] 23.00 [1.39 , 380.01] 3.50 [2.48 , 4.93] 1.22 [0.52 , 2.88]		
est for overall effect: Z = 2.8  .43.11 tremor  .vasthi 2001 leasley (E003) 1997 leasley (HGAD) 1996a chaudhry 2003 ling 2013 IGCU (Taiwan) 1998 chigooka 2001 liang 2009b i 2005f lin 2006a long 2009c follefson (HGAJ) 1997 lubair 2020  ubtotal (95% CI)	7 9 10 17 13 5 27 20 10 2 11 83 11 225	10 81 69 124 38 28 89 62 30 40 50 660 175 <b>1456</b>	2 7 8 0 1 6 2 1 0 0 48 9	350 198 139 38 26 93 54 30 40 50 1336 175 <b>2546</b>	5.3% 10.3% 11.9% 1.9% 3.2% 11.4% 6.0% 3.4% 1.6% 19.5% 11.2% 100.0%	19.44 [4.28 , 88.28] 4.10 [1.62 , 10.35] 2.38 [1.07 , 5.33] 27.00 [1.66 , 438.51] 4.64 [0.58 , 37.15] 4.70 [2.04 , 10.84] 8.71 [2.13 , 35.57] 10.00 [1.36 , 73.33] 5.00 [0.25 , 100.97] 23.00 [1.39 , 380.01] 3.50 [2.48 , 4.93] 1.22 [0.52 , 2.88]		
dest for overall effect: Z = 2.8  43.11 tremor  Evasthi 2001  Evasley (E003) 1997  Evasley (HGAD) 1996a  Ehaudhry 2003  Ehaudhry 2003  Eling 2013  EGCU (Taiwan) 1998  Ehigooka 2001  Eiang 2009b  Ei 2005f  Ein 2006a  Eong 2009c  Collefson (HGAJ) 1997  Eubair 2020  Eubtotal (95% CI)  Eiototal events:	7 9 10 17 13 5 27 20 10 2 11 83 11 225 Chi <sup>2</sup> = 20.9	10 81 69 124 38 28 89 62 30 40 50 660 175 <b>1456</b>	2 7 8 0 1 6 2 1 0 0 48 9	350 198 139 38 26 93 54 30 40 50 1336 175 <b>2546</b>	5.3% 10.3% 11.9% 1.9% 3.2% 11.4% 6.0% 3.4% 1.6% 19.5% 11.2% 100.0%	19.44 [4.28 , 88.28] 4.10 [1.62 , 10.35] 2.38 [1.07 , 5.33] 27.00 [1.66 , 438.51] 4.64 [0.58 , 37.15] 4.70 [2.04 , 10.84] 8.71 [2.13 , 35.57] 10.00 [1.36 , 73.33] 5.00 [0.25 , 100.97] 23.00 [1.39 , 380.01] 3.50 [2.48 , 4.93] 1.22 [0.52 , 2.88]		

Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 43: Adverse effects/events: 3b. Specific - extrapyramidal - various specific effects - short term

	Halope	ridol	Olanza	pine		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
4.44.1 akat hisia							
Crespo-Facorro 2006	7	35	1	30	4.1%	6.00 [0.78 , 46.04]	
Kahn (EUFEST) 2005	19	73	10	97		2.52 [1.25 , 5.10]	
Lilly (S029) 2007	13	117	9	121			
Lilly 2006a	12	40	2	31	8.5%		T
Rosenheck (HGFI) 2003	14	150	9	159		1.65 [0.74 , 3.70]	
Subtotal (95% CI)		415	·	438		2.15 [1.42 , 3.25]	
Total events:	65	.23	31	150	2001070	2.25 [2.12,5.25]	•
Heterogeneity: $Tau^2 = 0.0$		50. df = 4		8): I <sup>2</sup> = 09	6		
Test for overall effect: Z =			. (	o,, .			
4.44.2 dyskinetic movem	ents						
Kahn (EUFEST) 2005	2	73	0	97	9.0%	6.62 [0.32 , 135.87]	-
Lilly (S029) 2007	9	107	7	121	91.0%	1.45 [0.56 , 3.77]	,
Subtotal (95% CI)		180		218		1.67 [0.67 , 4.14]	
Total events:	11		7			· · · · ·	
Heterogeneity: Tau <sup>2</sup> = 0.0	0; Chi <sup>2</sup> = 0	.88, df =	1 (P = 0.3	5); I <sup>2</sup> = 0%	6		
Test for overall effect: Z =	1.10 (P = 0	0.27)					
4 44 2 double with a contra							
4.44.3 dystonia, acute		70	•	0.7	100.00/	0.07.[0.4000.44]	
Kahn (EUFEST) 2005	1	73	0		100.0%	3.97 [0.16 , 96.14]	
Subtotal (95% CI)		73		97	100.0%	3.97 [0.16, 96.14]	
Total events:	1		0				
Heterogeneity: Not applica							
Test for overall effect: Z =	0.85 (P = 0.85)	).40)					
4.44.4 parkinsonism							
Kahn (EUFEST) 2005	25	73	6	97			-
Lilly (S029) 2007	16	75	8	68	50.9%	1.81 [0.83 , 3.97]	+
Subtotal (95% CI)		148		165	100.0%	3.14 [1.05 , 9.36]	
Total events:	41		14				
Heterogeneity: $Tau^2 = 0.4$ Test for overall effect: $Z =$			1 (P = 0.0	6); $I^2 = 73$	3%		
4.44.5 dysarthria							
Lilly 2006a	2	40	0	21	100.0%	3.90 [0.19 , 78.46]	<u>_</u>
Subtotal (95% CI)	2	40 <b>40</b>	U	31			
Total events:	2	40	0	31	100.0%	3.90 [0.19 , 78.46]	
Heterogeneity: Not applica			U				
Test for overall effect: Z =		37)					
Tool for overall effect. Z =	J.00 (1 = 1	,					
4.44.6 tremor							
Lilly (S029) 2007	9	133	2	141	100.0%	4.77 [1.05 , 21.68]	<b>-</b>
Subtotal (95% CI)		133		141	100.0%	4.77 [1.05, 21.68]	
Total events:	9		2				
Heterogeneity: Not applica							
Test for overall effect: $Z =$	2.02 (P = 0)	0.04)					
							0.01 0.1 1 10 10

Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 44: Adverse effects/events: 3c. Specific - extrapyramidal - various specific effects - medium term

	Halope	ridol	Olanza	pine		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
4.45.1 akat hisia							
Crespo-Facorro 2006	3	53	0	55	4.1%	7.26 [0.38 , 137.25]	-
Lilly (HGGN) 2000	24	97	14	159	95.9%	2.81 [1.53 , 5.17]	
Subtotal (95% CI)		150		214	100.0%	2.92 [1.61, 5.30]	
Total events:	27		14				_
Heterogeneity: Tau <sup>2</sup> = 0	0.00; Chi <sup>2</sup> =	0.38, df	= 1 (P = 0)	$.54$ ); $I^2 =$	0%		
Test for overall effect: 2	1 = 3.52 (P :	= 0.0004	)				
4.45.2 t remor							
<b>4.45.2 tremor</b> Lilly (HGGN) 2000	13	97	13	159	100.0%	1.64 [0.79 , 3.39]	_
4.45.2 tremor Lilly (HGGN) 2000 Subtotal (95% CI)	13	97 <b>97</b>		159 <b>159</b>		1.64 [0.79 , 3.39] <b>1.64 [0.79 , 3.39</b> ]	
Lilly (HGGN) 2000	13 13						
Lilly (HGGN) 2000 <b>Subtotal (95% CI)</b> Total events:	13						•
Lilly (HGGN) 2000 Subtotal (95% CI) Total events: Heterogeneity: Not app	13 olicable	97					•
Lilly (HGGN) 2000 Subtotal (95% CI) Total events:	13 olicable	97					•
Lilly (HGGN) 2000 <b>Subtotal (95% CI)</b> Total events: Heterogeneity: Not app	13 olicable	97					0.01 0.1 1 10 100

Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 45: Adverse effects/events: 3d. Specific - extrapyramidal - various specific effects - long term

	Hal	loperido	ι	Ola	anzapine	•		Mean Difference	Mean Di	fference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Rando	m, 95% CI
Lilly 2006a	25	8.49	40	2.25	0.96	31	100.0%	22.75 [20.10 , 25.40]		
Total (95% CI) Heterogeneity: Not ap	plicable		40			31	100.0%	22.75 [20.10 , 25.40]		•
Test for overall effect: Test for subgroup diffe	Z = 16.81 (F		,						-50 -25 Olanzapine	0 25 50 Haloperidol


Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 46: Adverse effects/events: 3e. Specific - extrapyramidal - average endpoint score - medium term (BAS total, high=poor)

	udy or Subgroup	Mean SD	Total	Mean						
				meall	SD	Total	Weight	IV, Random, 95% CI	IV, Randor	m, 95% CI
	ly 2006a	22.3 6.04	40	6.3	2	31	100.0%	16.00 [14.00 , 18.00]		
Total (95% CI) 40 31 100.0% 16.00 [14.00 , 18.00] Heterogeneity: Not applicable		icable	40			31	100.0%	16.00 [14.00,18.00]		•


Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 47: Adverse effects/events: 3f. Specific - extrapyramidal - average endpoint score - medium term (SAS total, high=poor)

	Halope	eridol	Olanza	apine		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
4.53.1 decrease - sho	rt term						
Ishigooka 2001	7	89	1	93	52.4%	7.31 [0.92 , 58.26]	
Subtotal (95% CI)		89		93	<b>52.4</b> %	7.31 [0.92, 58.26]	
Total events:	7		1				
Heterogeneity: Not ap	plicable						
Test for overall effect:	Z = 1.88 (F	P = 0.06					
4.53.2 decrease-med	ium term						
Lilly (S029) 2007	4	133	1	141	47.6%	4.24 [0.48 , 37.46]	
Subtotal (95% CI)		133		141	47.6%	4.24 [0.48 , 37.46]	
Total events:	4		1				
Heterogeneity: Not ap	plicable						
Test for overall effect:	Z = 1.30 (F	P = 0.19					
Total (95% CI)		222		234	100.0%	5.64 [1.26 , 25.36]	
Total events:	11		2				
Heterogeneity: Tau <sup>2</sup> =	0.00; Chi <sup>2</sup>	= 0.13, d	f = 1 (P =	0.72); l <sup>2</sup> :	= 0%		0.01 0.1 1 10 100
Test for overall effect:	Z = 2.26 (F	P = 0.02					Olanzapine Haloperidol
Test for subgroup diffe	erences: Ch	$ni^2 = 0.13$	df = 1 (P	= 0.72),	$l^2 = 0\%$		

Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 53: Adverse effects/events: 4b. Specific - metabolic - weight decrease



Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 54: Adverse effects/events: 4c. Specific - metabolic - weight - high BMI (>=25kg/m2) - medium term



Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 55: Adverse effects/events: 4d. Specific - metabolic - weight - average endpoint (kg)


Barak 2002 2.1 1.8 10 4.5 0.6 10 50.7% -2.40 [-3.58, -1.22] Lieberman (HGDH) 2003 2.6 4.5 131 7.3 6.1 132 49.3% -4.70 [-5.99, -3.41]  Total (95% CI) 141 142 100.0% -3.53 [-5.79, -1.28]		Ha	operido	l	Ola	anzapine	•		Mean Difference	Mean Differenc	e
Lieberman (HGDH) 2003 2.6 4.5 131 7.3 6.1 132 49.3% -4.70 [-5.99 , -3.41]	Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95%	CI
Total (95% CI) 141 142 100.0% -3.53 [-5.79,-1.28]	Barak 2002	2.1	1.8	10	4.5	0.6	10	50.7%	-2.40 [-3.58 , -1.22]	-	
	Lieberman (HGDH) 2003	2.6	4.5	131	7.3	6.1	132	49.3%	-4.70 [-5.99 , -3.41]	-	
		Chi <sup>2</sup> – 6 64	df = 1 (P		l <sup>2</sup> – 85%		142	100.0%	-3.53 [-5.79,-1.28]	•	

Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 56: Adverse effects/events: 4e. Specific - metabolic - weight - average increase - short term

	i i u	loperidol	l	Ola	anzapine	•		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Saddichha 2007	76	6.5	31	81	8.9	35	100.0%	-5.00 [-8.73 , -1.27]	-
<b>Fotal (95% CI)</b> Heterogeneity: Not app	olicable		31			35	100.0%	-5.00 [-8.73 , -1.27]	•

Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 57: Adverse effects/events: 4f. Specific - metabolic - weight - waist circumference at endpoint - short term (high=poor)


	Haloperio Events To	otal	Olanzapi Events T		Weight	Risk Ratio IV, Random, 95% CI	Risk Ratio IV, Random, 95% CI
.60.1 cholesterol - hig	h - shart ta	m					
Krakowski 2006	0	18	2	16	100.0%	0.18 [0.01 , 3.47]	
Subtotal (95% CI)	Ü	18	۷	16	100.0%	0.18 [0.01, 3.47]	
, ,	0	10	2	10	100.070	0.16 [0.01 , 5.47]	
otal events:			2				
leterogeneity: Not applicest for overall effect: Z		.26)					
.60.2 cholesterol - hig	h - medium t	erm					
Crespo-Facorro 2006	4	21	4	25	9.2%	1.19 [0.34 , 4.19]	
(ahn (EUFEST) 2005	15	33	37	66	78.6%	0.81 [0.53 , 1.25]	
illy (S029) 2007	8	133	5	141	12.2%	1.70 [0.57 , 5.05]	=
Subtotal (95% CI)	O	187	3	232			<del></del>
	27	101	46	232	100.0%	0.92 [0.63 , 1.35]	<b>*</b>
otal events:		70 df		2). 12	00/		
leterogeneity: $Tau^2 = 0$ lest for overall effect: Z	-		= 2 (P = 0.43	5); I <sup>-</sup> = (	U%		
.60.3 glucose - high - s	short term						
Krakowski 2006	0	23	6	25	30.3%	0.08 [0.00 , 1.40]	
Saddichha 2007	7	31	4	35	39.3%	1.98 [0.64 , 6.11]	` <u> </u>
Zubair 2020	0	175	19	175	30.4%	0.03 [0.00 , 0.42]	
ubtotal (95% CI)	· ·	229		235		0.20 [0.01, 3.93]	
otal events:	7	223	29	233	100.070	0.20 [0.01 , 3.93]	
eterogeneity: $Tau^2 = 5$ est for overall effect: Z	.49; Chi <sup>2</sup> = 10			)05); l²	= 81%		
.60.4 glucose - high - ı	medium term	1					
Crespo-Facorro 2006	1	21	0	25	7.7%	3.55 [0.15 , 82.72]	
(ahn (EUFEST) 2005	6	33	19	63	50.0%	0.60 [0.27 , 1.36]	<b></b> ■+
illy (S029) 2007	10	133	6	141	42.3%	1.77 [0.66 , 4.73]	<del></del>
ubtotal (95% CI)		187		229	100.0%	1.09 [0.44 , 2.72]	
otal events:	17		25			- , -	
eterogeneity: Tau <sup>2</sup> = 0 est for overall effect: Z			= 2 (P = 0.18	3); I <sup>2</sup> = 4	41%		
.60.5 HDL - low - short							
(ahn (EUFEST) 2005	6	32	16	65	67.8%	0.76 [0.33 , 1.76]	-
addichha 2007	3	31	9	35	32.2%	0.38 [0.11 , 1.27]	-
ubtotal (95% CI)		63		100	100.0%	0.61 [0.30 , 1.21]	
otal events:	9		25				•
eterogeneity: $Tau^2 = 0$ est for overall effect: Z	= 1.42 (P = 0		= 1 (P = 0.35	$(3);    ^2 = 0$	0%		
							1
.60.6 LDL - high - medi		64	0.5	00	100.004	0.07.50.05 1.47	
Kahn (EUFEST) 2005	um term 16	31	35		100.0%	0.97 [0.65 , 1.47]	
(ahn (EUFEST) 2005 (ubtotal (95% CI)	16	31 <b>31</b>		66 <b>66</b>		0.97 [0.65 , 1.47] <b>0.97 [0.65 , 1.47</b> ]	•
ahn (EUFEST) 2005 ubtotal (95% CI) otal events:	16 16		35 35				•
	16 16 icable	31					•
Cahn (EUFEST) 2005  ubtotal (95% CI)  rotal events:  leterogeneity: Not applicate for overall effect: Z	16 16 icable = 0.13 (P = 0	<b>31</b> 0.90)					•
Sahn (EUFEST) 2005  ubtotal (95% CI)  otal events: leterogeneity: Not applicest for overall effect: Z  .60.7 trygliceride - hig	16 16 icable = 0.13 (P = 0	<b>31</b> 0.90)					
Kahn (EUFEST) 2005  ubtotal (95% CI)  rotal events: leterogeneity: Not applicest for overall effect: Z  .60.7 trygliceride - hig  frakowski 2006	16 16 icable = 0.13 (P = 0	<b>31</b> 0.90)	35	66	100.0%	0.97 [0.65 , 1.47]	
ahn (EUFEST) 2005 ubtotal (95% CI) otal events: eterogeneity: Not appl est for overall effect: Z  60.7 trygliceride - hig rakowski 2006 addichha 2007	16 16 icable = 0.13 (P = 0 gh - short ter	31 0.90) rm 14	35 5	20	36.5% 63.5%	0.97 [0.65 , 1.47] 0.86 [0.24 , 3.02] 0.32 [0.15 , 0.70]	
ahn (EUFEST) 2005 ubtotal (95% CI) otal events: leterogeneity: Not appliest for overall effect: Z  60.7 trygliceride - higinakowski 2006 addichha 2007 ubtotal (95% CI)	16 16 icable = 0.13 (P = 0 gh - short ter	31 0.90) rm 14 31	35 5	20 35	36.5% 63.5%	0.97 [0.65 , 1.47] 0.86 [0.24 , 3.02]	
Kahn (EUFEST) 2005 Subtotal (95% CI) Total events: Heterogeneity: Not appl	16 16 icable = 0.13 (P = 0 gh - short ter 3 6 1.19; Chi² = 1.	31 0.90) 7m 14 31 45 69, df =	5 21 26	20 35 55	36.5% 63.5% 100.0%	0.97 [0.65 , 1.47] 0.86 [0.24 , 3.02] 0.32 [0.15 , 0.70]	
Kahn (EUFEST) 2005 Gubtotal (95% CI) Total events: Heterogeneity: Not application overall effect: Z G.60.7 trygliceride - high crakowski 2006 Gaddichha 2007 Gubtotal (95% CI) Total events: Heterogeneity: Tau² = 0 Test for overall effect: Z	16  16  icable = 0.13 (P = 0)  gh - short ter 3 6  9  i.19; Chi² = 1. = 1.65 (P = 0)	31 0.90) rm 14 31 45 69, df =	5 21 26	20 35 55	36.5% 63.5% 100.0%	0.97 [0.65 , 1.47] 0.86 [0.24 , 3.02] 0.32 [0.15 , 0.70]	
Kahn (EUFEST) 2005 Gubtotal (95% CI) Total events: Heterogeneity: Not applicest for overall effect: Z G.60.7 trygliceride - high Krakowski 2006 Gaddichha 2007 Gubtotal (95% CI) Total events: Heterogeneity: Tau² = 0 Test for overall effect: Z G.60.8 trygliceride - high Krakowski 2006 Test for overall effect: Z	16  16  icable = 0.13 (P = 0)  gh - short ter 3 6  9  1.19; Chi <sup>2</sup> = 1. = 1.65 (P = 0)	31 0.90) rm 14 31 45 69, df = 0.10)	35 21 26 = 1 (P = 0.19	20 35 55 9); l <sup>2</sup> = 4	36.5% 63.5% 100.0%	0.97 [0.65 , 1.47]  0.86 [0.24 , 3.02]  0.32 [0.15 , 0.70]  0.46 [0.18 , 1.16]	
Kahn (EUFEST) 2005 Gubtotal (95% CI) Fotal events: Heterogeneity: Not applicest for overall effect: Z G.60.7 trygliceride - high crakowski 2006 Gaddichha 2007 Gubtotal (95% CI) Fotal events: Heterogeneity: Tau² = 0 Fest for overall effect: Z G.60.8 trygliceride - high crespo-Facorro 2006	16  16  icable = 0.13 (P = 0)  gh - short ter 3 6  .19; Chi <sup>2</sup> = 1. = 1.65 (P = 0)  gh - medium t 3	31 0.90) rm 14 31 45 69, df = 0.10)	35 5 21 26 = 1 (P = 0.19	20 35 <b>55</b> 9); l <sup>2</sup> = 4	36.5% 63.5% 100.0% 41%	0.97 [0.65 , 1.47]  0.86 [0.24 , 3.02]  0.32 [0.15 , 0.70]  0.46 [0.18 , 1.16]	
Kahn (EUFEST) 2005 Gubtotal (95% CI) Fotal events: Heterogeneity: Not applicest for overall effect: Z  G.60.7 trygliceride - high crakowski 2006 Gaddichha 2007 Gubtotal (95% CI) Fotal events: Heterogeneity: Tau² = 0 Fest for overall effect: Z  G.60.8 trygliceride - high crespo-Facorro 2006 Gahn (EUFEST) 2005	16  16  icable = 0.13 (P = 0)  gh - short ter 3 6  1.19; Chi <sup>2</sup> = 1. = 1.65 (P = 0)  gh - medium t 3 13	31 0.90) 7m 14 31 45 69, df = 0.10) term 21 33	35 5 21 26 = 1 (P = 0.19 9 26	20 35 55 59); I <sup>2</sup> = 4	36.5% 63.5% 100.0% 41%	0.97 [0.65 , 1.47]  0.86 [0.24 , 3.02]  0.32 [0.15 , 0.70]  0.46 [0.18 , 1.16]  0.40 [0.12 , 1.28]  1.00 [0.60 , 1.68]	
Kahn (EUFEST) 2005 Gubtotal (95% CI) Fotal events: Heterogeneity: Not applicest for overall effect: Z  G.60.7 trygliceride - high crakowski 2006 Gaddichha 2007 Gubtotal (95% CI) Fotal events: Heterogeneity: Tau² = 0 Fest for overall effect: Z  G.60.8 trygliceride - high crespo-Facorro 2006 Gahn (EUFEST) 2005 Gilly (S029) 2007	16  16  icable = 0.13 (P = 0)  gh - short ter 3 6  .19; Chi <sup>2</sup> = 1. = 1.65 (P = 0)  gh - medium t 3	31 0.90) 7m 14 31 45 69, df = 0.10) 21 33 133	35 5 21 26 = 1 (P = 0.19	20 35 55 59); I <sup>2</sup> = 4 25 66 141	36.5% 63.5% 100.0% 41% 13.2% 67.0% 19.7%	0.97 [0.65 , 1.47]  0.86 [0.24 , 3.02]  0.32 [0.15 , 0.70]  0.46 [0.18 , 1.16]  0.40 [0.12 , 1.28]  1.00 [0.60 , 1.68]  0.82 [0.32 , 2.15]	
Kahn (EUFEST) 2005 Gubtotal (95% CI) Total events: Heterogeneity: Not applicest for overall effect: Z  G.60.7 trygliceride - high (rakowski 2006 Gaddichha 2007 Gubtotal (95% CI) Total events: Heterogeneity: Tau² = 0 Test for overall effect: Z  G.60.8 trygliceride - high (respo-Facorro 2006 Gahn (EUFEST) 2005 Gubtotal (95% CI)  Gubtotal (95% CI)	16  16  icable = 0.13 (P = 0)  gh - short ter 3 6  1.19; Chi² = 1. = 1.65 (P = 0)  gh - medium t 3 13 7	31 0.90) 7m 14 31 45 69, df = 0.10) term 21 33	35 5 21 26 = 1 (P = 0.19 9 26 9	20 35 55 59); I <sup>2</sup> = 4	36.5% 63.5% 100.0% 41% 13.2% 67.0% 19.7%	0.97 [0.65 , 1.47]  0.86 [0.24 , 3.02]  0.32 [0.15 , 0.70]  0.46 [0.18 , 1.16]  0.40 [0.12 , 1.28]  1.00 [0.60 , 1.68]	
Kahn (EUFEST) 2005 Gubtotal (95% CI) Total events: Heterogeneity: Not applicest for overall effect: Z  G.60.7 trygliceride - high crakowski 2006 Gaddichha 2007 Gubtotal (95% CI) Total events: Heterogeneity: Tau² = 0 Test for overall effect: Z  G.60.8 trygliceride - high crespo-Facorro 2006 Gahn (EUFEST) 2005 Gubtotal (95% CI) Total events:	16  16  icable = 0.13 (P = 0)  gh - short ter 3 6  .19; Chi² = 1. = 1.65 (P = 0)  gh - medium t 3 13 7	31 0.90) 7m 14 31 45 69, df = 0.10) 21 33 133 187	35 5 21 26 = 1 (P = 0.19 9 26 9	20 35 55 59); I <sup>2</sup> = 4 25 66 141 232	36.5% 63.5% 100.0% 41% 13.2% 67.0% 19.7% 100.0%	0.97 [0.65 , 1.47]  0.86 [0.24 , 3.02]  0.32 [0.15 , 0.70]  0.46 [0.18 , 1.16]  0.40 [0.12 , 1.28]  1.00 [0.60 , 1.68]  0.82 [0.32 , 2.15]	
Kahn (EUFEST) 2005 Kubtotal (95% CI) Kotal events: Keterogeneity: Not applicest for overall effect: Z  Kotal events: Kotal (95% CI) Kotal (95% CI) Kotal events: Keterogeneity: Tau² = 0 Kotal events: Keterogeneity: Tau² = 0 Kotal events: Kotal (95% CI) Kotal events:	16  16  icable = 0.13 (P = 0)  gh - short ter 3 6  1.19; Chi² = 1. = 1.65 (P = 0)  gh - medium t 3 13 7  23 1.00; Chi² = 2.	31 0.90) 7m 14 31 45 69, df = 0.10) 21 33 133 187	35 5 21 26 = 1 (P = 0.19 9 26 9	20 35 55 59); I <sup>2</sup> = 4 25 66 141 232	36.5% 63.5% 100.0% 41% 13.2% 67.0% 19.7% 100.0%	0.97 [0.65 , 1.47]  0.86 [0.24 , 3.02]  0.32 [0.15 , 0.70]  0.46 [0.18 , 1.16]  0.40 [0.12 , 1.28]  1.00 [0.60 , 1.68]  0.82 [0.32 , 2.15]	
ahn (EUFEST) 2005  ubtotal (95% CI)  otal events: leterogeneity: Not appliest for overall effect: Z  .60.7 tryg liceride - high rakowski 2006 addichha 2007  ubtotal (95% CI) otal events: leterogeneity: Tau² = 0 lest for overall effect: Z  .60.8 tryg liceride - high respo-Facorro 2006 ahn (EUFEST) 2005 lilly (S029) 2007  ubtotal (95% CI) otal events:	16  16  icable = 0.13 (P = 0)  gh - short ter 3 6  1.19; Chi² = 1. = 1.65 (P = 0)  gh - medium t 3 13 7  23 1.00; Chi² = 2.	31 0.90) 7m 14 31 45 69, df = 0.10) 21 33 133 187	35 5 21 26 = 1 (P = 0.19 9 26 9	20 35 55 59); I <sup>2</sup> = 4 25 66 141 232	36.5% 63.5% 100.0% 41% 13.2% 67.0% 19.7% 100.0%	0.97 [0.65 , 1.47]  0.86 [0.24 , 3.02]  0.32 [0.15 , 0.70]  0.46 [0.18 , 1.16]  0.40 [0.12 , 1.28]  1.00 [0.60 , 1.68]  0.82 [0.32 , 2.15]	



Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 61: Adverse effects/events: 5b. Specific - metabolic - metabolism-related serum levels (high=poor)


	На	loperido	l	Ol	anzapine	•		Mean Difference	Mean Di	fference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Rando	m, 95% CI
4.62.1 short term										
Saddichha 2007	35.6	8.2	31	39.5	13.9	35	51.8%	-3.90 [-9.33 , 1.53]	<b></b> _	_
Subtotal (95% CI)			31			35	51.8%	-3.90 [-9.33 , 1.53]		-
Heterogeneity: Not app	olicable									
Test for overall effect:	Z = 1.41 (P	= 0.16)								
4.62.2 medium term										
Raposo 2011	55	12	16	43	12	18	48.2%	12.00 [3.92 , 20.08]		
Subtotal (95% CI)			16			18	48.2%	12.00 [3.92, 20.08]		
Heterogeneity: Not app	olicable									
Test for overall effect:	Z = 2.91 (P	= 0.004)								
Total (95% CI)			47			53	100.0%	3.76 [-11.81 , 19.33]		
Heterogeneity: Tau <sup>2</sup> =	114.06; Chi	$^2 = 10.24$	l, df = 1 (P	P = 0.001);	$I^2 = 90\%$					
Test for overall effect:	Z = 0.47 (P	= 0.64)							-20 -10 (	) 10 20
Test for subgroup diffe	rences: Chi	$^{2} = 10.24$	df = 1 (P	- 0.001)	12 - 90 29	<b>'</b>			Olanzapine	Haloperidol

Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 62: Adverse effects/events: 5c. Specific - metabolic - metabolism-related HDL serum levels - endpoint (high=poor)




Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 64: Adverse effects/events: 6. Specific - metabolic - various binary - short term

	Halope	ridol	Olanza	pine		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
4 CF 1 blooms 1 ***							
<b>4.65.1 blurred vision</b> Avasthi 2001	5	10	1	17	6.4%	8.50 [1.15 , 62.80]	
Ding 2013	6	38	8	38	19.2%	0.75 [0.29 , 1.96]	
Liu 2010l	4	50	0				<del></del>
	1			50	3.3%	9.00 [0.50 , 162.89]	<del>-</del>
Liu 2012ao		39	1	37		0.95 [0.06 , 14.62]	
Mousavi 2013	0	10	1	10	2.9%	0.33 [0.02 , 7.32]	•
Qin 2006a	8	40	2	40	10.4%	4.00 [0.90 , 17.68]	-
Song 2009c	6	50	2	50	9.7%	3.00 [0.64 , 14.16]	<del>  •</del>
Tollefson (HGAJ) 1997	120	660	169	1336	44.5%	1.44 [1.16 , 1.78]	<del>-</del>
Subtotal (95% CI)		897		1578	100.0%	1.70 [0.99, 2.93]	•
Total events:	150		184	_			
Heterogeneity: $Tau^2 = 0$ . Test for overall effect: $Z = 0$			/ (P = 0.1	9); I <sup>2</sup> = 3	0%		
4.65.2 constipation							
Avasthi 2001	3	10	6	17	13.0%	0.85 [0.27 , 2.67]	
Ding 2013	3	38	1	38	4.0%	3.00 [0.33 , 27.57]	
HGCU (Taiwan) 1998	4	28	1	26	4.4%	3.71 [0.44 , 31.11]	
Jiang 2009b	11	62	8	54	20.9%	1.20 [0.52 , 2.76]	
Li 2005f	6	30	5	30		1.20 [0.41 , 3.51]	
Liu 2010l	4	50	2	50	6.9%	2.00 [0.38 , 10.43]	<u>_</u>
Mousavi 2013	0	10	1	10	2.1%	0.33 [0.02 , 7.32]	
Qin 2006a	16	40	5	40	18.6%	3.20 [1.30 , 7.90]	
Song 2009c	18	50	4	50	15.8%	4.50 [1.64 , 12.36]	<del>-</del>
Subtotal (95% CI)	10	318	7	315		1.86 [1.18, 2.95]	
Total events:	65	310	33	313	_50.0 /0	2.30 [2.20 , 2.33]	
Heterogeneity: Tau <sup>2</sup> = 0.0		961 df –		9)· I <sup>2</sup> _ 1	7%		
Test for overall effect: Z =		-	0 (1 = 0.2	.5), 1 = 1	7 70		
4.65.3 salivation - too li							
Avasthi 2001	3	10	5	17	8.3%	1.02 [0.31 , 3.38]	<del></del>
Beasley (HGAD) 1996a	3	69	14	198	8.2%	0.61 [0.18 , 2.08]	<del></del>
Ding 2013	10	38	11	38	12.3%	0.91 [0.44 , 1.88]	<del></del>
Jiang 2009b	5	62	9	54	9.6%	0.48 [0.17 , 1.36]	
Li 2005f	2	30	3	30	5.4%	0.67 [0.12 , 3.71]	
Liu 2010l	10	50	2	50	6.6%	5.00 [1.15 , 21.67]	
Liu 2012ao	2	39	3	37	5.3%	0.63 [0.11 , 3.57]	
Mousavi 2013	0	10	1	10	2.1%	0.33 [0.02 , 7.32]	<del></del>
Pan 2005	5	42	4	42	8.0%	1.25 [0.36 , 4.33]	
Qin 2006a	26	40	5	40	11.2%	5.20 [2.22 , 12.18]	
Song 2009c	8	50	2	50		4.00 [0.89 , 17.91]	<del>                                     </del>
Tollefson (HGAJ) 1997	127	660	320	1336	16.8%	0.80 [0.67 , 0.96]	-
Subtotal (95% CI)		1100	-	1902		1.19 [0.74 , 1.92]	
Total events:	201		379			· , , - · · · · · · · · · · · · · · · ·	
Heterogeneity: $Tau^2 = 0.3$ Test for overall effect: Z =	35; Chi <sup>2</sup> = 2	-		0.002); I <sup>2</sup>	= 63%		
		J. 10 <sub>j</sub>					
4.65.4 salivation - too m		10		47	16.00/	1 07 [0 06 4 57]	
Avasthi 2001	3	10	4	17	16.0%	1.27 [0.36 , 4.57]	<del>-  •</del>
Beasley (E003) 1997	5	81	2	350		10.80 [2.13 , 54.69]	
Ishigooka 2001	15	89	4	93		3.92 [1.35 , 11.36]	
Kinon 2004	4	48	0	52			<del></del>
Qin 2006a	22	40	2	40		11.00 [2.77 , 43.71]	
Tollefson (HGAJ) 1997 Subtotal (95% CI)	148	660 <b>928</b>	143	1336 <b>1888</b>	32.9% <b>100.0%</b>	2.10 [1.70 , 2.58] <b>3.67 [1.81 , 7.42</b> ]	•
Total events:	197		155			· -	
Heterogeneity: $Tau^2 = 0.3$ Test for overall effect: $Z =$			= 5 (P = 0.	.04); $I^2 =$	58%		
4.65.5 headache							
HGCU (Taiwan) 1998	3	28	2	26	21.7%	1.39 [0.25 , 7.68]	
Kinon 2004	12	48	6	52	78.3%	2.17 [0.88 , 5.32]	
Subtotal (95% CI)	12	76	3	78		1.97 [0.89 , 4.36]	
Total events:	15	10	8	10		[0.05 , 7.50]	
Heterogeneity: Tau <sup>2</sup> = 0.0 Test for overall effect: Z =	00; $Chi^2 = 0$			55); I <sup>2</sup> = 0	%		
4.65.6 nervousess							
	_	48	4	52	100.0%	2.17 [0.70 , 6.74]	<u> </u>
Kinon 2004	8	40				[0 0 , 0,	
Kinon 2004 Subtotal (95% CI)	8	48			100.0%	2.17 [0.70 , 6.74]	



Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 65: Adverse effects/events: 7a. Specific - anticholinergic - various - short term

	Halope	ridol	Olanza	pine		Risk Ratio	Risk	Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	IV, Random, 95% CI	IV, Rando	om, 95% CI
4.66.1 dysarthria								
Lilly 2006a	2	40	0	31	100.0%	3.90 [0.19 , 78.46]		
Subtotal (95% CI)		40		31	100.0%	3.90 [0.19, 78.46]		
Total events:	2		0					
Heterogeneity: Not app	olicable							
Test for overall effect:	Z = 0.89 (P)	P = 0.37						
4.66.2 urination diffic	ulties							
Lilly 2006a	2	40	0	31	100.0%	3.90 [0.19 , 78.46]		
Subtotal (95% CI)		40		31	100.0%	3.90 [0.19, 78.46]		
Total events:	2		0					
Heterogeneity: Not app	olicable							
Test for overall effect:	Z = 0.89 (P)	P = 0.37						
4.66.3 rash								
Lilly 2006a	0	40	2	31	100.0%	0.16 [0.01 , 3.14]	<del></del>	
Subtotal (95% CI)		40		31	100.0%	0.16 [0.01, 3.14]		
Total events:	0		2					
Heterogeneity: Not app	olicable							
Test for overall effect:	Z = 1.21 (P	P = 0.23						
4.66.4 anemia								
Lilly 2006a	2	40	0	31	100.0%	3.90 [0.19 , 78.46]		
Subtotal (95% CI)		40		31	100.0%	3.90 [0.19, 78.46]	-	
Total events:	2		0					
Heterogeneity: Not app	olicable							
Test for overall effect:	Z = 0.89 (P)	9 = 0.37						
								l
Test for subgroup diffe	erences: Ch	$i^2 = 0.00$	df = 3 (P)	< 0.0000	1), $I^2 = 0\%$	ò	0.01 0.1	1 10 100
							Olanzapine	Haloperidol



Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 67: Adverse effects/events: 7c. Specific - anticholinergic - various - long term

tudy or Subgroup	Haloperi Events	idol Fotal	Olanza Events	pine Total	Weight	Risk Ratio IV, Random, 95% CI	Risk Ratio IV, Random, 95% CI
.68.1 agitation - short t	erm						
Beasley (HGAD) 1996a	21	69	48	198	73.0%	1.26 [0.81 , 1.94]	<u></u>
IGCU (Taiwan) 1998	6	28	0	26		12.10 [0.72 , 204.75]	
(inon 2004	5	48	5	52		1.08 [0.33 , 3.51]	
ubtotal (95% CI)	-	145		276		1.35 [0.73, 2.51]	
otal events:	32		53				
leterogeneity: Tau <sup>2</sup> = 0.09 est for overall effect: Z = 9	9; Chi² = 2.			9); I <sup>2</sup> = 2	0%		
.68.2 agitation - mediun	nterm						
illy (S029) 2007	1	133	4	141	100.0%	0.27 [0.03 , 2.34]	
ubtotal (95% CI)		133		141	100.0%	0.27 [0.03 , 2.34]	
otal events:	1		4				
leterogeneity: Not applicatest for overall effect: Z =		.23)					
.68.3 agitation - long te	rm						
illy (HGGN) 2000	8	97	7	159	100.0%	1.87 [0.70 , 5.00]	
ubtotal (95% CI)	Ŭ	97	•		100.0%	1.87 [0.70, 5.00]	
otal events:	8	31	7	133	_50.0 /0	2.0. [0.10, 3.00]	
leterogeneity: Not applica est for overall effect: Z =	ble	.21)	,				
		,					
.68.4 anxiety - short ter			. <del></del>	20	05.00/	1 05 [0 77 0 07]	
shigooka 2001	22	89	17	93			-
(inon 2004	2	48	6	52		0.36 [0.08 , 1.70]	<del></del>
ubtotal (95% CI)	_	137		145	100.0%	0.86 [0.25 , 2.94]	
otal events:	24		23				7
eterogeneity: $Tau^2 = 0.52$ est for overall effect: $Z = 0.52$	-		1 (P = 0.1	2); I <sup>2</sup> = 5	9%		
.68.5 anxiet y - medium t		100	47		04.00/	1 00 [1 10 0 00]	
lly (S029) 2007	31	133	17	141	91.0%	1.93 [1.12 , 3.32]	-
ly 2006a	3	40	2	31	9.0%	1.16 [0.21 , 6.54]	<del></del>
ubtotal (95% CI)		173		172	100.0%	1.85 [1.10, 3.10]	•
otal events:	34		19				
leterogeneity: $Tau^2 = 0.00$ est for overall effect: $Z = 3$			I (P = 0.5	8); 1- = 0	%		
	•						
.68.6 anxiety - long term	1	97	28	150	100.0%	0.64 [0.34 1.23]	
illy (HGGN) 2000		97	28		100.0%	0.64 [0.34 , 1.23]	-
illy (HGGN) 2000 ubtotal (95% CI)	<b>1</b>	97 <b>97</b>		159 <b>159</b>		0.64 [0.34 , 1.23] <b>0.64 [0.34 , 1.23</b> ]	•
illy (HGGN) 2000	11 11 11 ble	97	28 28			•	•
illy (HGGN) 2000  ubtotal (95% CI)  otal events: leterogeneity: Not applica est for overall effect: Z =  .68.7 excitement - short	11 11 ble 1.33 (P = 0	97				•	
illy (HGGN) 2000  ubtotal (95% CI)  otal events: leterogeneity: Not applica est for overall effect: Z =  .68.7 excitement - short	11 11 ble 1.33 (P = 0	97		159		•	
illy (HGGN) 2000  ubtotal (95% CI)  otal events: leterogeneity: Not applica est for overall effect: Z =  .68.7 excitement - short shigooka 2001	11 11 ble 1.33 (P = 0	<b>97</b> .18)	28	<b>159</b> 93	100.0%	0.64 [0.34 , 1.23]	
Illy (HGGN) 2000  ubtotal (95% CI)  otal events: eterogeneity: Not applica est for overall effect: Z =  68.7 excitement - short higooka 2001  ubtotal (95% CI)	11 11 ble 1.33 (P = 0	<b>97</b> .18)	28	<b>159</b> 93	<b>100.0%</b> 100.0%	0.64 [0.34 , 1.23] 1.04 [0.56 , 1.96]	•
illy (HGGN) 2000  ubtotal (95% CI)  otal events: leterogeneity: Not applica est for overall effect: Z =	11 11 ble 1.33 (P = 0 * term 16 16 ble	97 .18) .89 .89	28	<b>159</b> 93	<b>100.0%</b> 100.0%	0.64 [0.34 , 1.23] 1.04 [0.56 , 1.96]	•
illy (HGGN) 2000  ubtotal (95% CI)  otal events: leterogeneity: Not applica est for overall effect: Z =  .68.7 excitement - short shigooka 2001  ubtotal (95% CI) otal events: leterogeneity: Not applica est for overall effect: Z = 6	11 11 ble 1.33 (P = 0 term 16 16 ble 0.14 (P = 0	97 .18) .89 .89	28	<b>159</b> 93	<b>100.0%</b> 100.0%	0.64 [0.34 , 1.23] 1.04 [0.56 , 1.96]	•
illy (HGGN) 2000  ubtotal (95% CI)  otal events: eterogeneity: Not applica est for overall effect: Z =  .68.7 excitement - short ehigooka 2001  ubtotal (95% CI) otal events: eterogeneity: Not applica est for overall effect: Z = 6  .68.8 hostility - short te	11 11 ble 1.33 (P = 0 term 16 16 ble 0.14 (P = 0	97 .18) .89 .89	28	93 93	<b>100.0%</b> 100.0%	0.64 [0.34 , 1.23] 1.04 [0.56 , 1.96]	•
ulty (HGGN) 2000 ubtotal (95% CI) otal events: eterogeneity: Not applica est for overall effect: Z =  68.7 excitement - short higooka 2001 ubtotal (95% CI) otal events: eterogeneity: Not applica est for overall effect: Z =  68.8 hostility - short te easley (HGAD) 1996a	11 11 ble 1.33 (P = 0 term 16 16 ble 0.14 (P = 0	97 .18) .89 .89)	28 16 16	93 93	100.0% 100.0% 100.0%	0.64 [0.34 , 1.23] 1.04 [0.56 , 1.96] 1.04 [0.56 , 1.96] 0.61 [0.27 , 1.42]	•
ulty (HGGN) 2000 ubtotal (95% CI) otal events: eterogeneity: Not applica est for overall effect: Z =  68.7 excitement - short higooka 2001 ubtotal (95% CI) otal events: eterogeneity: Not applica est for overall effect: Z =  68.8 hostility - short te easley (HGAD) 1996a ubtotal (95% CI)	11 11 ble 1.33 (P = 0 term 16 16 ble 0.14 (P = 0	97 .18) .89 .89)	28 16 16	93 93 198	100.0% 100.0% 100.0%	0.64 [0.34 , 1.23] 1.04 [0.56 , 1.96] 1.04 [0.56 , 1.96]	•
ulty (HGGN) 2000 ubtotal (95% CI) otal events: eterogeneity: Not applica est for overall effect: Z =  68.7 excitement - short higooka 2001 ubtotal (95% CI) otal events: eterogeneity: Not applica est for overall effect: Z = 6  68.8 hostility - short te easley (HGAD) 1996a ubtotal (95% CI) otal events:	11 11 ble 1.33 (P = 0 term 16 ble 0.14 (P = 0 term 6 6	97 .18) .89 .89)	28 16 16	93 93 198	100.0% 100.0% 100.0%	0.64 [0.34 , 1.23] 1.04 [0.56 , 1.96] 1.04 [0.56 , 1.96] 0.61 [0.27 , 1.42]	
Illy (HGGN) 2000  Jubtotal (95% CI)  Jotal events:  Leterogeneity: Not applical  Leterostal (95% CI)  Jubtotal (95% CI)  Jubtotal (95% CI)  Jubtotal (95% CI)  Jubtotal events:  Leterogeneity: Not applical  Leterostal (95% CI)  Jubtotal (95% CI)	11 11 ble 1.33 (P = 0 1.4 (P = 0	97 .18) .89 .89) .69	28 16 16	93 93 198	100.0% 100.0% 100.0%	0.64 [0.34 , 1.23] 1.04 [0.56 , 1.96] 1.04 [0.56 , 1.96] 0.61 [0.27 , 1.42]	•
illy (HGGN) 2000  ubtotal (95% CI)  otal events: eterogeneity: Not applical est for overall effect: Z =  68.7 excitement - short chigooka 2001  ubtotal (95% CI) otal events: eterogeneity: Not applical est for overall effect: Z =  68.8 hostility - short te easley (HGAD) 1996a  ubtotal (95% CI) otal events: eterogeneity: Not applical est for overall effect: Z =  68.8 hostility - short te easley (HGAD) 1996a  ubtotal (95% CI) otal events: eterogeneity: Not applical est for overall effect: Z =	11 11 ble 1.33 (P = 0 1.33 (P	97 .18) .89 .89) .69	28 16 16	93 93 198	100.0% 100.0% 100.0%	0.64 [0.34 , 1.23] 1.04 [0.56 , 1.96] 1.04 [0.56 , 1.96] 0.61 [0.27 , 1.42]	
illy (HGGN) 2000  ubtotal (95% CI)  otal events: eterogeneity: Not applical est for overall effect: Z =  .68.7 excitement - short .chigooka 2001  ubtotal (95% CI) otal events: eterogeneity: Not applical est for overall effect: Z =  .68.8 hostility - short te easley (HGAD) 1996a  ubtotal (95% CI) otal events: eterogeneity: Not applical est for overall effect: Z =  .68.9 slow response - sh	11 11 ble 1.33 (P = 0 1.33 (P	97 .18) .89 .89) .69	28 16 16	93 93 198 198	100.0% 100.0% 100.0%	0.64 [0.34 , 1.23] 1.04 [0.56 , 1.96] 1.04 [0.56 , 1.96] 0.61 [0.27 , 1.42]	•
illy (HGGN) 2000  ubtotal (95% CI)  otal events: leterogeneity: Not applical est for overall effect: Z =  .68.7 excitement - short shigooka 2001  ubtotal (95% CI) otal events: leterogeneity: Not applical est for overall effect: Z =  .68.8 hostility - short te easley (HGAD) 1996a  ubtotal (95% CI) otal events: leterogeneity: Not applical est for overall effect: Z =  .68.9 slow response - sh ong 2009c	11 11 ble 1.33 (P = 0 1.33 (P	97 .18) .89 .89) .69 .69	28 16 16 28 28	93 93 198 198	100.0% 100.0% 100.0% 100.0%	0.64 [0.34, 1.23]  1.04 [0.56, 1.96]  1.04 [0.56, 1.96]  0.61 [0.27, 1.42]  0.61 [0.27, 1.42]	*
illy (HGGN) 2000  ubtotal (95% CI)  otal events: leterogeneity: Not applical est for overall effect: Z =  .68.7 excitement - short shigooka 2001  ubtotal (95% CI)  otal events: leterogeneity: Not applical est for overall effect: Z =  .68.8 hostility - short te easley (HGAD) 1996a  ubtotal (95% CI)  otal events: leterogeneity: Not applical est for overall effect: Z =  .68.9 slow response - sh ong 2009c  ubtotal (95% CI)	11 11 ble 1.33 (P = 0 1.33 (P	.18) .89 .89) .69 .26)	28 16 16 28 28	93 93 198 198	100.0% 100.0% 100.0% 100.0%	0.64 [0.34, 1.23]  1.04 [0.56, 1.96]  1.04 [0.56, 1.96]  0.61 [0.27, 1.42]  0.61 [0.27, 1.42]	*
illy (HGGN) 2000  ubtotal (95% CI)  otal events: leterogeneity: Not applica cest for overall effect: Z =  .68.7 excitement - short shigooka 2001  ubtotal (95% CI)  otal events: leterogeneity: Not applica	11 11 ble 1.33 (P = 0 1.33 (P	97 .18) .89 .89) .69 .69 .50	28 16 16 28 28	93 93 198 198	100.0% 100.0% 100.0% 100.0%	0.64 [0.34, 1.23]  1.04 [0.56, 1.96]  1.04 [0.56, 1.96]  0.61 [0.27, 1.42]  0.61 [0.27, 1.42]	
Illy (HGGN) 2000  Jubtotal (95% CI)  Jotal events:  Leterogeneity: Not applical  Leterogeneity: Not applical	11 11 ble 1.33 (P = 0  term 16 16 ble 0.14 (P = 0  rm 6 ble 1.14 (P = 0  ort term 10 10 ble 2.15 (P = 0	97 .18) .89 .89) .69 .69 .50	28 16 16 28 28	93 93 198 198	100.0% 100.0% 100.0% 100.0%	0.64 [0.34, 1.23]  1.04 [0.56, 1.96]  1.04 [0.56, 1.96]  0.61 [0.27, 1.42]  0.61 [0.27, 1.42]	
illy (HGGN) 2000  ubtotal (95% CI)  otal events: eterogeneity: Not applical est for overall effect: Z =  68.7 excitement - short chigooka 2001  ubtotal (95% CI) otal events: eterogeneity: Not applical est for overall effect: Z =  68.8 hostility - short te easley (HGAD) 1996a  ubtotal (95% CI) otal events: eterogeneity: Not applical est for overall effect: Z =  68.9 slow response - sh ong 2009c  ubtotal (95% CI) otal events: eterogeneity: Not applical est for overall effect: Z =  68.9 slow response - sh ong 2009c  ubtotal (95% CI) otal events: eterogeneity: Not applical est for overall effect: Z =  68.10 withdrawal - short	11 11 ble 1.33 (P = 0  term 16 16 ble 0.14 (P = 0  rm 6 ble 1.14 (P = 0  ort term 10 10 ble 2.15 (P = 0	97 .18) .89 .89) .69 .69 .50	28 16 16 28 28	93 93 198 198 50	100.0% 100.0% 100.0% 100.0%	0.64 [0.34, 1.23]  1.04 [0.56, 1.96]  1.04 [0.56, 1.96]  0.61 [0.27, 1.42]  0.61 [0.27, 1.42]	
illy (HGGN) 2000  ubtotal (95% CI)  fotal events: leterogeneity: Not applical est for overall effect: Z =  .68.7 excitement - short shigooka 2001  ubtotal (95% CI) fotal events: leterogeneity: Not applical est for overall effect: Z =  .68.8 hostility - short te leasley (HGAD) 1996a  ubtotal (95% CI) fotal events: leterogeneity: Not applical est for overall effect: Z =  .68.9 slow response - sh long 2009c  ubtotal (95% CI) fotal events: leterogeneity: Not applical est for overall effect: Z =  .68.9 slow response - sh long 2009c  ubtotal (95% CI) fotal events: leterogeneity: Not applical	11 11 ble 1.33 (P = 0 term 16 16 ble 0.14 (P = 0 rm 6 ble 1.14 (P = 0 ort term 10 ble 2.15 (P = 0	97 .18) .89 .89) .69 .69 .50 .50	28 16 16 28 28 2	93 93 198 198 50 50	100.0% 100.0% 100.0% 100.0% 100.0%	0.64 [0.34, 1.23]  1.04 [0.56, 1.96]  1.04 [0.56, 1.96]  0.61 [0.27, 1.42]  0.61 [0.27, 1.42]  5.00 [1.15, 21.67]  5.00 [1.15, 21.67]	

							I
Heterogeneity: Not applica		7)					
Test for overall effect: Z =	1.84 (P = 0.0	7)					
4.68.11 concentration dif	ficulty - med	dium ter	m				
Crespo-Facorro 2006	1	56	2	55	100.0%	0.49 [0.05 , 5.26]	
Subtotal (95% CI)		56		55	100.0%	0.49 [0.05, 5.26]	
Total events:	1		2				
Heterogeneity: Not applica	ble						
Test for overall effect: Z =	0.59 (P = 0.5	6)					
4.68.12 delusions - mediu	m term						
Lilly (S029) 2007	7	133	11	141	100.0%	0.67 [0.27, 1.69]	
Subtotal (95% CI)		133		141	100.0%	0.67 [0.27 , 1.69]	
Total events:	7		11			- , -	
Heterogeneity: Not applica	ble						
Test for overall effect: Z =		0)					
4.68.13 suicide attempt-ı	madium tarr	n					
4.88.13 suicide attempt-1 Lilly (S029) 2007	nealum terr 4	n 133	5	1/1	100.0%	0 85 10 22 2 001	<u> </u>
, ,	4		5			0.85 [0.23 , 3.09]	
Subtotal (95% CI)	4	133	5	141	100.0%	0.85 [0.23, 3.09]	
Total events:	4 blo		Э				
Heterogeneity: Not applica Test for overall effect: Z = 0		0)					
4.68.14 hallucinat ions-me	dium term						
Lilly (S029) 2007	1	131	4	141	100.0%	0.27 [0.03 , 2.38]	
Subtotal (95% CI)		131	7		100.0%	0.27 [0.03 , 2.38]	
Total events:	1	131	4	141	100.0 /0	0.21 [0.03 , 2.36]	
Heterogeneity: Not applica			7				
Test for overall effect: $Z = \frac{1}{2}$		(4)					
rest for overall effect. Z =	1.10 (P = 0.2	4)					
4.68.15 hallucinations-lor	ng term						
Lilly (HGGN) 2000	11	97	18	159	100.0%	1.00 [0.49, 2.03]	-
Subtotal (95% CI)		97		159	100.0%	1.00 [0.49, 2.03]	_
Total events:	11		18				<b>T</b>
Heterogeneity: Not applica	ble						
Test for overall effect: Z =	0.00 (P = 1.0	0)					
4.68.16 depression - long	term						
Lilly (HGGN) 2000	11	97	28	159	100.0%	0.64 [0.34 , 1.23]	_
Subtotal (95% CI)		97		159	100.0%	0.64 [0.34 , 1.23]	
Total events:	11		28			- , -	
Heterogeneity: Not applica							
Test for overall effect: Z =		8)					
4.68.17 pain - long term							
Lilly (HGGN) 2000	7	97	20	159	100.0%	0.57 [0.25 , 1.31]	
Subtotal (95% CI)	•	97		159	100.0%	0.57 [0.25 , 1.31]	
Total events:	7		20			[,]	
Heterogeneity: Not applica							
Test for overall effect: Z =		9)					
4.68.18 rhinitis - long teri	m						
Lilly (HGGN) 2000	19	97	19	159	100.0%	1.64 [0.91 , 2.94]	<u> </u>
Subtotal (95% CI)	-	97	-	159	100.0%	1.64 [0.91, 2.94]	
Total events:	19		19			,	
Heterogeneity: Not applica			. •				
Test for overall effect: Z =		0)					
Tank for order 200	OL'2 C	00 45	47 /D ^	000043	12 00/		
Test for subgroup difference	ces: $Chi^2 = 0$ .	00, df =	1/ (P < 0.	.00001)	), I <sup>2</sup> = 0%		0.01 0.1 1 10 100
							Olanzapine Haloperidol

Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 68: Adverse effects/events: 8a. Specific - arousal - various [non-sleep] measures

Study or Subgroup	Haloper Events	idol Total	Olanza Events	pine Total	Weight	Risk Ratio IV, Random, 95% CI	Risk Ratio IV, Random, 95% CI
4.69.1 drowsiness - shor	+ + 0 =						
<b>4.69.1 drowsiness - snor</b> Avasthi 2001	tterm 5	10	9	17	0.00/	0.04[0.44 0.00]	
	23		59		8.2%	0.94 [0.44 , 2.03]	_
Beasley (HGAD) 1996a		69		198	20.0%	1.12 [0.75 , 1.66]	*
Ding 2013	8	38	12	38	8.1%	0.67 [0.31 , 1.44]	
Ishigooka 2001	6	89	9	93	5.3%	0.70 [0.26 , 1.88]	<del></del>
Jiang 2009b	8	62	6	54	5.3%	1.16 [0.43 , 3.14]	<del></del>
Li 2005f	4	30	3	30	2.8%	1.33 [0.33 , 5.45]	<del></del>
Liu 2012ao	1	39	4	37	1.3%	0.24 [0.03 , 2.03]	
Pan 2005	8	42	12	42	7.9%	0.67 [0.30 , 1.46]	<del></del>
Qin 2006a	12	40	2	40	2.7%	6.00 [1.43 , 25.11]	<del></del>
Song 2009c	3	50	1	50	1.2%	3.00 [0.32 , 27.87]	<del>-   •</del>
Tollefson (HGAJ) 1997	223	660	369	1336	37.1%	1.22 [1.07 , 1.40]	•
Subtotal (95% CI)		1129		1935	100.0%	1.07 [0.84, 1.37]	<b>•</b>
Total events:	301		486				
Heterogeneity: $Tau^2 = 0.0$	04; Chi <sup>2</sup> = 13	3.66, df	= 10 (P = 0)	).19); I <sup>2</sup> =	: 27%		
Test for overall effect: $Z =$	0.55 (P = 0)	.59)					
4.69.2 drowsiness - dayt	•		_		100.00	0.05 (0.00 0.0=	_
Crespo-Facorro 2006	0	56	9		100.0%	0.05 [0.00 , 0.87]	
Subtotal (95% CI)		56		55	100.0%	0.05 [0.00, 0.87]	
Total events:	0		9				
Heterogeneity: Not applic							
Test for overall effect: Z =	2.06 (P = 0	.04)					
A CO Desidente de la companya de la							
4.69.3 sedation - short t		40	4	10	100.00/	0.05 [0.00 4.00]	_
Mousavi 2013	1	10	4		100.0%	0.25 [0.03 , 1.86]	
Subtotal (95% CI)		10		10	100.0%	0.25 [0.03, 1.86]	
Total events:	1		4				
Heterogeneity: Not applic		4.5					
Test for overall effect: Z =	: 1.35 (P = 0	.18)					
4.69.4 sleep - difficulty i	n gotting t	o sloon	short to	m			
Beasley (E003) 1997	2	81	- 311011 (e) 25	350	6.8%	0.25 [0.00 1.42]	
• • •						0.35 [0.08 , 1.43]	
Beasley (HGAD) 1996a	14	69	42	198	21.7%	0.96 [0.56 , 1.64]	<del>-</del>
Ishigooka 2001	42	89	19	93	24.3%	2.31 [1.46 , 3.65]	-
Liu 2010l	0	50	4	50	1.9%	0.11 [0.01 , 2.01]	<del></del>
Liu 2012ao	5	39	5	37	9.3%	0.95 [0.30 , 3.01]	<del></del>
Tollefson (HGAJ) 1997	207	660	329	1336	33.2%	1.27 [1.10 , 1.47]	-
Zhang 2016al	1	36	2	36	2.8%	0.50 [0.05 , 5.27]	<del></del>
Subtotal (95% CI)		1024		2100	100.0%	1.15 [0.76, 1.73]	•
Total events:	271		426				
Heterogeneity: Tau² = 0.1 Test for overall effect: Z =			= 6 (P = 0.0	03); I <sup>2</sup> = 9	58%		
4.69.5 sleep - insomnia -							
Lilly (S029) 2007	8	133	6		100.0%	1.41 [0.50 , 3.97]	-
Subtotal (95% CI)		133		141	100.0%	1.41 [0.50, 3.97]	
Total events:	8		6				
Heterogeneity: Not applic							
Test for overall effect: Z =	0.66 (P = 0	.51)					
4.69.6 sleep - increased	hours - land	, term					
Crespo-Facorro 2006	ilours - toliş 1	56	3	55	100.0%	0.33 [0.04 , 3.05]	
Subtotal (95% CI)	ı	<b>56</b>	3	55			
Total events:	1	36	3	55	100.0%	0.33 [0.04, 3.05]	
			3				
Heterogeneity: Not applic Test for overall effect: Z =		.33)					
. Socior overall ellect. Z =	3.55 (i = 0	.00)					
4.69.7 somnolence - long	g term						
Crespo-Facorro 2006	0	56	19	55	41.3%	0.03 [0.00 , 0.41]	
Lilly (HGGN) 2000	18	97	41	159	58.7%	0.72 [0.44 , 1.18]	
Subtotal (95% CI)	10	153	71	214		0.18 [0.01, 4.58]	
Total events:	18	133	60	214	100.0%	U.10 [U.U1 , 4.38]	
Heterogeneity: Tau <sup>2</sup> = 4.5		40. df –		2): I <sup>2</sup> = 8	1%		
Test for overall effect: Z =			. (1 = 0.07	_,, 1 = 0	. 70		
4.69.8 somnolence-medi	ium term						
		100	3	141	100.0%	0.71 [0.12 , 4.16]	
	2	1.5.5					
Lilly (S029) 2007	2	133 <b>133</b>	3				
	2	133 133	3	141		0.71 [0.12, 4.16]	

4.69.9 insomnia - short to	erm							
Kinon 2004	6	48	3	52	100.0%	2.17 [0.57 , 8.19]	<b></b>	
Subtotal (95% CI)		48		52	100.0%	2.17 [0.57, 8.19]		
Total events:	6		3					
Heterogeneity: Not applica	able							
Test for overall effect: Z =	1.14 (P = 0.2	25)						
4.69.10 somnolence - sho	rt term							
Kinon 2004	12	48	9	52	100.0%	1.44 [0.67 , 3.12]		
Subtotal (95% CI)		48		52	100.0%	1.44 [0.67, 3.12]	<u> </u>	
Total events:	12		9					
Heterogeneity: Not applica	able							
Test for overall effect: Z =	0.94 (P = 0.3	35)						
4.69.11 insomnia - long to	erm							
Lilly (HGGN) 2000	20	97	26	159	100.0%	1.26 [0.75 , 2.13]	•	
Subtotal (95% CI)		97		159	100.0%	1.26 [0.75 , 2.13]	<u> </u>	
Total events:	20		26					
Heterogeneity: Not applica	able							
Test for overall effect: Z =	0.86 (P = 0.3)	39)						

Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 69: Adverse effects/events: 8b. Specific - arousal - sleep/sleepiness - various binary outcomes

Study or Subgroup	-	lol otal	Olanza <sub>l</sub> Events	oine Total	Weight	Risk Ratio IV, Random, 95% CI	Risk Ratio IV, Random, 95% CI
4.70.1 cardiac disorders	- unspecifie	d - sho	rt term				
Gründer (NeSSy) 2012	0	27	1	21	100.0%	0.26 [0.01, 6.12]	
Subtotal (95% CI)		27		21	100.0%	0.26 [0.01, 6.12]	
Total events:	0		1				
Heterogeneity: Not application	able						
Test for overall effect: Z =	0.83 (P = 0.4	40)					
4.70.2 cardiovascular - p	alpitations -	short	term				
Ding 2013	5	38	9	38	17.0%	0.56 [0.21 , 1.50]	
Li 2005f	1	30	2	30	3.7%	0.50 [0.05 , 5.22]	
Qin 2006a	4	40	2	40	7.3%	2.00 [0.39 , 10.31]	<del></del>
Song 2009c	7	50	3	50	11.1%	2.33 [0.64 , 8.51]	<del>  • •</del>
Tollefson (HGAJ) 1997	87	660	116	1336	60.9%	1.52 [1.17 , 1.97]	
Subtotal (95% CI)		818		1494	100.0%	1.31 [0.82, 2.09]	•
Total events:	104		132				_
Heterogeneity: Tau <sup>2</sup> = 0.0 Test for overall effect: Z =	-		4 (P = 0.27	7); $I^2 = 2$	2%		
1 70 2 alaat wa aa walia a wa	h !!	aba					
<b>4.70.3 elect rocardiog ra</b> Jiang 2009b	m abnormali 3	ty - sho 54	ort term 2	62	36.7%	1 72 [0 20 0 02]	_
Jiang 2009b Liu 2012ao	3 1	39	3	62 37	24.2%	1.72 [0.30 , 9.93] 0.32 [0.03 , 2.91]	
Qin 2006a	2	39 40	0	40	13.7%		-
Song 2009c	4	50	1	50	25.4%	-	<del></del>
~	4	183	'	189	100.0%	4.00 [0.46 , 34.54]	
<b>Subtotal (95% CI)</b> Total events:	10	183	6	189	100.0%	1.64 [0.52, 5.15]	
Heterogeneity: Tau <sup>2</sup> = 0.1		n df	-	5\· I2 O	0/		
Test for overall effect: $Z =$			3 (F = 0.30	0), 1 = 9	70		
4.70.4 hypotension - pos	stural - short	term					
Xianzhen 2004	3	60	3	60	100.0%	1.00 [0.21 , 4.76]	_
Subtotal (95% CI)		60		60	100.0%	1.00 [0.21, 4.76]	
Total events:	3		3				
Heterogeneity: Not application  Test for overall effect: Z = 4.70.5 QTc interval proto	= 0.00 (P = 1.0	·	rt term				
-							
Gründer (NeSSy) 2012	0	27	2	21	31.1%	0.16 [0.01 , 3.11]	
	0 1	27 175	2 17	21 175	31.1% 68.9%	0.16 [0.01 , 3.11] 0.06 [0.01 , 0.44]	
Zubair 2020					68.9%		
Zubair 2020 Subtotal (95% CI) Total events:	1	175 <b>202</b>	17 19	175 <b>196</b>	68.9% <b>100.0%</b>	0.06 [0.01 , 0.44]	
Zubair 2020 <b>Subtotal (95% CI)</b> Total events: Heterogeneity: Tau <sup>2</sup> = 0.0	1 1 00; Chi² = 0.2	175 <b>202</b> 9, df =	17 19	175 <b>196</b>	68.9% <b>100.0%</b>	0.06 [0.01 , 0.44]	
Zubair 2020  Subtotal (95% CI)  Total events:  Heterogeneity: Tau <sup>2</sup> = 0.0  Test for overall effect: Z =	1 00; Chi² = 0.2 2.98 (P = 0.0) 0000000000000000000000000000000000	175 <b>202</b> 9, df = 003) 5s - me	17 19 1 (P = 0.59	175 <b>196</b> 9); I <sup>2</sup> = 0	68.9% <b>100.0%</b> %	0.06 [0.01 , 0.44] 0.08 [0.02 , 0.42]	
Zubair 2020  Subtotal (95% CI)  Total events:  Heterogeneity: Tau <sup>2</sup> = 0.0  Test for overall effect: Z =  4.70.6 QTc interval prote  Kahn (EUFEST) 2005	1 00; Chi <sup>2</sup> = 0.2 - 2.98 (P = 0.0	175 <b>202</b> 9, df = 003) 5s - mea	17 19 1 (P = 0.59	175 <b>196</b> 9); I <sup>2</sup> = 0	68.9% <b>100.0%</b> %	0.06 [0.01 , 0.44] 0.08 [0.02 , 0.42] 0.75 [0.08 , 6.79]	
Zubair 2020  Subtotal (95% CI)  Total events:  Heterogeneity: Tau² = 0.0  Test for overall effect: Z =  4.70.6 QTc interval prolo  Kahn (EUFEST) 2005  Subtotal (95% CI)	1 00; Chi <sup>2</sup> = 0.2 2.98 (P = 0.0 0 ongation > 0.3	175 <b>202</b> 9, df = 003) 5s - me	17 19 1 (P = 0.59 dium term 3	175 <b>196</b> 9); I <sup>2</sup> = 0	68.9% <b>100.0%</b> %	0.06 [0.01 , 0.44] 0.08 [0.02 , 0.42]	
Zubair 2020  Subtotal (95% CI)  Total events:  Heterogeneity: Tau² = 0.0  Test for overall effect: Z =  4.70.6 QTc interval prolo  Kahn (EUFEST) 2005  Subtotal (95% CI)  Total events:	1 00; Chi <sup>2</sup> = 0.2 2.98 (P = 0.0 0 ongation > 0.3	175 <b>202</b> 9, df = 003) 5s - mea	17 19 1 (P = 0.59	175 <b>196</b> 9); I <sup>2</sup> = 0	68.9% <b>100.0%</b> %	0.06 [0.01 , 0.44] 0.08 [0.02 , 0.42] 0.75 [0.08 , 6.79]	
Zubair 2020  Subtotal (95% CI)  Total events:  Heterogeneity: Tau² = 0.0  Test for overall effect: Z =  4.70.6 QTc interval prolo  Kahn (EUFEST) 2005  Subtotal (95% CI)  Total events:  Heterogeneity: Not applica	1 00; Chi <sup>2</sup> = 0.2 2.98 (P = 0.0 0 ongation > 0.3 1 1 able	175 202 9, df = 003) 5s - mee 19	17 19 1 (P = 0.59 dium term 3	175 <b>196</b> 9); I <sup>2</sup> = 0	68.9% <b>100.0%</b> %	0.06 [0.01 , 0.44] 0.08 [0.02 , 0.42] 0.75 [0.08 , 6.79]	
Zubair 2020  Subtotal (95% CI)  Total events: Heterogeneity: Tau² = 0.0  Test for overall effect: Z =  4.70.6 QTc interval prolo  Kahn (EUFEST) 2005  Subtotal (95% CI)  Total events: Heterogeneity: Not applic.  Test for overall effect: Z =	1 00; Chi <sup>2</sup> = 0.2 2.98 (P = 0.0 congation > 0.5 1 able = 0.25 (P = 0.8	175 202 9, df = 003) 5s - med 19 19	17 19 1 (P = 0.59 dium term 3 3	175 <b>196</b> 9); I <sup>2</sup> = 0	68.9% <b>100.0%</b> %	0.06 [0.01 , 0.44] 0.08 [0.02 , 0.42] 0.75 [0.08 , 6.79]	
Zubair 2020  Subtotal (95% CI)  Total events: Heterogeneity: Tau² = 0.0  Test for overall effect: Z =  4.70.6 QTc interval prolo  Kahn (EUFEST) 2005  Subtotal (95% CI)  Total events: Heterogeneity: Not applic. Test for overall effect: Z =  4.70.7 cardiovascular - d	1 00; Chi <sup>2</sup> = 0.2 2.98 (P = 0.0 congation > 0.5 1 able = 0.25 (P = 0.8	175 202 9, df = 003) 5s - med 19 19	17 19 1 (P = 0.59 dium term 3 3	175 <b>196</b> 9); I <sup>2</sup> = 0	68.9% <b>100.0%</b> %	0.06 [0.01 , 0.44] 0.08 [0.02 , 0.42] 0.75 [0.08 , 6.79]	
Zubair 2020  Subtotal (95% CI)  Total events: Heterogeneity: Tau² = 0.0  Test for overall effect: Z =  4.70.6 QTc interval proto  Kahn (EUFEST) 2005  Subtotal (95% CI)  Total events: Heterogeneity: Not applic. Test for overall effect: Z =  4.70.7 cardiovascular - d  Beasley (HGAD) 1996a	1 20; Chi <sup>2</sup> = 0.2 2.98 (P = 0.0 2.00 ongation > 0.1 1 1 able 0.25 (P = 0.8	175 202 9, df = 003) 5s - mee 19 19 30)	17 19 1 (P = 0.59 dium term 3 3	175 196 3); I <sup>2</sup> = 0 43 43	68.9% 100.0% % 100.0% 100.0%	0.06 [0.01, 0.44] 0.08 [0.02, 0.42] 0.75 [0.08, 6.79] 0.75 [0.08, 6.79]	
Zubair 2020  Subtotal (95% CI)  Total events: Heterogeneity: Tau² = 0.0  Test for overall effect: Z =  4.70.6 QTc interval proto  Kahn (EUFEST) 2005  Subtotal (95% CI)  Total events: Heterogeneity: Not applic. Test for overall effect: Z =  4.70.7 cardiovascular - d  Beasley (HGAD) 1996a  HGCU (Taiwan) 1998	1 200; Chi <sup>2</sup> = 0.2 2.298 (P = 0.0 2.298 in a congation > 0.9 1 1 able 6.0.25 (P = 0.8 5	175 202 9, df = 2003) 5s - med 19 19 19 30) ort ter 69	17 19 1 (P = 0.59 dium term 3 3	175 196 3); I <sup>2</sup> = 0 43 43	68.9% 100.0% % 100.0% 100.0%	0.06 [0.01 , 0.44] 0.08 [0.02 , 0.42] 0.75 [0.08 , 6.79] 0.75 [0.08 , 6.79] 0.62 [0.25 , 1.58] 1.24 [0.31 , 5.01]	
Zubair 2020  Subtotal (95% CI)  Total events: Heterogeneity: Tau² = 0.0  Test for overall effect: Z =  4.70.6 QTc interval proto  Kahn (EUFEST) 2005  Subtotal (95% CI)  Total events: Heterogeneity: Not applic. Test for overall effect: Z =  4.70.7 cardiovascular - d  Beasley (HGAD) 1996a  HGCU (Taiwan) 1998  Liu 2010I	1 20; Chi <sup>2</sup> = 0.2 2.98 (P = 0.0 2.00 ongation > 0.9 1 1 able 6.0.25 (P = 0.8 5 4	175 202 9, df = 203) 5s - med 19 19 30) ort ter 69 28	17 19 1 (P = 0.59  dium term 3 3	175 196 3); I <sup>2</sup> = 0 43 43 43	68.9% 100.0% 100.0% 100.0% 21.1% 14.9% 5.6%	0.06 [0.01, 0.44] 0.08 [0.02, 0.42] 0.75 [0.08, 6.79] 0.75 [0.08, 6.79] 0.62 [0.25, 1.58] 1.24 [0.31, 5.01] 0.09 [0.01, 1.60]	
Zubair 2020  Subtotal (95% CI)  Total events: Heterogeneity: Tau² = 0.0  Test for overall effect: Z = 4.70.6 QTc interval proto Kahn (EUFEST) 2005  Subtotal (95% CI)  Total events: Heterogeneity: Not applicate for overall effect: Z = 4.70.7 cardiovascular - d  Beasley (HGAD) 1996a  HGCU (Taiwan) 1998  Liu 20101  Liu 2012ao	1 20; Chi <sup>2</sup> = 0.2 2.98 (P = 0.0 2.00 ongation > 0.9 1 1 able 0.25 (P = 0.8 5 4 0	175 202 9, df = 003) 5s - mea 19 19 30) ort ter 69 28 50 39	17 19 1 (P = 0.59  dium term 3 3  m 23 3 5	175 196 9); I <sup>2</sup> = 0 43 43 43 198 26 50 37	68.9% 100.0% % 100.0% 100.0% 21.1% 14.9% 5.6% 15.9%	0.06 [0.01, 0.44] 0.08 [0.02, 0.42] 0.75 [0.08, 6.79] 0.75 [0.08, 6.79] 0.62 [0.25, 1.58] 1.24 [0.31, 5.01] 0.09 [0.01, 1.60] 0.95 [0.26, 3.52]	
Zubair 2020  Subtotal (95% CI)  Total events:  Heterogeneity: Tau² = 0.0  Test for overall effect: Z = 4.70.6 QTc interval proto  Kahn (EUFEST) 2005  Subtotal (95% CI)  Total events:  Heterogeneity: Not applicate for overall effect: Z = 4.70.7 cardiovascular - d  Beasley (HGAD) 1996a  HGCU (Taiwan) 1998  Liu 2010I  Liu 2012ao  Pan 2005	1 20; Chi <sup>2</sup> = 0.2 2.98 (P = 0.0 2.00 ngation > 0.9 1 1 able 0.25 (P = 0.8 5 4 0 4 5	175 202 9, df = 003) 5s - mea 19 19 30) ort ter 69 28 50 39 42	17 19 1 (P = 0.58  dium term 3 3  m 23 3 5 4 7	175 196 9); I <sup>2</sup> = 0 43 43 43 198 26 50 37 42	68.9% 100.0% % 100.0% 100.0% 21.1% 14.9% 5.6% 15.9% 19.1%	0.06 [0.01, 0.44] 0.08 [0.02, 0.42] 0.75 [0.08, 6.79] 0.75 [0.08, 6.79] 0.62 [0.25, 1.58] 1.24 [0.31, 5.01] 0.09 [0.01, 1.60] 0.95 [0.26, 3.52] 0.71 [0.25, 2.07]	
Zubair 2020  Subtotal (95% CI)  Total events:  Heterogeneity: Tau² = 0.0  Test for overall effect: Z = 4.70.6 QTc interval proto  Kahn (EUFEST) 2005  Subtotal (95% CI)  Total events:  Heterogeneity: Not applicate for overall effect: Z = 4.70.7 cardiovascular - d  Beasley (HGAD) 1996a  HGCU (Taiwan) 1998  Liu 2010l  Liu 2012ao  Pan 2005  Qin 2006a	1 20; Chi <sup>2</sup> = 0.2 2.98 (P = 0.0 2.00 ngation > 0.8 1 1 able 0.25 (P = 0.8 4 0 4 5 6	175 202 9, df = 003) 5s - mea 19 19 30) ort ter 69 28 50 39 42 40	17 19 1 (P = 0.58  dium term 3 3  m 23 5 4 7 1	175 196 9); I <sup>2</sup> = 0 43 43 43 198 26 50 37 42 40	68.9% 100.0% % 100.0% 100.0% 21.1% 14.9% 5.6% 15.9% 19.1% 9.2%	0.06 [0.01, 0.44] 0.08 [0.02, 0.42] 0.75 [0.08, 6.79] 0.75 [0.08, 6.79] 0.62 [0.25, 1.58] 1.24 [0.31, 5.01] 0.09 [0.01, 1.60] 0.95 [0.26, 3.52] 0.71 [0.25, 2.07] 6.00 [0.76, 47.60]	
Zubair 2020  Subtotal (95% CI)  Total events:  Heterogeneity: Tau² = 0.0  Test for overall effect: Z = 4.70.6 QTc interval proto  Kahn (EUFEST) 2005  Subtotal (95% CI)  Total events:  Heterogeneity: Not applicate for overall effect: Z = 4.70.7 cardiovascular - d  Beasley (HGAD) 1996a  HGCU (Taiwan) 1998  Liu 2010I  Liu 2012ao  Pan 2005  Qin 2006a  Song 2009c	1 20; Chi <sup>2</sup> = 0.2 2.98 (P = 0.0 2.00 ngation > 0.9 1 1 able 0.25 (P = 0.8 5 4 0 4 5	175 202 9, df = 003) 5s - mea 19 19 30) ort ter 69 28 50 39 42 40 50	17 19 1 (P = 0.58  dium term 3 3  m 23 3 5 4 7	175 196 9); I <sup>2</sup> = 0 43 43 43 198 26 50 37 42 40 50	68.9% 100.0% % 100.0% 100.0% 21.1% 14.9% 5.6% 15.9% 19.1% 9.2% 14.2%	0.06 [0.01, 0.44] 0.08 [0.02, 0.42]  0.75 [0.08, 6.79] 0.75 [0.08, 6.79]  0.62 [0.25, 1.58] 1.24 [0.31, 5.01] 0.09 [0.01, 1.60] 0.95 [0.26, 3.52] 0.71 [0.25, 2.07] 6.00 [0.76, 47.60] 5.00 [1.15, 21.67]	
Zubair 2020  Subtotal (95% CI)  Total events: Heterogeneity: Tau² = 0.0  Test for overall effect: Z =  4.70.6 QTc interval proto  Kahn (EUFEST) 2005  Subtotal (95% CI)  Total events: Heterogeneity: Not applicate for overall effect: Z =  4.70.7 cardiovascular - d  Beasley (HGAD) 1996a  HGCU (Taiwan) 1998  Liu 2010l  Liu 2012ao  Pan 2005  Qin 2006a  Song 2009c  Subtotal (95% CI)	1 20; Chi <sup>2</sup> = 0.2 2.98 (P = 0.0 2.00 ngation > 0.8 1 1 able 0.25 (P = 0.8 4 0 4 5 6	175 202 9, df = 003) 5s - mea 19 19 30) ort ter 69 28 50 39 42 40	17 19 1 (P = 0.59  dium term 3 3 5 4 7 1 2	175 196 9); I <sup>2</sup> = 0 43 43 43 198 26 50 37 42 40	68.9% 100.0% % 100.0% 100.0% 21.1% 14.9% 5.6% 15.9% 19.1% 9.2%	0.06 [0.01, 0.44] 0.08 [0.02, 0.42] 0.75 [0.08, 6.79] 0.75 [0.08, 6.79] 0.62 [0.25, 1.58] 1.24 [0.31, 5.01] 0.09 [0.01, 1.60] 0.95 [0.26, 3.52] 0.71 [0.25, 2.07] 6.00 [0.76, 47.60]	
Zubair 2020  Subtotal (95% CI)  Total events:  Heterogeneity: Tau² = 0.0  Test for overall effect: Z = 4.70.6 QTc interval proto  Kahn (EUFEST) 2005  Subtotal (95% CI)  Total events:  Heterogeneity: Not application of the control o	1 1 00; Chi <sup>2</sup> = 0.2 2.98 (P = 0.0 0 ngation > 0.8 1 1 able 0.25 (P = 0.8 1 izziness - sho 4 0 4 5 6 10 34 46; Chi <sup>2</sup> = 11.	175 202 9, df = 1003) 5s - mea 19 19 30) ort ter 69 28 50 39 42 40 50 318 65, df =	17 19 1 (P = 0.58  dium term 3 3  m 23 5 4 7 1 2	175 196 198 198 26 50 37 42 40 50 443	68.9% 100.0% % 100.0% 100.0% 21.1% 14.9% 5.6% 15.9% 19.1% 9.2% 14.2% 100.0%	0.06 [0.01, 0.44] 0.08 [0.02, 0.42]  0.75 [0.08, 6.79] 0.75 [0.08, 6.79]  0.62 [0.25, 1.58] 1.24 [0.31, 5.01] 0.09 [0.01, 1.60] 0.95 [0.26, 3.52] 0.71 [0.25, 2.07] 6.00 [0.76, 47.60] 5.00 [1.15, 21.67]	
Gründer (NeSSy) 2012 Zubair 2020 Subtotal (95% CI) Total events: Heterogeneity: Tau² = 0.0 Test for overall effect: Z = 4.70.6 QTc interval proto Kahn (EUFEST) 2005 Subtotal (95% CI) Total events: Heterogeneity: Not applic. Test for overall effect: Z = 4.70.7 cardiovascular - d Beasley (HGAD) 1996a HGCU (Taiwan) 1998 Liu 2010l Liu 2012ao Pan 2005 Qin 2006a Song 2009c Subtotal (95% CI) Total events: Heterogeneity: Tau² = 0.4 Test for overall effect: Z =	1 1 00; Chi² = 0.2 2.98 (P = 0.0 0 ngation > 0.8 1 1 able 0.25 (P = 0.8 8 8 8 8 8 1 1 1 4 1 1 1 1 1 1 1 1 1 1	175 202 9, df = 1003) 5s - med 19 19 30) ort ter 69 28 50 39 42 40 50 318 65, df =	17 19 1 (P = 0.58  dium term 3 3  m 23 5 4 7 1 2	175 196 198 198 26 50 37 42 40 50 443	68.9% 100.0% % 100.0% 100.0% 21.1% 14.9% 5.6% 15.9% 19.1% 9.2% 14.2% 100.0%	0.06 [0.01, 0.44] 0.08 [0.02, 0.42]  0.75 [0.08, 6.79] 0.75 [0.08, 6.79]  0.62 [0.25, 1.58] 1.24 [0.31, 5.01] 0.09 [0.01, 1.60] 0.95 [0.26, 3.52] 0.71 [0.25, 2.07] 6.00 [0.76, 47.60] 5.00 [1.15, 21.67]	
Zubair 2020  Subtotal (95% CI)  Total events: Heterogeneity: Tau² = 0.0 Test for overall effect: Z =  4.70.6 QTc interval prolo Kahn (EUFEST) 2005  Subtotal (95% CI) Total events: Heterogeneity: Not application Test for overall effect: Z =  4.70.7 cardiovascular - d Beasley (HGAD) 1996a HGCU (Taiwan) 1998 Liu 2010l Liu 2012ao Pan 2005 Qin 2006a Song 2009c  Subtotal (95% CI) Total events: Heterogeneity: Tau² = 0.4 Test for overall effect: Z =	1 1 00; Chi² = 0.2 2.98 (P = 0.0 0 ngation > 0.8 1 1 able 0.25 (P = 0.8 8 8 8 8 8 1 1 1 4 1 1 1 1 1 1 1 1 1 1	175 202 9, df = 1003) 5s - med 19 19 30) ort ter 69 28 50 39 42 40 50 318 65, df =	17 19 1 (P = 0.58  dium term 3 3  m 23 5 4 7 1 2	175 196 198 26 50 37 42 40 50 443 07);   <sup>2</sup> =	68.9% 100.0% % 100.0% 100.0% 21.1% 14.9% 5.6% 15.9% 19.1% 9.2% 14.2% 100.0%	0.06 [0.01, 0.44] 0.08 [0.02, 0.42]  0.75 [0.08, 6.79] 0.75 [0.08, 6.79]  0.62 [0.25, 1.58] 1.24 [0.31, 5.01] 0.09 [0.01, 1.60] 0.95 [0.26, 3.52] 0.71 [0.25, 2.07] 6.00 [0.76, 47.60] 5.00 [1.15, 21.67]	
Zubair 2020  Subtotal (95% CI)  Total events: Heterogeneity: Tau² = 0.0  Test for overall effect: Z =  4.70.6 QTc interval prolo  Kahn (EUFEST) 2005  Subtotal (95% CI)  Total events: Heterogeneity: Not application  Test for overall effect: Z =  4.70.7 cardiovascular - d  Beasley (HGAD) 1996a  HGCU (Taiwan) 1998  Liu 2010l  Liu 2012ao  Pan 2005  Qin 2006a  Song 2009c  Subtotal (95% CI)  Total events: Heterogeneity: Tau² = 0.4  Test for overall effect: Z =	1 1 00; Chi² = 0.2 2.98 (P = 0.0 0 ngation > 0.9 1 1 able 0.25 (P = 0.8 1 izziness - sho 4 0 4 5 6 10 34 46; Chi² = 11.4 0.31 (P = 0.3) 0 n - medium	175 202 9, df = 1903) 5s - mean 19 19 30) ort ter 69 28 50 39 42 40 50 318 65, df =	17 19 1 (P = 0.59  dium term 3 3  m 23 5 4 7 1 2 45 = 6 (P = 0.0	175 196 3);   <sup>2</sup> = 0 43 43 43 43 40 50 443 07);   <sup>2</sup> =	68.9% 100.0% 100.0% 100.0% 21.1% 14.9% 5.6% 15.9% 19.1% 9.2% 14.2% 100.0% 48%	0.06 [0.01, 0.44] 0.08 [0.02, 0.42]  0.75 [0.08, 6.79] 0.75 [0.08, 6.79]  0.62 [0.25, 1.58] 1.24 [0.31, 5.01] 0.09 [0.01, 1.60] 0.95 [0.26, 3.52] 0.71 [0.25, 2.07] 6.00 [0.76, 47.60] 5.00 [1.15, 21.67] 1.13 [0.53, 2.37]	
Zubair 2020  Subtotal (95% CI)  Total events: Heterogeneity: Tau² = 0.0  Test for overall effect: Z =  4.70.6 QTc interval proto Kahn (EUFEST) 2005  Subtotal (95% CI)  Total events: Heterogeneity: Not applica Test for overall effect: Z =  4.70.7 cardiovascular - d  Beasley (HGAD) 1996a  HGCU (Taiwan) 1998  Liu 2010l  Liu 2012ao  Pan 2005  Qin 2006a  Song 2009c  Subtotal (95% CI)  Total events: Heterogeneity: Tau² = 0.4  Test for overall effect: Z =  4.70.8 blood hypertensic  Lilly 2006a  Subtotal (95% CI)	1 1 00; Chi² = 0.2 2.98 (P = 0.0 0 ngation > 0.9 1 1 able 0.25 (P = 0.8 1 izziness - sho 4 0 4 5 6 10 34 46; Chi² = 11.4 0.31 (P = 0.3) 0 n - medium	175 202 9, df = 003) 5s - mean 19 19 30) ort ter 69 28 50 39 42 40 50 318 65, df = 76) term 40	17 19 1 (P = 0.59  dium term 3 3  m 23 5 4 7 1 2 45 = 6 (P = 0.0	175 196 3);   <sup>2</sup> = 0 43 43 43 43 40 50 443 07);   <sup>2</sup> =	68.9% 100.0% 100.0% 100.0% 21.1% 14.9% 5.6% 15.9% 19.1% 9.2% 14.2% 100.0%	0.06 [0.01, 0.44] 0.08 [0.02, 0.42]  0.75 [0.08, 6.79] 0.75 [0.08, 6.79]  0.62 [0.25, 1.58] 1.24 [0.31, 5.01] 0.09 [0.01, 1.60] 0.95 [0.26, 3.52] 0.71 [0.25, 2.07] 6.00 [0.76, 47.60] 5.00 [1.15, 21.67] 1.13 [0.53, 2.37]	
Zubair 2020  Subtotal (95% CI)  Total events: Heterogeneity: Tau² = 0.0  Test for overall effect: Z =  4.70.6 QTc interval proto Kahn (EUFEST) 2005  Subtotal (95% CI)  Total events: Heterogeneity: Not applicated for overall effect: Z =  4.70.7 cardiovascular - d  Beasley (HGAD) 1996a  HGCU (Taiwan) 1998  Liu 2010l  Liu 2012ao  Pan 2005  Qin 2006a  Song 2009c  Subtotal (95% CI)  Total events: Heterogeneity: Tau² = 0.4  Test for overall effect: Z =  4.70.8 blood hypertensically application of the control of the c	1 1 00; Chi² = 0.2 2.98 (P = 0.0 0 ngation > 0.9 1 1 able 0.25 (P = 0.8 1 izziness - sho 4 0 4 5 6 10 34 46; Chi² = 11.0 0 - medium 2 able	175 <b>202</b> 9, df = 003) 5s - mea 19 19 30) ort ter 69 28 50 39 42 40 50 318 65, df = 76) term 40 40	17 19 1 (P = 0.59  dium term 3 3 3  m 23 5 4 7 1 2 45 = 6 (P = 0.0	175 196 3);   <sup>2</sup> = 0 43 43 43 43 40 50 443 07);   <sup>2</sup> =	68.9% 100.0% 100.0% 100.0% 21.1% 14.9% 5.6% 15.9% 19.1% 9.2% 14.2% 100.0%	0.06 [0.01, 0.44] 0.08 [0.02, 0.42]  0.75 [0.08, 6.79] 0.75 [0.08, 6.79]  0.62 [0.25, 1.58] 1.24 [0.31, 5.01] 0.09 [0.01, 1.60] 0.95 [0.26, 3.52] 0.71 [0.25, 2.07] 6.00 [0.76, 47.60] 5.00 [1.15, 21.67] 1.13 [0.53, 2.37]	


Lilly 2006a	2	40	0	31	100.0%	3.90 [0.19 , 78.46]	
Subtotal (95% CI)		40		31	100.0%	3.90 [0.19 , 78.46]	
Total events:	2		0				
Heterogeneity: Not applica	ble						
Test for overall effect: Z =	0.89 (P = 0.3	37)					
4.70.10 blood hypertensi	on - short t	erm					
Saddichha 2007	1	31	21	35	100.0%	0.05 [0.01 , 0.38]	<b>←</b>
Subtotal (95% CI)		31		35	100.0%	0.05 [0.01, 0.38]	
Total events:	1		21				
Heterogeneity: Not applica	ble						
Test for overall effect: $Z = Z$	2.94 (P = 0.0	003)					
4.70.11 myocardial tiredr	ness - short	term					
Qin 2006a	6	40	2	40	50.0%	3.00 [0.64 , 13.98]	<del>                                     </del>
Zhang 2010ae	6	40	2	40	50.0%	3.00 [0.64 , 13.98]	<del>                                     </del>
Subtotal (95% CI)		80		80	100.0%	3.00 [1.01, 8.91]	
Total events:	12		4				
Heterogeneity: Tau <sup>2</sup> = 0.00	0; $Chi^2 = 0.0$	0, df = 1	(P = 1.00)	$I^2 = 0$	%		
Γest for overall effect: Z =	1.98 (P = 0.0	05)					
1.70.12 nodal tachycardia	a - short ter	m					
Pan 2005	5	42	2	42	50.7%	2.50 [0.51 , 12.17]	<del></del>
Zheng 2003b	2	34	4	34	49.3%	0.50 [0.10 , 2.55]	
Subtotal (95% CI)		76		76	100.0%	1.13 [0.23, 5.48]	
Total events:	7		6				T
Heterogeneity: Tau <sup>2</sup> = 0.62	2; Chi <sup>2</sup> = 1.9	3, df = 1 (	P = 0.16	$I^2 = 48$	3%		
Test for overall effect: $Z = 0$	0.15 (P = 0.8	38)					
	01.12	00 11	44 (D. 0	00001)	12 00/		
Test for subgroup difference	ces: Uni* = 0	.uu. at =	II(P < 0.	UUUU1)	. I = U%		0.01 0.1 1 10 100

Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 70: Adverse effects/events: 9a. Specific - cardiovascular - various binary measures

Study or Subgroup					anzapine	2		Mean Difference	Mean Difference
,	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
4.71.1 systolic									
Buchanan 2003	122.5	18.4	32	130.2	14.6	28	13.4%	-7.70 [-16.06, 0.66]	
Saddichha 2007	119	4.5	31	125.2	8.7	35	86.6%	-6.20 [-9.49 , -2.91]	-
Subtotal (95% CI)			63			63	100.0%	-6.40 [-9.46 , -3.34]	
4.71.2 diastolic									
Buchanan 2003	78.6	8.8	32	79.6	10.3	28	31.0%	-1.00 [-5.88 , 3.88]	
Saddichha 2007	79.2	4.9	31	81.4	8.4	35	69.0%	-2.20 [-5.47 , 1.07]	
Subtotal (95% CI)			63			63	100.0%	-1.83 [-4.55 , 0.89]	
Heterogeneity: Tau <sup>2</sup> = 0	0.00; Chi <sup>2</sup> =	0.16, df	= 1 (P = 0	.69); I <sup>2</sup> = 0	%				
Toot for averall affects 7	z = 1.32 (P	= 0.19)							
Test for overall effect: Z	- (								
rest for overall ellect. 2	- (								-10 -5 0 5 10

Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 71: Adverse effects/events: 9b. Specific - cardiovascular - blood pressure endpoint - short term (high=poor)


	Halope	ridol	Olanza	pine		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
4.72.1 anorexia - short t		00	4	00	40.40/	0.00 [4.05 44.00]	
Ishigooka 2001	15 28	89	4	93	40.1%	3.92 [1.35 , 11.36]	
Qin 2006a		40		40	50.1%	7.00 [2.70 , 18.13]	
Song 2009c	4	50	1	50	9.8%	4.00 [0.46 , 34.54]	
Subtotal (95% CI)	47	179	0	183	100.0%	5.25 [2.68, 10.30]	•
Total events:	47	<b>70</b> 1/	9	a) 12 a.	.,		
Heterogeneity: $Tau^2 = 0.0$ Test for overall effect: $Z =$	-	-	2 (P = 0.7	0); I <sup>2</sup> = 0°	%		
4.72.2 appetite - increas							
Tollefson (HGAJ) 1997	103	660	343		100.0%	0.61 [0.50 , 0.74]	
Subtotal (95% CI)		660		1336	100.0%	0.61 [0.50, 0.74]	<b>♦</b>
Total events:	103		343				
Heterogeneity: Not applic Test for overall effect: Z =		0.00001)					
4.72.3 diarrhoea - short	term						
HGCU (Taiwan) 1998	1	28	3	26	22.0%	0.31 [0.03 , 2.79]	
Qin 2006a	2	40	0	40	13.0%	5.00 [0.25 , 100.97]	
Zubair 2020	6	175	15	175	65.0%	0.40 [0.16 , 1.01]	
Subtotal (95% CI)	·	243		241	100.0%	0.52 [0.17, 1.66]	
Total events:	9	5	18		/ 0	[ , 2.00]	
Heterogeneity: $Tau^2 = 0.3$ Test for overall effect: $Z = 0.3$	31; Chi <sup>2</sup> = 2			7); I <sup>2</sup> = 24	4%		
4.72.4 gastrointestinal	•	,	fied - sho	rt term			
Gründer (NeSSy) 2012	3	27	1 1eu - 3110 1	21	100.0%	2.33 [0.26 , 20.85]	_
Subtotal (95% CI)	3	27 <b>27</b>	ı		100.0%	2.33 [0.26 , 20.85]	
Total events:	3	21	1	21	±00.0%	2.00 [0.20 , 20.00]	
Heterogeneity: Not applic			1				
Test for overall effect: Z =		1 45)					
4 70 5 - 1-1	-14						
<b>4.72.5 sickness - nausea</b> Beasley (HGAD) 1996a	- snort ter 1	<b>m</b> 69	7	198	6.2%	0.44 [0.05 2.07]	
Ding 2013	3	38	4	38	11.9%	0.41 [0.05 , 3.27] 0.75 [0.18 , 3.13]	<u> </u>
Ishigooka 2001		89	2				
	10 4		2	93	11.1%	5.22 [1.18 , 23.18]	
Qin 2006a		40 660	162	40	9.4%	2.00 [0.39 , 10.31]	
Tollefson (HGAJ) 1997	111		102	1336		1.39 [1.11 , 1.73]	
Subtotal (95% CI)	100	896	177	1705	100.0%	1.43 [0.83, 2.46]	<b>—</b>
Total events:	129	07 46	177	C). 12 O	40/		
Heterogeneity: Tau <sup>2</sup> = 0.1 Test for overall effect: Z =			4 (P = 0.2	o), i⁻ = 24	<del>1</del> 70		
4.72.6 nausea -medium t	erm						
Lilly (S029) 2007	4	133	0			9.54 [0.52 , 175.46]	
Cubtatal (OFO/ CI)		122		141	100.0%		
Subtotal (95% CI)		133		141	100.070	9.54 [0.52 , 175.46]	
Total events:	4	133	0	141	100.070	9.54 [0.52 , 175.46]	
Total events: Heterogeneity: Not applic	able		0	141	100.070	9.54 [0.52 , 175.46]	
Total events: Heterogeneity: Not applic	able		0	141	100.0%	9.54 [0.52 , 175.46]	
Total events: Heterogeneity: Not applic Test for overall effect: Z =  4.72.7 nausea -long tern	able : 1.52 (P = 0 n	0.13)					
Total events: Heterogeneity: Not applic Test for overall effect: Z =  4.72.7 nausea -long tern Lilly (HGGN) 2000	able = 1.52 (P = 0	0.13) 97	24	159	100.0%	0.89 [0.47 , 1.66]	
Total events: Heterogeneity: Not applic Test for overall effect: Z =  4.72.7 nausea -long tern Lilly (HGGN) 2000  Subtotal (95% CI)	able = 1.52 (P = 0 <b>n</b> = 13	0.13)	24		100.0%		
Total events: Heterogeneity: Not applic Test for overall effect: Z =  4.72.7 nausea -long tern Lilly (HGGN) 2000  Subtotal (95% CI) Total events:	able = 1.52 (P = 0 n 13	0.13) 97		159	100.0%	0.89 [0.47 , 1.66]	•
Total events:  Heterogeneity: Not applic Test for overall effect: Z =  4.72.7 nausea -long tern Lilly (HGGN) 2000  Subtotal (95% CI) Total events:  Heterogeneity: Not applic Test for overall effect: Z =	able = 1.52 (P = 0 n 13 able	97 <b>97</b>	24	159	100.0%	0.89 [0.47 , 1.66]	
Total events: Heterogeneity: Not applic Test for overall effect: Z =  4.72.7 nausea -long tern Lilly (HGGN) 2000  Subtotal (95% CI) Total events: Heterogeneity: Not applic Test for overall effect: Z =	able 1.52 (P = 0)  13  13  able 0.37 (P = 0)	97 97 97	24	159	100.0%	0.89 [0.47 , 1.66]	
Total events: Heterogeneity: Not applic Test for overall effect: Z =  4.72.7 nausea -long tern Lilly (HGGN) 2000  Subtotal (95% CI) Total events: Heterogeneity: Not applic Test for overall effect: Z =  4.72.8 sickness - vomitin	able 1.52 (P = 0)  13  13  able 0.37 (P = 0)	97 97 97	24	159 <b>159</b>	100.0%	0.89 [0.47 , 1.66]	•
Total events: Heterogeneity: Not applic Test for overall effect: Z =  4.72.7 nausea -long tern Lilly (HGGN) 2000  Subtotal (95% CI) Total events: Heterogeneity: Not applic Test for overall effect: Z =  4.72.8 sickness - vomitin Tollefson (HGAJ) 1997	able 1.52 (P = 0  13  13  able 0.37 (P = 0	97 97 97 0.71)	24 24	159 <b>159</b>	100.0% <b>100.0%</b>	0.89 [0.47 , 1.66] <b>0.89 [0.47 , 1.66]</b>	
Total events: Heterogeneity: Not applic Test for overall effect: Z =  4.72.7 nausea -long tern Lilly (HGGN) 2000  Subtotal (95% CI) Total events: Heterogeneity: Not applic Test for overall effect: Z =  4.72.8 sickness - vomitin Tollefson (HGAJ) 1997  Subtotal (95% CI)	able 1.52 (P = 0  13  13  able 0.37 (P = 0	97 97 0.71) erm 660	24 24	159 <b>159</b>	100.0% <b>100.0%</b>	0.89 [0.47 , 1.66] <b>0.89 [0.47 , 1.66]</b> 1.69 [1.28 , 2.24]	•
Total events: Heterogeneity: Not applic Test for overall effect: Z =  4.72.7 nausea -long tern Lilly (HGGN) 2000  Subtotal (95% CI) Total events: Heterogeneity: Not applic Test for overall effect: Z =  4.72.8 sickness - vomitin Tollefson (HGAJ) 1997  Subtotal (95% CI) Total events: Heterogeneity: Not applic	able 1.52 (P = 0)  13 able 0.37 (P = 0)  18 81 able	97 97 0.71) erm 660 660	24 24 97	159 <b>159</b>	100.0% <b>100.0%</b>	0.89 [0.47 , 1.66] <b>0.89 [0.47 , 1.66]</b> 1.69 [1.28 , 2.24]	•
Total events: Heterogeneity: Not applic Test for overall effect: Z =  4.72.7 nausea -long tern Lilly (HGGN) 2000  Subtotal (95% CI) Total events: Heterogeneity: Not applic Test for overall effect: Z =  4.72.8 sickness - vomitin Tollefson (HGAJ) 1997  Subtotal (95% CI) Total events: Heterogeneity: Not applic	able 1.52 (P = 0)  13 able 0.37 (P = 0)  18 81 able	97 97 0.71) erm 660 660	24 24 97	159 <b>159</b>	100.0% <b>100.0%</b>	0.89 [0.47 , 1.66] <b>0.89 [0.47 , 1.66]</b> 1.69 [1.28 , 2.24]	•
Total events: Heterogeneity: Not applic Test for overall effect: Z =  4.72.7 nausea -long tern Lilly (HGGN) 2000  Subtotal (95% CI) Total events: Heterogeneity: Not applic Test for overall effect: Z =  4.72.8 sickness - vomitin Tollefson (HGAJ) 1997  Subtotal (95% CI) Total events: Heterogeneity: Not applic Test for overall effect: Z =	able 1.52 (P = 0)  13 able 0.37 (P = 0)  81 81 able 3.68 (P = 0)	97 97 0.71) erm 660 660	24 24 97	159 <b>159</b>	100.0% <b>100.0%</b>	0.89 [0.47 , 1.66] <b>0.89 [0.47 , 1.66]</b> 1.69 [1.28 , 2.24]	•
Total events: Heterogeneity: Not applic Test for overall effect: Z =  4.72.7 nausea -long tern Lilly (HGGN) 2000 Subtotal (95% CI) Total events: Heterogeneity: Not applic Test for overall effect: Z =  4.72.8 sickness - vomitin Tollefson (HGAJ) 1997 Subtotal (95% CI)	able 1.52 (P = 0)  13 able 0.37 (P = 0)  81 81 able 3.68 (P = 0)	97 97 0.71) erm 660 660	24 24 97	159 159 1336 1336	100.0% <b>100.0%</b>	0.89 [0.47 , 1.66] <b>0.89 [0.47 , 1.66]</b> 1.69 [1.28 , 2.24]	
Total events: Heterogeneity: Not applic Test for overall effect: Z =  4.72.7 nausea -long tern Lilly (HGGN) 2000  Subtotal (95% CI) Total events: Heterogeneity: Not applic Test for overall effect: Z =  4.72.8 sickness - vomitin Tollefson (HGAJ) 1997  Subtotal (95% CI) Total events: Heterogeneity: Not applic Test for overall effect: Z =  4.72.9 diarrhoea - long t Lilly (HGGN) 2000	able 1.52 (P = 0)  13 able 0.37 (P = 0)  13 able 13 able 13 able 20.37 (P = 0) 81 81 able 23.68 (P = 0)	97 97 0.71) erm 660 660	24 24 97 97	159 159 1336 1336	100.0% 100.0% 100.0% 100.0%	0.89 [0.47, 1.66] 0.89 [0.47, 1.66] 1.69 [1.28, 2.24] 1.69 [1.28, 2.24]	•
Total events: Heterogeneity: Not applic Test for overall effect: Z =  4.72.7 nausea -long tern Lilly (HGGN) 2000  Subtotal (95% CI) Total events: Heterogeneity: Not applic Test for overall effect: Z =  4.72.8 sickness - vomitin Tollefson (HGAJ) 1997  Subtotal (95% CI) Total events: Heterogeneity: Not applic Test for overall effect: Z =  4.72.9 diarrhoea - long t	able 1.52 (P = 0)  13 able 0.37 (P = 0)  13 able 13 able 13 able 20.37 (P = 0) 81 81 able 23.68 (P = 0)	97 97 0.71) erm 660 660 0.0002)	24 24 97 97	159 <b>159</b> 1336 <b>1336</b>	100.0% 100.0% 100.0% 100.0%	0.89 [0.47 , 1.66] 0.89 [0.47 , 1.66] 1.69 [1.28 , 2.24] 1.69 [1.28 , 2.24]	•
Total events: Heterogeneity: Not applic Test for overall effect: Z =  4.72.7 nausea -long tern Lilly (HGGN) 2000  Subtotal (95% CI) Total events: Heterogeneity: Not applic Test for overall effect: Z =  4.72.8 sickness - vomitin Tollefson (HGAJ) 1997  Subtotal (95% CI) Total events: Heterogeneity: Not applic Test for overall effect: Z =  4.72.9 diarrhoea - long t Lilly (HGGN) 2000  Subtotal (95% CI)	able 1.52 (P = 0)  13 able 10.37 (P = 0)  13 able 13 able 13 13 able 14 15 15	97 97 0.71) erm 660 660 0.0002)	24 24 97 97	159 <b>159</b> 1336 <b>1336</b>	100.0% 100.0% 100.0% 100.0%	0.89 [0.47 , 1.66] 0.89 [0.47 , 1.66] 1.69 [1.28 , 2.24] 1.69 [1.28 , 2.24]	



Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 72: Adverse effects/events: 10a. Specific - gastrointestinal

5 20 Haloperidol


Olanzapine



Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 73: Adverse effects/events: 10b. Specific - hepatic/haematological disfunction - short term

	Halope	ridol	Olanza	pine		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
4.74.1 short term							
Crespo-Facorro 2006	17	37	15	33	44.7%	1.01 [0.61 , 1.69]	-
Subtotal (95% CI)		37		33	44.7%	1.01 [0.61, 1.69]	•
Total events:	17		15				Ţ
Heterogeneity: Not appl	licable						
Test for overall effect: Z	z = 0.04 (P)	= 0.97)					
4.74.2 medium term							
Crespo-Facorro 2006	4	20	4	25	7.4%	1.25 [0.36 , 4.38]	
Kahn (EUFEST) 2005	12	27	29	58	47.9%	0.89 [0.54 , 1.46]	-
Subtotal (95% CI)		47		83	55.3%	0.93 [0.59, 1.47]	<u> </u>
Total events:	16		33				Ť
Heterogeneity: $Tau^2 = 0$	0.00; Chi <sup>2</sup> =	0.25, df	= 1 (P = 0	.62); I <sup>2</sup> =	0%		
Test for overall effect: Z	z = 0.31 (P)	= 0.76)					
Total (95% CI)		84		116	100.0%	0.97 [0.69 , 1.36]	
Total events:	33		48				Ĭ
Heterogeneity: $Tau^2 = 0$	0.00; Chi <sup>2</sup> =	0.30, df	= 2 (P = 0	.86); I <sup>2</sup> =	0%		0.01 0.1 1 10 100
Test for overall effect: Z	' = 0.20 (P	= 0.84)					Olanzapine Haloperidol
Test for subgroup differ	rences: Chi	$^{2} = 0.06, $	df = 1 (P =	0.81), I <sup>2</sup>	= 0%		

Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 74: Adverse effects/events: 10c. Specific - hormonal - high prolactin levels




Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 75: Adverse effects/events: 10d. Specific - hormonal - serum levels - short term

	Halope	eridol	Olanza	pine		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
4.77.1 all causes							
Beasley (E003) 1997	1	81	3	350	14.5%	1.44 [0.15 , 13.67]	<del></del>
Tollefson (HGAJ) 1997	2	660	12	1336	33.0%	0.34 [0.08 , 1.50]	<del></del>
Subtotal (95% CI)		741		1686	47.5%	0.54 [0.14 , 2.05]	
Total events:	3		15				
Heterogeneity: Tau <sup>2</sup> = 0. Test for overall effect: Z	-	-	= 1 (P = 0.	29); I <sup>2</sup> = 1	10%		
4.77.2 suicide and accid	dental inju	ry					
Beasley (E003) 1997	1	81	3	350	14.5%	1.44 [0.15 , 13.67]	
Ishigooka 2001	1	89	0	93	7.2%	3.13 [0.13 , 75.92]	
Tollefson (HGAJ) 1997	0	660	9	1336	9.1%	0.11 [0.01 , 1.83]	
Subtotal (95% CI)		830		1779	30.9%	0.78 [0.12 , 5.20]	
Total events:	2		12				
Heterogeneity: Tau <sup>2</sup> = 0. Test for overall effect: Z	-	-	= 2 (P = 0.	23); I <sup>2</sup> = 3	31%		
4.77.3 other causes							
Beasley (E003) 1997	0	81	0	350		Not estimable	
Tollefson (HGAJ) 1997	1	660	3	1336	14.4%	0.67 [0.07 , 6.47]	<del></del>
Subtotal (95% CI)		741		1686	14.4%	0.67 [0.07 , 6.47]	
Total events:	1		3				
Heterogeneity: Not appli Test for overall effect: Z		= 0.73)					
	0.0 . (.	00)					
4.77.4 unknown		600	0	1220	7.00/	6.07.[0.05 140.75]	
Tollefson (HGAJ) 1997	1	660		1336			
Subtotal (95% CI) Total events:	1	660	0	1336	7.2%	6.07 [0.25 , 148.75]	
			U				
Heterogeneity: Not appli Test for overall effect: Z		= 0.27)					
Total (95% CI)		2972		6487	100.0%	0.74 [0.31 , 1.75]	
, ,	7		30			- ,	<b>—</b>
Total events:			0 (D 0	40). 12	20/		. <del> </del>
Heterogeneity: $Tau^2 = 0$	.00; Chi² =	5.98, df =	= 6 (P = 0.	43); I <sup>-</sup> = (	J70		0 0 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
	-		= 6 (P = 0.	43); 1 = (	J70		0.001 0.1 1 10 1000 Olanzapine Haloperidol

Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 77: Adverse effects/events: 12. Specific - death - during study or within 30 days of study discontinuation

-		•		Weight		Risk Ratio IV, Random, 95% CI
rm						
6	10	8	17	68.5%	1.27 [0.62 , 2.60]	<b>——</b>
9	50	3	50	31.5%	3.00 [0.86 , 10.43]	<del>□</del>
	60		67	100.0%	1.67 [0.77, 3.64]	•
15		11				
		1 (P = 0.24)	); I <sup>2</sup> = 2	7%		
erm						
2	133	3	141	100.0%	0.71 [0.12 , 4.16]	
	133		141	100.0%	0.71 [0.12 , 4.16]	
2		3				
ble						
0.38 (P = 0.	70)					
m						
1	56	6	55	100.0%	0.16 [0.02 , 1.32]	
	56		55	100.0%	0.16 [0.02, 1.32]	
1		6				
ble						
1.70 (P = 0.0	09)					
me - mediu						
1	40	3			0.26 [0.03 , 2.36]	<del></del>
	40		31	100.0%	0.26 [0.03 , 2.36]	
1		3				
ble 1 20 (P – 0 :	23)					
1.20 (1 = 0	_0)					
erm 1	50	0	50	100.0%	3 00 [0 13 71 92]	
Į.		U			•	
1	30	0	30	100.070	3.00 [0.13 , 71.92]	
		U				
	50)					
pecified - sl	ort te	erm				
0	27	1	21	100.0%	0.26 [0.01 , 6.12]	
	27		21	100.0%	0.26 [0.01,6.12]	
0		1				
ble						
0.83 (P = 0.4	40)					
ınspecified	- shor	t term				
1	27	1	21	100.0%	0.78 [0.05 , 11.72]	
	27		21	100.0%	0.78 [0.05 , 11.72]	
1		1				
ble						
0.18 (P = 0.8	36)					
m 10		. =		100 == 0	10470 10	$\perp$
10		10				
	89		93	100.0%	1.04 [0.46 , 2.39]	•
		10				
	92)					
orders. un	specifi	ied - short t	erm			
, will	27	4		100.0%	1.36 [0.46 , 4.04]	
7			21		1.36 [0.46 , 4.04]	
7				/ 0		
7 7	27	4				
7		4				
	27	4				
7 ble 0.56 (P = 0.5	<b>27</b> 58)					
7 ble 0.56 (P = 0.5	<b>27</b> 58) cified	- short tern	1	100.0%	0,39   0,14   1   121	
7 ble 0.56 (P = 0.4	27 58) cified - 27		<b>1</b> 21	100.0% 100.0%	0.39 [0.14 , 1.12] 0.39 [0.14 . 1.12]	
7 ble 0.56 (P = 0.4 ders, unspe 4	<b>27</b> 58) cified	- <b>short tern</b> 8	1		0.39 [0.14 , 1.12] <b>0.39 [0.14 , 1.12</b> ]	
7 ble 0.56 (P = 0.4	27 58) cified - 27	- short tern	<b>1</b> 21			
	rm 6 9 15 1; Chi² = 1.3 1.29 (P = 0.3 erm 2 ble 0.38 (P = 0.3 m 1 ble 1.70 (P = 0.4 1 ble 1.20 (P = 0.4 1 ble 0.68 (P = 0.4 1 ble 0.83 (P = 0.4 1 ble 0.18 (P = 0.4 1 ble 0.18 (P = 0.4 1 1 ble 0.18 (P = 0.4 1 1 ble 0.19 (P = 0.4 1 1 1 ble 0.19 (P = 0.4 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	rm  6 10 9 50 60 15 0; Chi² = 1.36, df = 1.29 (P = 0.20)  erm  2 133 2 ble 0.38 (P = 0.70)  m  1 56 56 1 ble 1.70 (P = 0.09)  me - medium term 1 40 40 1 ble 1.20 (P = 0.23)  erm 1 50 50 1 ble 0.68 (P = 0.50)  pecified - short te 0 27 27 0 ble 0.83 (P = 0.40)  inspecified - short te 0 27 27 1 ble 0.18 (P = 0.86)  m  1 89 89 10	rm  6 10 8 9 50 3 60 15 11 0; Chi² = 1.36, df = 1 (P = 0.24) 1.29 (P = 0.20)  erm  2 133 3 133 2 3 ble 0.38 (P = 0.70)  m  1 56 6 56 1 6 ble 1.70 (P = 0.09)  me - medium term 1 40 3 40 1 3 ble 1.20 (P = 0.23)  erm 1 50 0 50 1 0 ble 0.68 (P = 0.50)  pecified - short term 0 27 1 27 0 1 ble 0.83 (P = 0.40)  inspecified - short term 1 27 1 27 1 ble 0.18 (P = 0.86)  m  1 0 89 10 89 10 10 ble	rm  6 10 8 17 9 50 3 50 60 67 15 11 0; Chi² = 1.36, df = 1 (P = 0.24); l² = 2 1.29 (P = 0.20)  erm  2 133 3 141 133 141 2 3 ble 0.38 (P = 0.70)  m  1 56 6 55 56 55 1 6 6 1 7 6 ble 1.70 (P = 0.09)  me - medium term 1 40 3 31 40 31 1 3 ble 1.20 (P = 0.23)  erm  1 50 0 50 50 50 1 0 0 ble 0.68 (P = 0.50)  pecified - short term 0 27 1 21 27 21 0 1 0 ble 0.83 (P = 0.40)  inspecified - short term 1 27 1 21 27 21 1 1 1 1 ble 0.18 (P = 0.86)  m  10 89 10 93 89 93 10 10 10 ble 0.89 93 10 10 00 ble	rm  6	From 1



Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 78: Adverse effects/events: 13. Specific - others

	Ha	loperido	l	Ol	anzapine	•		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
4.79.1 total									
Buchanan 2003	59.4	19.1	28	59.7	20.7	26	22.0%	-0.30 [-10.95 , 10.35]	<b>←</b>
Chaudhry 2003	62.52	22.09	115	66.14	22.99	130	78.0%	-3.62 [-9.27 , 2.03]	
Subtotal (95% CI)			143			156	100.0%	-2.89 [-7.88, 2.10]	
Heterogeneity: Tau <sup>2</sup> =	0.00; Chi <sup>2</sup> =	0.29, df	= 1 (P = 0)	$1.59$ ; $I^2 = 0$	%				
Test for overall effect:	Z = 1.14 (P	= 0.26)							
4.79.2 interpersonal	relations								
Chaudhry 2003	23.14	9.83	115	23.6	9.8	130	100.0%	-0.46 [-2.92, 2.00]	
Subtotal (95% CI)			115			130	100.0%	-0.46 [-2.92, 2.00]	
Heterogeneity: Not app	plicable								$\overline{}$
Test for overall effect:	Z = 0.37 (P	= 0.71)							
4.79.3 intrapsychic fo	oundation	s							
Chaudhry 2003	23.43	7.82	115	24.01	8.05	130	100.0%	-0.58 [-2.57 , 1.41]	_
Subtotal (95% CI)			115			130	100.0%	-0.58 [-2.57, 1.41]	
Heterogeneity: Not app	plicable								$\neg$
Test for overall effect:	Z = 0.57 (P	= 0.57)							
4.79.4 common obje	cts and act	ivities							
Chaudhry 2003	5.84	2.48	115	6.25	2.42	130	100.0%	-0.41 [-1.03 , 0.21]	
Subtotal (95% CI)			115			130	100.0%	-0.41 [-1.03, 0.21]	•
Heterogeneity: Not app	plicable								1
Test for overall effect:	Z = 1.31 (P	= 0.19)							
4.79.5 instrumental	role								
Chaudhry 2003	8.06	3.83	115	9.01	4.25	130	100.0%	-0.95 [-1.96 , 0.06]	<u>-</u>
Subtotal (95% CI)			115			130	100.0%	-0.95 [-1.96 , 0.06]	•
Heterogeneity: Not app									Ť
Test for overall effect:	Z = 1.84 (P	= 0.07)							
4.79.6 common obje		ivities							
Chaudhry 2003	5.84	2.48	115	6.25	2.42	130	100.0%	-0.41 [-1.03 , 0.21]	
Subtotal (95% CI)			115			130	100.0%	-0.41 [-1.03, 0.21]	▼
Heterogeneity: Not app									
Test for overall effect:	Z = 1.31 (P	= 0.19)							
									-10 -5 0 5 1

Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 79: Quality of life: 2a. Specific - average endpoint score - short term (QLS-Heinrich&Carpenter, high=good)


	Hal	loperido	l	Ol	anzapin	2		Mean Difference	Mean Difference		Ris	sk of	f Bia:	s
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI	Α	ВС	: D	E	F
4.80.1 environment														
Chaudhry 2003	59.18	14.43	113	60.37	13.26	129	50.0%	-1.19 [-4.70 , 2.32]		● (	₽ 4	•	•	?
Zhang 2016al	40.2	8.1	36	34.2	7.1	36	50.0%	6.00 [2.48 , 9.52]	<del></del>	?	? (	? ?	•	?
Subtotal (95% CI)			149			165	100.0%	2.40 [-4.64,9.45]						
Heterogeneity: Tau <sup>2</sup> =	22.63; Chi <sup>2</sup>	= 8.04, d	f = 1 (P =	0.005); I <sup>2</sup>	= 88%									
Test for overall effect: 2	Z = 0.67 (P	= 0.50)												
4.80.2 physical healt	h													
Chaudhry 2003	63.43	14.88	113	66	13.92	129	49.3%	-2.57 [-6.22 , 1.08]	<del></del>	•	<b>⊕</b> (	9	•	?
Zhang 2016al	49.7	6.9	36	43.5	6.4	36	50.7%	6.20 [3.13 , 9.27]	_	?	? (	?	•	?
Subtotal (95% CI)			149			165	100.0%	1.87 [-6.72,10.47]						
Heterogeneity: Tau2 =	35.50; Chi <sup>2</sup>	= 12.99,	df = 1 (P :	= 0.0003);	$I^2 = 92\%$									
Test for overall effect:	Z = 0.43 (P	= 0.67)												
4.80.3 psychological	healt h													
Chaudhry 2003	59.18	15.52	113	59.82	16.74	129	48.3%	-0.64 [-4.71, 3.43]	_ <b></b>	● (	<b>Đ 4</b>	•	•	?
Zhang 2016al	35.3	6.2	36	43.7	6.4	36	51.7%	-8.40 [-11.31 , -5.49]	-	?	? (	? ?	•	?
Subtotal (95% CI)			149			165	100.0%	-4.66 [-12.26, 2.94]						
Heterogeneity: Tau <sup>2</sup> =	26.85; Chi <sup>2</sup>	= 9.25, d	f = 1 (P =	0.002); I <sup>2</sup>	= 89%									
Test for overall effect: 2	Z = 1.20 (P	= 0.23)												
4.80.4 social relation	ships													
Chaudhry 2003	54.72	16.7	113	55.36	16.2	129	49.3%	-0.64 [-4.80 , 3.52]		● (	<b>⊕</b> €	<b>)</b> (	•	?
Zhang 2016al	39.3	7.7	36	29	6.6	36	50.7%	10.30 [6.99, 13.61]	T	?	? (	? ?	•	?
Subtotal (95% CI)			149			165	100.0%	4.91 [-5.81,15.63]					Ţ	
Heterogeneity: Tau <sup>2</sup> =	56.16; Chi <sup>2</sup>	= 16.26,	df = 1 (P -	< 0.0001);	$I^2 = 94\%$									
Test for overall effect:	Z = 0.90 (P	= 0.37)												
Test for subgroup diffe	rences: Chi	<sup>2</sup> = 0.00,	df = 3 (P <	< 0.00001)	, I <sup>2</sup> = 0%				-20 -10 0 10 2 Olanzapine Haloperidol	0				
Risk of bias legend														
(A) Random sequence	generation	(selectio	n bias)											
(P) Allocation concoals														

- (B) Allocation concealment (selection bias)
- (C) Blinding of participants and personnel (performance bias)
- (D) Blinding of outcome assessment (detection bias)
- (E) Incomplete outcome data (attrition bias)
  (F) Selective reporting (reporting bias)
  (G) Other bias

 $\label{lem:comparison} \begin{tabular}{ll} Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 80: Quality of life: 2b. Specific -average endpoint score - short term (WHO-QOL-BREF, high=good) \\ \end{tabular}$ 

tudy or Subgroup	Mean	SD 1	le to	Mean	SD	Total	Weight	IV Random 95% CI	IV Pandom 95% CI
cuayor sungroup	Mean	ן עכ	otal	Mean	ספ	iotal	weignt	IV, Random, 95% CI	IV, Random, 95% CI
.81.1 physiological fur	ction								
Song 2009c	68.9	22.71	50	86	18.3	50	46.8%	-17.10 [-25.18 , -9.02]	4=
Tollefson (HGAJ) 1997	82.63	19.99	383	84.19	19.4	772	53.2%	-1.56 [-3.99 , 0.87]	
Subtotal (95% CI)			433			822	100.0%	-8.83 [-24.03, 6.37]	
Heterogeneity: Tau <sup>2</sup> = 111.	47: Chi <sup>2</sup> =	13.02. df =		.0003): I <sup>2</sup> =	92%				
Test for overall effect: $Z = 1$			,	,,					
I 01 2 nhysical role									
<b>I.81.2 physical role</b> Song 2009c	41	32.8	50	68	30.7	50	46.0%	-27.00 [-39.45 , -14.55]	
Tollefson (HGAJ) 1997	68.63	33.42	383	74.3	30.29	772	54.0%	-5.67 [-9.64 , -1.70]	_
Subtotal (95% CI)	00.00	00.12	433	7 1.0	00.20		100.0%	-15.48 [-36.32,5.35]	
Heterogeneity: Tau <sup>2</sup> = 205.	25; Chi² =	10.23, df =		.001); I <sup>2</sup> = 9	90%	022	100.070	-13.40 [-30.32 , 3.33]	
Test for overall effect: $Z = 1$	.46 (P = 0.	15)							
I.81.3 somatic pain									
Song 2009c	66.92	25.49	50	75.34	24.32	50	8.9%	-8.42 [-18.19 , 1.35]	
Follefson (HGAJ) 1997	77.78	21.67	383	80.9	19.77	772	91.1%	-3.12 [-5.70 , -0.54]	
Subtotal (95% CI)			433				100.0%	-3.59 [-6.55,-0.63]	
Heterogeneity: Tau <sup>2</sup> = 0.77	Chi <sup>2</sup> = 1.0	)6. df = 1 (P		$1^2 = 5\%$				,,	
Test for overall effect: $Z = 2$			- 0.00),	676					
1 01 Agonoval basish									
I <b>.81.4 general health</b> Song 2009c	57.63	20.87	50	60.87	19.74	50	8.9%	-3.24 [-11.20 , 4.72]	_
Follefson (HGAJ) 1997	59.31	20.67	383	62.21	20.08	772	91.1%	-2.90 [-5.39 , -0.41]	
Subtotal (95% CI)	JJ.J1	20.40	433	UE.E I	20.00		100.0%	-2.93 [-5.31,-0.55]	<b>_</b>
Heterogeneity: Tau <sup>2</sup> = 0.00	Chi² - n r	11 df = 1 (D		I <sup>2</sup> _ ∩o/		022	100.070	-2.33 [-3.31, -0.35]	<b>—</b>
Heterogeneity: $\Gamma au^2 = 0.00$ $\Gamma$ est for overall effect: $Z = 2$		,	= 0.94);	ı = U%					
01 5116 4 111									
I.81.5 life vitality	617	10.26	ΕO	72.1	16 1	E0	25.5%	-10 /0 17 20 2 /01	_
Song 2009c	61.7 46.22	19.36 17.57	50 383	72.1 51.79	16.1 18.64	50 772	25.5% 74.5%	-10.40 [-17.38 , -3.42]	<del></del> _
Follefson (HGAJ) 1997	46.22	17.57		51./9	18.64			-5.57 [-7.77 , -3.37]	<b>_</b>
Subtotal (95% CI)	Oh:2 1 0	.7 4£ 4 (D	433	12 400/		822	100.0%	-6.80 [-10.93,-2.68]	•
Heterogeneity: Tau² = 4.70 Fest for overall effect: Z = 3			' = 0.20);	F = 40%					
	, -	,							
4.81.6 social function	00.5	00.00		74.0	04.40		00.70/	10.001.00.05	
Song 2009c	60.5	26.96	50	71.3	21.48	50	29.7%	-10.80 [-20.35 , -1.25]	<del>-</del>
Follefson (HGAJ) 1997	58.82	25.21	383	62.36	24.18	772	70.3%	-3.54 [-6.59 , -0.49]	_
Subtotal (95% CI)	00		433	. 12 =-		822	100.0%	-5.70[-12.20,0.81]	
Heterogeneity: Tau² = 13.2 Test for overall effect: Z = 1			P = 0.16	); I <sup>2</sup> = 50%					
		,							
4.81.7 emotional funct		20.00		77 4	05.00		00.007	17.701.00.10 5.45	
Song 2009c	59.64	36.22	50	77.4	25.89	50	28.6%	-17.76 [-30.10 , -5.42]	<del></del>
Tollefson (HGAJ) 1997	47.79	34.26	383	56.51	34.84	772	71.4%	-8.72 [-12.94 , -4.50]	
Subtotal (95% CI)			433			822	100.0%	-11.30 [-19.31,-3.30]	
Heterogeneity: Tau² = 18.7 Fest for overall effect: Z = 2			P = 0.17	$l); l^2 = 46\%$					
	(. – 0.	,							
1.81.8 mental health	60.00	20.57	EO	72.00	16.00	EO	0 70/	_3 86111 00 0 511	
Song 2009c	69.02	20.57	50 383	72.88	16.82	50 772	8.7%	-3.86 [-11.23 , 3.51]	
Tollefson (HGAJ) 1997	55.59	18.81	383	60.82	17.91	772	91.3%	-5.23 [-7.50 , -2.96]	<b>-</b>
Subtotal (95% CI)	Chi <sup>2</sup> 0 <sup>4</sup>	2 df 4 /5	433	12 _ 00/		822	100.0%	-5.11 [-7.28,-2.94]	<b>◆</b>
Heterogeneity: Tau² = 0.00 Fest for overall effect: Z = 4			· = U./3);	r = U%					
		,							
1.81.9 health change	E0 F	24.00	F0	EE F	20.75	F.0	100.00/	20011101 701	
Song 2009c	53.5	24.23	50	55.5	22.75		100.0%	-2.00 [-11.21 , 7.21]	
Subtotal (95% CI)	alo		50			50	100.0%	-2.00 [-11.21,7.21]	
Heterogeneity: Not applica Fest for overall effect: Z = 0		67)							
	, -	,							
1.81.10 total score	E0.04	10.10	F0	70.04	15.00		100.00/	140010050 700	_
Song 2009c	59.04	16.18	50	73.24	15.96		100.0%	-14.20 [-20.50 , -7.90]	<b>←</b>
Subtotal (95% CI)	.1.		50			50	100.0%	-14.20 [-20.50,-7.90]	
Heterogeneity: Not applica Test for overall effect: Z = 4		00001)							
	_ (. < 0.	• · /							
1.81.11 health - current	0.55	. n-					400.051	0.0010.55	
Lilly 2006a	2.28	1.25	40	2.3	1.11		100.0%	-0.02 [-0.57 , 0.53]	<b>I</b>
Subtotal (95% CI)			40			31	100.0%	-0.02 [-0.57, 0.53]	<b>♦</b>
Heterogeneity: Not applica									
C+ f II - ff+- 7 0	.07 (P = 0.	94)							
Test for overall effect: $Z = 0$	•								ı
est for overall effect: $Z = 0$ Test for subgroup difference		) 00 df = 14	) (P > 0 '	10001) I <sup>2</sup>	- N%-				-20 -10 0 10

Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 81: Quality of life: 2c. Specific - average endpoint score - short term (SF-36, high=good)



Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 83: Leaving the study early: 2. Any reason


Study or Subgroup	Haloperi Events 1	dol Total	Olanza Events	pine Total	Weight	Risk Ratio IV, Random, 95% CI	Risk Ratio IV, Random, 95% CI
ocaay or Subgroup		vial	-vents	ivial	arcigiit	, Random, 3370 Cl	iv, Kandoni, 3370 Ci
4.84.1 clinical deterioratio							
Buchanan 2003	3	34	2	29		1.28 [0.23 , 7.14]	<del></del>
de Hann 2003	1	12	1	12		1.00 [0.07 , 14.21]	<del></del>
Krakowski 2006	7	36	2	37		3.60 [0.80 , 16.17]	<del>  •</del>
Lahti 2007	1	14	0	18		3.80 [0.17 , 86.76]	-
Lindenmayer 2007	1	19	1	16		0.84 [0.06 , 12.42]	-
Subtotal (95% CI)		115		112	100.0%	1.93 [0.76 , 4.87]	•
Total events: Heterogeneity: $Tau^2 = 0.00$ ; Test for overall effect: $Z = 1$			6 (P = 0.80)	; I <sup>2</sup> = 0%			
4.84.2 death - short term							
Chaudhry 2003	0	132	1	144	49.4%	0.36 [0.01, 8.84]	
Gründer (NeSSy) 2012	0	27	1	21	50.6%	0.26 [0.01, 6.12]	
Subtotal (95% CI)		159		165	100.0%	0.31 [0.03, 2.90]	
Total events:	0		2				
Heterogeneity: $Tau^2 = 0.00$ ; Test for overall effect: $Z = 1$			(P = 0.89)	; I <sup>2</sup> = 0%			
4.84.3 lack of efficacy - sho	ort term						
Altamura (HGBQ) 1999	3	15	0	13		6.13 [0.35 , 108.58]	<del>                                     </del>
Barak 2002	1	10	3	10		0.33 [0.04 , 2.69]	
Beasley (E003) 1997	16	81	40	350		1.73 [1.02 , 2.93]	<del>  •</del>
Beasley (HGAD) 1996a	19	69	64	198		0.85 [0.55 , 1.31]	+
Boulay 2002	1	13	0	14		3.21 [0.14 , 72.55]	<del>-   •</del>
HGCJ (Hong Kong) 1998	3	14	1	17		3.64 [0.42 , 31.27]	<del></del>
HGCU (Taiwan) 1998	5	28	2	26		2.32 [0.49 , 10.94]	<del>  • -</del>
HGFH (Korea) 1998	1	51	0	53		3.12 [0.13 , 74.76]	-
Kinon 2004	2	48	5	52		0.43 [0.09 , 2.13]	<del></del>
Lieberman (HGDH) 2003	16	131	8	132		2.02 [0.89 , 4.55]	-
Tollefson (HGAJ) 1997	212	660	277	1336		1.55 [1.33 , 1.80]	•
Walther 2014	0	14	2	15		0.21 [0.01 , 4.09]	•
Wang 2012k	2	120	12	252	4.3%	0.35 [0.08 , 1.54]	<del></del>
Subtotal (95% CI)		1254		2468	100.0%	1.29 [0.93, 1.80]	<b>♦</b>
Total events:	281		414				ľ
Heterogeneity: $Tau^2 = 0.09$ ; Test for overall effect: $Z = 1$		,	2 (P = 0.0	$(8); I^2 = 3$	88%		
4.84.4 loss to follow-up - s	hort term						
Avasthi 2001	2	10	1	17		3.40 [0.35 , 32.90]	<del></del>
Beasley (HGAD) 1996a	5	69	6	198		2.39 [0.75 , 7.59]	+-
Chaudhry 2003	10	132	7	144	15.8%	1.56 [0.61 , 3.98]	<del></del>
HGCU (Taiwan) 1998	1	28	0	26	1.4%	2.79 [0.12 , 65.66]	
Kinon 2004	2	48	4	52	5.1%	0.54 [0.10 , 2.82]	<del></del>
Tollefson (HGAJ) 1997	11	660	15	1336	23.3%	1.48 [0.69 , 3.21]	
Wang 2012k	14	120	35	252	41.3%	0.84 [0.47 , 1.50]	
Subtotal (95% CI)		1067		2025	100.0%	1.22 [0.84, 1.77]	•
Total events:	45		68				<b>Y</b>
Heterogeneity: $Tau^2 = 0.00$ ; Test for overall effect: $Z = 1$			(P = 0.50)	$I^2 = 0\%$			
4.84.5 no n-co mpliance - sh	ort term						
Chaudhry 2003	6	132	8	144	14.7%	0.82 [0.29 , 2.30]	
Gründer (NeSSy) 2012	0	27	3	25	1.8%	0.13 [0.01 , 2.45]	<del></del>
HGCJ (Hong Kong) 1998	1	14	0	17	1.6%	3.60 [0.16 , 82.05]	
HGCU (Taiwan) 1998	1	28	1	26	2.1%	0.93 [0.06 , 14.09]	
Kinon 2004	4	48	2	52	5.7%	2.17 [0.42 , 11.30]	<del></del>
Tollefson (HGAJ) 1997	29	660	44	1336	74.0%	1.33 [0.84 , 2.11]	<b>—</b>
Subtotal (95% CI) Total events:	41	909	58	1600	100.0%	1.23 [0.83, 1.83]	•
Heterogeneity: Tau <sup>2</sup> = 0.00;	$Chi^2 = 3.91$			$I^2 = 0\%$			
Test for overall effect: $Z = 1$	hut unwillin	ng to co	ntinue - s	hort ter	m		
		.,		350		0.96 [0.86 , 1.07]	
Test for overall effect: Z = 1  4.84.6 not eligible/eligible Beasley (E003) 1997	67	81	302	330			<del></del>
<b>4.84.6 not eligible/eligible</b> Beasley (E003) 1997		81 69	153	198		1.11 [0.98 , 1.25]	<u>.</u>
<b>4.84.6 not eligible/eligible</b> Beasley (E003) 1997 Beasley (HGAD) 1996a	67				31.6%		•
	67 59	69	153	198	31.6% 35.6%	1.27 [1.20 , 1.35]	
<b>4.84.6 not eligible/eligible</b> Beasley (E003) 1997 Beasley (HGAD) 1996a Tollefson (HGAJ) 1997	67 59	69 660	153	198 1336	31.6% 35.6%		•

	ort term		_			0.07.50.40. == ===	
Chaudhry 2003	1	132	0	144	1.2%	3.27 [0.13 , 79.59]	-
de Hann 2003	0	10	2	12	1.5%	0.24 [0.01 , 4.42]	
HGCJ (Hong Kong) 1998	2	14	0	17	1.4%	6.00 [0.31 , 115.56]	-
HGCU (Taiwan) 1998	2	28	2	26	3.5%	0.93 [0.14 , 6.12]	
Kinon 2004	6	48	3	52	7.1%	2.17 [0.57, 8.19]	
_indenmayer 2007	1	19	0	16	1.3%	2.55 [0.11, 58.60]	
Tollefson (HGAJ) 1997	49	660	48	1336	83.9%	2.07 [1.40 , 3.04]	_
Subtotal (95% CI)		911		1603	100.0%	2.00 [1.40 , 2.85]	
Total events:	61		55				<b>\</b>
Heterogeneity: $Tau^2 = 0.00$ ; C Test for overall effect: $Z = 3.83$	$hi^2 = 3.36,$			l <sup>2</sup> = 0%			
4.84.8 physician decision - sh	ort term						
Chaudhry 2003	3	132	1	144	20.7%	3.27 [0.34 , 31.08]	
HGCJ (Hong Kong) 1998	1	14	0	17	10.7%	3.60 [0.16 , 82.05]	
HGCU (Taiwan) 1998	3	28	3	26	46.0%	0.93 [0.21 , 4.20]	
Kinon 2004	4	48	1	52	22.5%	4.33 [0.50 , 37.42]	<u>T -</u>
Subtotal (95% CI)		222		239	100.0%	1.97 [0.71, 5.49]	
Total events:	11	_	5			,	
Heterogeneity: $Tau^2 = 0.00$ ; C Test for overall effect: $Z = 1.30$	,	,	P = 0.61);	I <sup>2</sup> = 0%			
1.84.9 protocol violation - sh	ort term						
Beasley (HGAD) 1996a	2	69	10	198	68.2%	0.57 [0.13 , 2.55]	
Buchanan 2003	0	34	1	29	15.2%	0.29 [0.01, 6.76]	
Chaudhry 2003	0	132	2	144	16.6%	0.22 [0.01 , 4.50]	
Subtotal (95% CI)		235		371	100.0%	0.44 [0.13 , 1.51]	
Total events:	2		13				
Heterogeneity: $Tau^2 = 0.00$ ; C Test for overall effect: $Z = 1.31$			P = 0.82);	I <sup>2</sup> = 0%			
4.84.10 unspecified - short to							
Gründer (NeSSy) 2012	20	27	12	25	100.0%	1.54 [0.97 , 2.46]	<b>-</b>
Subtotal (95% CI)		27		25	100.0%	1.54 [0.97 , 2.46]	
5 a 5 t a t (55 70 C)							
Total events:	20		12			,	
Total events: Heterogeneity: Not applicable Fest for overall effect: Z = 1.83		·)	12				•
Total events: Heterogeneity: Not applicable	B (P = 0.07	·)	12				
Fotal events: Heterogeneity: Not applicable Fest for overall effect: Z = 1.83	B (P = 0.07	19	12		100.0%	2.55 [0.11 , 58.60]	
Total events: Heterogeneity: Not applicable Test for overall effect: Z = 1.83  3.84.11 violent behavior - sho	3 (P = 0.07						
Total events:  Heterogeneity: Not applicable  Test for overall effect: Z = 1.83  1.84.11 violent behavior - sho  Lindenmayer 2007  Subtotal (95% CI)	3 (P = 0.07	19		16	100.0%	2.55 [0.11 , 58.60]	
Total events:  Heterogeneity: Not applicable Test for overall effect: Z = 1.83  4.84.11 violent behavior - sho Lindenmayer 2007  Subtotal (95% CI)  Total events:  Heterogeneity: Not applicable	3 (P = 0.07  prt term  1	19 <b>19</b>	0	16	100.0%	2.55 [0.11 , 58.60]	
Total events:  Heterogeneity: Not applicable Test for overall effect: Z = 1.83  4.84.11 violent behavior - sho Lindenmayer 2007  Subtotal (95% CI) Total events:  Heterogeneity: Not applicable Test for overall effect: Z = 0.58	3 (P = 0.07  prt term  1  1  9 (P = 0.56	19 <b>19</b>	0	16	100.0%	2.55 [0.11, 58.60] 2.55 [0.11, 58.60]	
Total events: Heterogeneity: Not applicable Test for overall effect: Z = 1.83  4.84.11 violent behavior - sho Lindenmayer 2007  Subtotal (95% CI) Total events: Heterogeneity: Not applicable Test for overall effect: Z = 0.59  4.84.12 withdrawal of inform	3 (P = 0.07  prt term  1  1  9 (P = 0.56	19 <b>19</b>	0	16	100.0%	2.55 [0.11 , 58.60]	
Total events: Heterogeneity: Not applicable Test for overall effect: Z = 1.83  4.84.11 violent behavior - sho Lindenmayer 2007  Subtotal (95% CI) Total events: Heterogeneity: Not applicable Test for overall effect: Z = 0.59  4.84.12 withdrawal of inform Gründer (NeSSy) 2012	1 1 9 (P = 0.56	19 <b>19</b> i) nt - shor	0 0 t term	16 <b>16</b>	100.0% <b>100.0</b> %	2.55 [0.11, 58.60] 2.55 [0.11, 58.60]	
Total events: Heterogeneity: Not applicable Test for overall effect: Z = 1.83  4.84.11 violent behavior - sho Lindenmayer 2007  Subtotal (95% CI) Total events: Heterogeneity: Not applicable Test for overall effect: Z = 0.59  4.84.12 withdrawal of inform Gründer (NeSSy) 2012  Krakowski 2006	1 1 9 (P = 0.56 ned conse	19 <b>19</b> 5) nt - shor 27	0 0 tterm 1	16 <b>16</b>	100.0% <b>100.0</b> % 7.8%	2.55 [0.11 , 58.60] <b>2.55 [0.11 , 58.60]</b> 0.31 [0.01 , 7.26]	
Total events: Heterogeneity: Not applicable Test for overall effect: Z = 1.83  4.84.11 violent behavior - sho Lindenmayer 2007  Subtotal (95% CI) Total events: Heterogeneity: Not applicable Test for overall effect: Z = 0.59  4.84.12 withdrawal of inform Gründer (NeSSy) 2012  Krakowski 2006 Lahti 2007	1 1 9 (P = 0.56 ned conse 0 4	19 19 19 nt - shor 27 36	0 0 tterm 1 4	16 <b>16</b> 25 37	100.0% 100.0% 7.8% 45.7%	2.55 [0.11 , 58.60] <b>2.55 [0.11 , 58.60]</b> 0.31 [0.01 , 7.26] 1.03 [0.28 , 3.80]	
Total events: Heterogeneity: Not applicable Test for overall effect: Z = 1.83  4.84.11 violent behavior - sho Lindenmayer 2007  Subtotal (95% CI) Total events: Heterogeneity: Not applicable Test for overall effect: Z = 0.59  4.84.12 withdrawal of inform Gründer (NeSSy) 2012  Krakowski 2006 Lahti 2007  Wang 2012k	1 1 9 (P = 0.56 ned conse 0 4 1	19 19 19 int - shor 27 36 14	0 0 <b>tterm</b> 1 4 1	16 16 25 37 18	7.8% 45.7% 10.9% 35.6%	2.55 [0.11 , 58.60] 2.55 [0.11 , 58.60] 0.31 [0.01 , 7.26] 1.03 [0.28 , 3.80] 1.29 [0.09 , 18.80]	
Fotal events: Heterogeneity: Not applicable Fest for overall effect: Z = 1.83  3.84.11 violent behavior - sho Lindenmayer 2007  Subtotal (95% CI) Fotal events: Heterogeneity: Not applicable Fest for overall effect: Z = 0.59  3.84.12 withdrawal of inform Gründer (NeSSy) 2012  Krakowski 2006 Lahti 2007  Wang 2012k  Subtotal (95% CI)	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	19 19 19 int - shor 27 36 14 120	0 0 <b>t term</b> 1 4 1 4	16 16 25 37 18 252	7.8% 45.7% 10.9% 35.6%	2.55 [0.11 , 58.60] 2.55 [0.11 , 58.60] 0.31 [0.01 , 7.26] 1.03 [0.28 , 3.80] 1.29 [0.09 , 18.80] 1.57 [0.36 , 6.93]	
Total events: Heterogeneity: Not applicable Test for overall effect: Z = 1.83  4.84.11 violent behavior - sho Lindenmayer 2007  Subtotal (95% CI) Total events: Heterogeneity: Not applicable Test for overall effect: Z = 0.59  4.84.12 withdrawal of inform Gründer (NeSSy) 2012  Krakowski 2006 Lahti 2007  Wang 2012k  Subtotal (95% CI) Total events: Heterogeneity: Tau² = 0.00; C	3 (P = 0.07  prt term	19 19 19 19 19 27 36 14 120 197 df = 3 (F	0 0 <b>t t erm</b> 1 4 1 4	16 16 25 37 18 252 332	7.8% 45.7% 10.9% 35.6%	2.55 [0.11 , 58.60] 2.55 [0.11 , 58.60] 0.31 [0.01 , 7.26] 1.03 [0.28 , 3.80] 1.29 [0.09 , 18.80] 1.57 [0.36 , 6.93]	
Total events: Heterogeneity: Not applicable Test for overall effect: Z = 1.83  3.84.11 violent behavior - sho Lindenmayer 2007  Subtotal (95% CI) Total events: Heterogeneity: Not applicable Test for overall effect: Z = 0.59  4.84.12 withdrawal of inform Gründer (NeSSy) 2012  Krakowski 2006 Lahti 2007  Wang 2012k  Subtotal (95% CI) Total events: Heterogeneity: Tau² = 0.00; C Test for overall effect: Z = 0.24	3 (P = 0.07 prt term 1 1 9 (P = 0.56  ned conse 0 4 1 3 8 hi² = 0.87, 4 (P = 0.81	19 19 19 19 19 27 36 14 120 197 df = 3 (F	0 0 <b>t t erm</b> 1 4 1 4	16 16 25 37 18 252 332	7.8% 45.7% 10.9% 35.6%	2.55 [0.11 , 58.60] 2.55 [0.11 , 58.60] 0.31 [0.01 , 7.26] 1.03 [0.28 , 3.80] 1.29 [0.09 , 18.80] 1.57 [0.36 , 6.93]	
Total events: Heterogeneity: Not applicable Test for overall effect: Z = 1.83  3.84.11 violent behavior - sho Lindenmayer 2007  Subtotal (95% CI) Total events: Heterogeneity: Not applicable Test for overall effect: Z = 0.59  4.84.12 withdrawal of inform Gründer (NeSSy) 2012  Krakowski 2006 Lahti 2007  Wang 2012k  Subtotal (95% CI) Total events: Heterogeneity: Tau² = 0.00; C Test for overall effect: Z = 0.24  4.84.13 personal conflict - sh	3 (P = 0.07 prt term 1 1 9 (P = 0.56  ned conse 0 4 1 3 8 hi² = 0.87, 4 (P = 0.81	19 19 19 19 19 27 36 14 120 197 df = 3 (F	0 0 <b>t t erm</b> 1 4 1 4	16 16 25 37 18 252 332 $l^2 = 0\%$	7.8% 45.7% 10.9% 35.6%	2.55 [0.11 , 58.60] 2.55 [0.11 , 58.60] 0.31 [0.01 , 7.26] 1.03 [0.28 , 3.80] 1.29 [0.09 , 18.80] 1.57 [0.36 , 6.93]	
Total events: Heterogeneity: Not applicable Test for overall effect: Z = 1.83  3.84.11 violent behavior - sho Lindenmayer 2007  Subtotal (95% CI) Total events: Heterogeneity: Not applicable Test for overall effect: Z = 0.59  4.84.12 withdrawal of inform Gründer (NeSSy) 2012  Krakowski 2006 Lahti 2007  Wang 2012k  Subtotal (95% CI) Total events: Heterogeneity: Tau² = 0.00; C Test for overall effect: Z = 0.24  4.84.13 personal conflict - sh Chaudhry 2003	3 (P = 0.07  ort term  1  1  0 (P = 0.56  ned conse  0  4  1  3  8  hi² = 0.87, 4 (P = 0.81	19 19 19 10 10 10 10 10 10 10 10 10 10 10 10 10	0 0 <b>t term</b> 1 4 1 4 1 0 P = 0.83);	16 16 25 37 18 252 332 $l^2 = 0\%$	7.8% 45.7% 10.9% 35.6% 100.0%	2.55 [0.11, 58.60] 2.55 [0.11, 58.60] 0.31 [0.01, 7.26] 1.03 [0.28, 3.80] 1.29 [0.09, 18.80] 1.57 [0.36, 6.93] 1.12 [0.46, 2.70]	
Fotal events: Heterogeneity: Not applicable Fest for overall effect: Z = 1.83  8.84.11 violent behavior - sho Lindenmayer 2007  Subtotal (95% CI) Fotal events: Heterogeneity: Not applicable Fest for overall effect: Z = 0.59  8.84.12 withdrawal of inform  Gründer (NeSSy) 2012  Krakowski 2006 Lahti 2007  Wang 2012k  Subtotal (95% CI) Fotal events: Heterogeneity: Tau² = 0.00; CI Fest for overall effect: Z = 0.24  8.84.13 personal conflict - sh Chaudhry 2003  Subtotal (95% CI)	3 (P = 0.07  ort term  1  1  0 (P = 0.56  ned conse  0  4  1  3  8  hi² = 0.87, 4 (P = 0.81	19 19 19 19 10 10 11 12 12 13 13 13	0 0 <b>t term</b> 1 4 1 4 1 0 P = 0.83);	16 16 25 37 18 252 332 $l^2 = 0\%$	7.8% 45.7% 100.0%	2.55 [0.11, 58.60] 2.55 [0.11, 58.60] 0.31 [0.01, 7.26] 1.03 [0.28, 3.80] 1.29 [0.09, 18.80] 1.57 [0.36, 6.93] 1.12 [0.46, 2.70]	
Total events: Heterogeneity: Not applicable Test for overall effect: Z = 1.83  3.84.11 violent behavior - sho Lindenmayer 2007  Subtotal (95% CI) Total events: Heterogeneity: Not applicable Test for overall effect: Z = 0.59  4.84.12 withdrawal of inform Gründer (NeSSy) 2012  Krakowski 2006 Lahti 2007  Wang 2012k  Subtotal (95% CI) Total events: Heterogeneity: Tau² = 0.00; C Test for overall effect: Z = 0.24  3.84.13 personal conflict - sh Chaudhry 2003  Subtotal (95% CI) Total events: Heterogeneity: Not applicable	3 (P = 0.07  ort term  1  1  0 (P = 0.56  ned conse  0  4  1  3  8  hi² = 0.87, 4 (P = 0.81	19 19 19 19 10 10 11 12 13 13 13 13 13 13	0 0 <b>t term</b> 1 4 1 4 1 0 P = 0.83);	16 16 25 37 18 252 332 $l^2 = 0\%$	7.8% 45.7% 100.0%	2.55 [0.11, 58.60] 2.55 [0.11, 58.60] 0.31 [0.01, 7.26] 1.03 [0.28, 3.80] 1.29 [0.09, 18.80] 1.57 [0.36, 6.93] 1.12 [0.46, 2.70]	
Total events: Heterogeneity: Not applicable Test for overall effect: Z = 1.83  3.84.11 violent behavior - sho Lindenmayer 2007  Subtotal (95% CI) Total events: Heterogeneity: Not applicable Test for overall effect: Z = 0.59  4.84.12 withdrawal of inform  Gründer (NeSSy) 2012  Krakowski 2006 Lahti 2007  Wang 2012k  Subtotal (95% CI) Total events: Heterogeneity: Tau² = 0.00; CI Test for overall effect: Z = 0.24  4.84.13 personal conflict - sh Chaudhry 2003  Subtotal (95% CI)  Total events: Heterogeneity: Not applicable Test for overall effect: Z = 0.44	3 (P = 0.07  prt term 1 1 9 (P = 0.56  ned conse 0 4 1 3 8 hi² = 0.87, 4 (P = 0.81	19 19 19 19 10 10 11 12 13 13 13 13 13 13	0 0 <b>t term</b> 1 4 1 4 1 0 P = 0.83);	16 16 25 37 18 252 332 $l^2 = 0\%$	7.8% 45.7% 100.0%	2.55 [0.11, 58.60] 2.55 [0.11, 58.60] 0.31 [0.01, 7.26] 1.03 [0.28, 3.80] 1.29 [0.09, 18.80] 1.57 [0.36, 6.93] 1.12 [0.46, 2.70]	
Total events: Heterogeneity: Not applicable Test for overall effect: Z = 1.83  3.84.11 violent behavior - sho Lindenmayer 2007  Subtotal (95% CI) Total events: Heterogeneity: Not applicable Test for overall effect: Z = 0.59  4.84.12 withdrawal of inform Gründer (NeSSy) 2012  Krakowski 2006 Lahti 2007  Wang 2012k  Subtotal (95% CI) Total events: Heterogeneity: Tau² = 0.00; CI Test for overall effect: Z = 0.24  4.84.13 personal conflict - sh Chaudhry 2003  Subtotal (95% CI) Total events: Heterogeneity: Not applicable Test for overall effect: Z = 0.44  4.84.14 sponsor decision - sh	3 (P = 0.07  prt term 1 1 9 (P = 0.56  ned conse 0 4 1 3 8 hi² = 0.87, 4 (P = 0.81	19 19 19 19 10 10 11 12 13 13 13 13 13 13	0 0 <b>t term</b> 1 4 1 4 1 0 P = 0.83);	16 16 25 37 18 252 332 $l^2 = 0\%$	7.8% 45.7% 100.0%	2.55 [0.11, 58.60] 2.55 [0.11, 58.60] 0.31 [0.01, 7.26] 1.03 [0.28, 3.80] 1.29 [0.09, 18.80] 1.57 [0.36, 6.93] 1.12 [0.46, 2.70]	
Total events: Heterogeneity: Not applicable Test for overall effect: Z = 1.83  3.84.11 violent behavior - sho Lindenmayer 2007	3 (P = 0.07  ort term  1  1  9 (P = 0.56  ned conse  0  4  1  3  8  hi² = 0.87, 4 (P = 0.81  ort term  5  4 (P = 0.666	19 19 19 19 19 19 19 19 19 19 19 19 19 1	0 0 <b>t term</b> 1 4 1 4 10 2 = 0.83);	16 16 16 25 37 18 252 332 $l^2 = 0\%$	100.0% 100.0% 7.8% 45.7% 10.9% 35.6% 100.0%	2.55 [0.11, 58.60] 2.55 [0.11, 58.60]  0.31 [0.01, 7.26] 1.03 [0.28, 3.80] 1.29 [0.09, 18.80] 1.57 [0.36, 6.93] 1.12 [0.46, 2.70]  0.78 [0.25, 2.40] 0.78 [0.25, 2.40]	
Total events: Heterogeneity: Not applicable Test for overall effect: Z = 1.83  3.84.11 violent behavior - sho Lindenmayer 2007  Subtotal (95% CI) Total events: Heterogeneity: Not applicable Test for overall effect: Z = 0.59  4.84.12 withdrawal of inform Gründer (NeSSy) 2012  Krakowski 2006 Lahti 2007  Wang 2012k  Subtotal (95% CI) Total events: Heterogeneity: Tau² = 0.00; CI Test for overall effect: Z = 0.24  4.84.13 personal conflict - sho Chaudhry 2003  Subtotal (95% CI) Total events: Heterogeneity: Not applicable Test for overall effect: Z = 0.44  4.84.14 sponsor decision - sh HGCJ (Hong Kong) 1998  Kinon 2004	3 (P = 0.07  ort term  1  1  9 (P = 0.56  ned conse  0  4  1  3  8  hi² = 0.87, 4 (P = 0.81  sort term  5  4 (P = 0.66  nort term  0	19 19 19 19 19 19 19 19 19 19 19 19 19 1	0 0 <b>t term</b> 1 4 1 4 10 2 = 0.83); 7 7	16 16 16 25 37 18 252 332 $l^2 = 0\%$	100.0% 100.0% 7.8% 45.7% 10.9% 35.6% 100.0%	2.55 [0.11, 58.60] 2.55 [0.11, 58.60]  0.31 [0.01, 7.26] 1.03 [0.28, 3.80] 1.29 [0.09, 18.80] 1.57 [0.36, 6.93] 1.12 [0.46, 2.70]  0.78 [0.25, 2.40] 0.78 [0.25, 2.40]  0.40 [0.02, 9.12] 0.36 [0.02, 8.64]	
Total events: Heterogeneity: Not applicable Test for overall effect: Z = 1.83  3.84.11 violent behavior - sho Lindenmayer 2007  Subtotal (95% CI) Total events: Heterogeneity: Not applicable Test for overall effect: Z = 0.59  4.84.12 withdrawal of inform Gründer (NeSSy) 2012 Krakowski 2006 Lahti 2007 Wang 2012k Subtotal (95% CI) Total events: Heterogeneity: Tau² = 0.00; CI Test for overall effect: Z = 0.24  3.84.13 personal conflict - sh Chaudhry 2003  Subtotal (95% CI) Total events: Heterogeneity: Not applicable Test for overall effect: Z = 0.44  4.84.14 sponsor decision - sh HGCJ (Hong Kong) 1998	3 (P = 0.07  ort term  1  1  9 (P = 0.56  ned conse  0  4  1  3  8  hi² = 0.87, 4 (P = 0.81  nort term  5  4 (P = 0.66  nort term  0  0	19 19 19 19 19 19 19 19 19 19 19 19 19 1	0 0 <b>t term</b> 1 4 1 4 10 2 = 0.83); 7 7	16 16 16 25 37 18 252 332 $l^2 = 0\%$ 144 144	100.0% 100.0% 7.8% 45.7% 10.9% 35.6% 100.0% 100.0%	2.55 [0.11, 58.60] 2.55 [0.11, 58.60]  0.31 [0.01, 7.26] 1.03 [0.28, 3.80] 1.29 [0.09, 18.80] 1.57 [0.36, 6.93] 1.12 [0.46, 2.70]  0.78 [0.25, 2.40]  0.78 [0.25, 2.40]  0.40 [0.02, 9.12] 0.36 [0.02, 8.64] 1.01 [0.19, 5.51]	
Total events: Heterogeneity: Not applicable Test for overall effect: Z = 1.83  3.84.11 violent behavior - sho Lindenmayer 2007  Subtotal (95% CI) Total events: Heterogeneity: Not applicable Test for overall effect: Z = 0.59  4.84.12 withdrawal of inform Gründer (NeSSy) 2012  Krakowski 2006 Lahti 2007  Wang 2012k  Subtotal (95% CI) Total events: Heterogeneity: Tau² = 0.00; C Test for overall effect: Z = 0.24  4.84.13 personal conflict - sh Chaudhry 2003  Subtotal (95% CI) Total events: Heterogeneity: Not applicable Test for overall effect: Z = 0.44  4.84.14 sponsor decision - sh HGCJ (Hong Kong) 1998  Kinon 2004 Tollefson (HGAJ) 1997	3 (P = 0.07  ort term  1  1  9 (P = 0.56  ned conse  0  4  1  3  8  hi² = 0.87, 4 (P = 0.81  nort term  5  4 (P = 0.66  nort term  0  0	19 19 19 19 19 19 19 19 19 19 19 19 19 1	0 0 <b>t term</b> 1 4 1 4 10 2 = 0.83); 7 7	16 16 16 25 37 18 252 332 $I^2 = 0\%$ 144 144 147 52 1336	100.0% 100.0% 7.8% 45.7% 10.9% 35.6% 100.0% 100.0% 18.6% 18.0% 63.4%	2.55 [0.11, 58.60] 2.55 [0.11, 58.60]  0.31 [0.01, 7.26] 1.03 [0.28, 3.80] 1.29 [0.09, 18.80] 1.57 [0.36, 6.93] 1.12 [0.46, 2.70]  0.78 [0.25, 2.40] 0.78 [0.25, 2.40]  0.40 [0.02, 9.12] 0.36 [0.02, 8.64]	

Gründer (NeSSy) 2012	0	27	1	25	7.8%	0.31 [0.01 , 7.26]	
Krakowski 2006	4	36	4	37	45.7%	1.03 [0.28 , 3.80]	
Lahti 2007	1	14	1	18	10.9%	1.29 [0.09 , 18.80]	
Wang 2012k	3	120	4	252	35.6%	1.57 [0.36 , 6.93]	
Subtotal (95% CI)		197		332	100.0%	1.12 [0.46 , 2.70]	
Total events:	8		10				T
Heterogeneity: Tau <sup>2</sup> = 0.00; C	$hi^2 = 0.87$	df = 3 (P)	= 0.83);	$I^2 = 0\%$			
Test for overall effect: $Z = 0.24$	4 (P = 0.81)	1)					
							0.01 0.1 1 10 100 Olanzapine Haloperidol

Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 84: Leaving the study early: 3a. Various reasons - short term

	Haloperid Events To	lol otal	Olanzap Events 1	ine Γotal	Weight	Risk Ratio IV, Random, 95% CI	Risk Ratio IV, Random, 95% CI
.85.1 diagnosis change - n	nedium terr	n					
San 2012	4	21	1	25	100.0%	4.76 [0.58 , 39.40]	
ubtotal (95% CI)		21		25	100.0%	4.76 [0.58, 39.40]	
otal events:	4		1				
Heterogeneity: Not applicable $Z = 1$ .		j)					
.85.2 death - medium tern	·	,					
illy (S029) 2007	3	134	1	141	66.4%	3.16 [0.33 , 29.97]	
illy 2006a	1	40	0	31	33.6%	2.34 [0.10 , 55.58]	
•	'		U				
ubtotal (95% CI)	4	174	1	172	100.0%	2.86 [0.46 , 17.88]	
otal events:		df 1	-	12 00/			
Heterogeneity: $Tau^2 = 0.00$ ; Test for overall effect: $Z = 1$ .			(F = 0.66),	1 = 0 /0			
.85.3 lack of efficacy - med	dium term						
(ahn (EUFEST) 2005	34	103	12	105	21.9%	2.89 [1.59 , 5.26]	-
illy (S029) 2007	6	134	3	141	11.8%	2.10 [0.54 , 8.25]	+-
illy 2006a	8	40	2	31	10.7%	3.10 [0.71 , 13.57]	+-
Parabiaghi (GiSAS) 2010	18	97	18	103	22.0%	1.06 [0.59 , 1.92]	-
Rosenheck (HGFI) 2003	19	150	28	159	22.8%	0.72 [0.42 , 1.23]	<b>-</b>
San 2012	7	21	2	25	10.9%	4.17 [0.97 , 17.95]	
subtotal (95% CI)		545		564	100.0%	1.71 [0.92, 3.17]	
otal events:	92	-	65			,	
deterogeneity: $Tau^2 = 0.36$ ; lest for overall effect: $Z = 1.0$			5 (P = 0.007	7); I <sup>2</sup> = 6	69%		
.85.4 loss to follow-up - m			_	4.44	0.00/	1.05 [0.07 10.05]	
illy (S029) 2007	1	134	1	141	8.8%	1.05 [0.07 , 16.65]	
illy 2006a	8	40	8	31	91.2%	0.78 [0.33 , 1.83]	-
ubtotal (95% CI)		174		172	100.0%	0.80 [0.35, 1.81]	•
otal events: leterogeneity: Tau <sup>2</sup> = 0.00;	9		9				
.85.5 non-compliance - me (ahn (EUFEST) 2005	edium term 16	103	13		100.0%	1.25 [0.64 , 2.48]	
ubtotal (95% CI)		103		105	100.0%	1.25 [0.64 , 2.48]	<b>*</b>
otal events:	16		13				
Heterogeneity: Not applicables for overall effect: $Z = 0$ .		)					
.85.6 patient's decision - :	medium ter	m					
. <b>85.6 patient's decision</b> - 1 illy (S029) 2007	medium ter 20	m 134	24	141	65.8%	0.88 [0.51 , 1.51]	_
illy (S029) 2007			24 1	141 31		• •	•
illy (S029) 2007 illy 2006a	20 5	134 40	1	31	5.6%	3.88 [0.48 , 31.49]	-
illy (S029) 2007 illy 2006a Parabiaghi (GiSAS) 2010	20	134 40 97		31 103	5.6% 28.6%	3.88 [0.48 , 31.49] 1.33 [0.55 , 3.22]	*
illy (S029) 2007 illy 2006a Parabiaghi (GiSAS) 2010 subtotal (95% CI)	20 5 10	134 40	1 8	31	5.6%	3.88 [0.48 , 31.49]	•
illy (S029) 2007 illy 2006a Parabiaghi (GiSAS) 2010	20 5 10 35 $Chi^2 = 2.18$ ,	134 40 97 <b>271</b> df = 2	1 8 33	31 103 <b>275</b>	5.6% 28.6% <b>100.0%</b>	3.88 [0.48 , 31.49] 1.33 [0.55 , 3.22]	•
illy (\$029) 2007 illy 2006a Parabiaghi (GiSAS) 2010 illy 2016 illy 2016 illy 2016 iotal events: leterogeneity: Tau² = 0.02; lest for overall effect: Z = 0.02	20 5 10 35 Chi <sup>2</sup> = 2.18, 28 (P = 0.78	134 40 97 <b>271</b> df = 2	1 8 33	31 103 <b>275</b>	5.6% 28.6% <b>100.0%</b>	3.88 [0.48 , 31.49] 1.33 [0.55 , 3.22]	•
illy (\$029) 2007 illy 2006a Parabiaghi (GiSAS) 2010 ibtotal (95% CI) fotal events: leterogeneity: Tau <sup>2</sup> = 0.02; fest for overall effect: Z = 0.02.	20 5 10 35 Chi <sup>2</sup> = 2.18, 28 (P = 0.78	134 40 97 <b>271</b> df = 2	1 8 33 (P = 0.34);	31 103 <b>275</b> $I^2 = 8\%$	5.6% 28.6% <b>100.0%</b>	3.88 [0.48 , 31.49] 1.33 [0.55 , 3.22] <b>1.07 [0.65 , 1.77</b> ]	•
illy (\$029) 2007 illy 2006a Parabiaghi (GiSAS) 2010 ibtotal (95% CI) fotal events: Reterogeneity: Tau <sup>2</sup> = 0.02; Fest for overall effect: Z = 0.02 illy (\$029) 2007	20 5 10 35 Chi <sup>2</sup> = 2.18, 28 (P = 0.78	134 40 97 <b>271</b> df = 2 3)	1 8 33	31 103 <b>275</b> $I^2 = 8\%$	5.6% 28.6% <b>100.0%</b>	3.88 [0.48 , 31.49] 1.33 [0.55 , 3.22] 1.07 [0.65 , 1.77]	•
illy (\$029) 2007 illy 2006a Parabiaghi (GiSAS) 2010 ibtotal (95% CI) fotal events: Heterogeneity: Tau² = 0.02; Fest for overall effect: Z = 0.0 illy (\$029) 2007 ibtotal (95% CI)	20 5 10 35 Chi <sup>2</sup> = 2.18, 28 (P = 0.78 medium ter 9	134 40 97 <b>271</b> df = 2	1 8 33 (P = 0.34);	31 103 <b>275</b> $I^2 = 8\%$	5.6% 28.6% <b>100.0%</b>	3.88 [0.48 , 31.49] 1.33 [0.55 , 3.22] <b>1.07 [0.65 , 1.77</b> ]	•
illy (\$029) 2007 illy 2006a Parabiaghi (GiSAS) 2010 ibtotal (95% CI) Total events: Heterogeneity: Tau² = 0.02; Fest for overall effect: Z = 0.0 illy (\$029) 2007 ibtotal (95% CI) Total events:	20 5 10 35 Chi <sup>2</sup> = 2.18, 28 (P = 0.78 medium ter 9	134 40 97 <b>271</b> df = 2 3)	1 8 33 (P = 0.34);	31 103 <b>275</b> $I^2 = 8\%$	5.6% 28.6% <b>100.0%</b>	3.88 [0.48 , 31.49] 1.33 [0.55 , 3.22] 1.07 [0.65 , 1.77]	•
illy (\$029) 2007 illy 2006a Parabiaghi (GiSAS) 2010 ibtotal (95% CI) fotal events: Heterogeneity: Tau² = 0.02; Fest for overall effect: Z = 0.0 illy (\$029) 2007 ibtotal (95% CI)	20 5 10 35 Chi <sup>2</sup> = 2.18, 28 (P = 0.78 <b>medium ter</b> 9	134 40 97 <b>271</b> df = 2 3) <b>m</b> 134 <b>134</b>	1 8 33 (P = 0.34);	31 103 <b>275</b> $I^2 = 8\%$	5.6% 28.6% <b>100.0%</b>	3.88 [0.48 , 31.49] 1.33 [0.55 , 3.22] 1.07 [0.65 , 1.77]	•
illy (\$029) 2007 illy 2006a Parabiaghi (GiSAS) 2010 ibbtotal (95% CI) rotal events: Heterogeneity: Tau² = 0.02; Fest for overall effect: Z = 0.1 illy (\$029) 2007 ibbtotal (95% CI) rotal events: Heterogeneity: Not applicable fest for overall effect: Z = 0.1 iest for overall effect: Z = 0.1 iest for overall effect: Z = 0.1 iest for overall effect: Z = 0.1 iest.85.8 protocol violation - 1 iilly (\$029) 2007	20 5 10 35 Chi <sup>2</sup> = 2.18, 28 (P = 0.78 medium ter 9 9 e 35 (P = 0.73	134 40 97 <b>271</b> df = 2 3) m 134 <b>134</b>	1 8 33 (P = 0.34);	31 103 <b>275</b> $I^2 = 8\%$	5.6% 28.6% <b>100.0%</b> 100.0% <b>100.0%</b>	3.88 [0.48 , 31.49] 1.33 [0.55 , 3.22] 1.07 [0.65 , 1.77] 0.86 [0.37 , 2.01] 0.86 [0.37 , 2.01]	•
illy (\$029) 2007 illy 2006a Parabiaghi (GiSAS) 2010 Pa	20 5 10 35 Chi <sup>2</sup> = 2.18, 28 (P = 0.78 medium ter 9 9 e 35 (P = 0.73	134 40 97 <b>271</b> df = 2 3) m 134 <b>134</b>	1 8 33 (P = 0.34);	31 103 <b>275</b> $I^2 = 8\%$	5.6% 28.6% <b>100.0%</b>	3.88 [0.48 , 31.49] 1.33 [0.55 , 3.22] 1.07 [0.65 , 1.77] 0.86 [0.37 , 2.01] 0.86 [0.37 , 2.01]	*
illy (\$029) 2007 illy 2006a Parabiaghi (GiSAS) 2010 ibbtotal (95% CI) rotal events: Heterogeneity: Tau² = 0.02; Fest for overall effect: Z = 0.1 illy (\$029) 2007 ibbtotal (95% CI) rotal events: Heterogeneity: Not applicable fest for overall effect: Z = 0.1 iest for overall effect: Z = 0.1 iest for overall effect: Z = 0.1 iest for overall effect: Z = 0.1 iest.85.8 protocol violation - 1 iilly (\$029) 2007	20 5 10 35 Chi² = 2.18, 28 (P = 0.78 medium ter 9 9 e 35 (P = 0.73	134 40 97 <b>271</b> df = 2 3) m 134 <b>134</b>	1 8 33 (P = 0.34); 11	31 103 <b>275</b> $I^2 = 8\%$ 141 <b>141</b>	5.6% 28.6% <b>100.0%</b> 100.0% <b>100.0%</b>	3.88 [0.48 , 31.49] 1.33 [0.55 , 3.22] 1.07 [0.65 , 1.77] 0.86 [0.37 , 2.01] 0.86 [0.37 , 2.01]	*
illy (\$029) 2007 illy 2006a Parabiaghi (GiSAS) 2010 ibubtotal (95% CI) iotal events: deterogeneity: Tau² = 0.02; fest for overall effect: Z = 0.6 illy (\$029) 2007 ibubtotal (95% CI) iotal events: deterogeneity: Not applicable fest for overall effect: Z = 0.6 ist for overall effect: Z =	20 5 10 35 Chi² = 2.18, 28 (P = 0.78 medium ter 9 9 e 35 (P = 0.73 medium ter 4	134 40 97 <b>271</b> df = 2 3) m 134 <b>134</b>	1 8 33 (P = 0.34); 11 11	31 103 <b>275</b> $I^2 = 8\%$ 141 <b>141</b>	5.6% 28.6% <b>100.0%</b> 100.0% <b>100.0%</b>	3.88 [0.48 , 31.49] 1.33 [0.55 , 3.22] 1.07 [0.65 , 1.77] 0.86 [0.37 , 2.01] 0.86 [0.37 , 2.01]	*
illy (\$029) 2007 illy 2006a Parabiaghi (GiSAS) 2010 ibubtotal (95% CI) iotal events: Heterogeneity: Tau² = 0.02; Fest for overall effect: Z = 0.1 illy (\$029) 2007 ibubtotal (95% CI) iotal events: Heterogeneity: Not applicable fest for overall effect: Z = 0.1 ist for overall effect: Z =	20 5 10 35 Chi² = 2.18, 28 (P = 0.78 medium ter 9 9 e 35 (P = 0.73 medium ter 4	134 40 97 <b>271</b> df = 2 3) m 134 <b>134</b> 40	1 8 33 (P = 0.34); 11 11	31 103 <b>275</b> $I^2 = 8\%$ 141 <b>141</b>	5.6% 28.6% 100.0% 100.0% 66.0% 34.0%	3.88 [0.48 , 31.49] 1.33 [0.55 , 3.22] 1.07 [0.65 , 1.77] 0.86 [0.37 , 2.01] 0.86 [0.37 , 2.01] 1.05 [0.27 , 4.12] 0.78 [0.12 , 5.20]	*
illy (\$029) 2007 illy 2006a Parabiaghi (GiSAS) 2010 Parabiaghi (GiSAS) 2012 Parabiaghi (GiSAS) 2012 Parabiaghi (GiSAS) 2017 Parabiaghi (GiSAS) 2010 Parabiaghi (GiSAS) 2012 Pa	20 5 10 35 Chi² = 2.18, 28 (P = 0.78 medium ter 9 9 835 (P = 0.73 medium ter 4 2 6 Chi² = 0.07,	134 40 97 <b>271</b> df = 2 3) m 134 <b>134</b> 40 <b>174</b> df = 1	1 8 33 (P = 0.34); 11 11	31 103 <b>275</b> $I^2 = 8\%$ 141 <b>141</b> 141 31 <b>172</b>	5.6% 28.6% 100.0% 100.0% 66.0% 34.0% 100.0%	3.88 [0.48 , 31.49] 1.33 [0.55 , 3.22] 1.07 [0.65 , 1.77] 0.86 [0.37 , 2.01] 0.86 [0.37 , 2.01] 1.05 [0.27 , 4.12] 0.78 [0.12 , 5.20]	*
illy (\$029) 2007 illy 2006a Parabiaghi (GiSAS) 2010 Parabiaghi (Tau² = 0.02; Parabiaghi (Tau² = 0.02; Parabiaghi (Tau² = 0.02; Parabiaghi (Tau² = 0.02; Parabiaghi (Tau² = 0.03; Parabiaghi (Tau² = 0.04; Parabiaghi (Tau² = 0.00;	20 5 10 35 Chi <sup>2</sup> = 2.18, 28 (P = 0.78 medium ter 9 9 8 35 (P = 0.73 medium ter 4 2 6 Chi <sup>2</sup> = 0.07, 09 (P = 0.93	134 40 97 <b>271</b> df = 2 3) m 134 <b>134</b> 40 <b>174</b> df = 1	1 8 33 (P = 0.34); 11 11	31 103 <b>275</b> $I^2 = 8\%$ 141 <b>141</b> 141 31 <b>172</b>	5.6% 28.6% 100.0% 100.0% 66.0% 34.0% 100.0%	3.88 [0.48 , 31.49] 1.33 [0.55 , 3.22] 1.07 [0.65 , 1.77] 0.86 [0.37 , 2.01] 0.86 [0.37 , 2.01] 1.05 [0.27 , 4.12] 0.78 [0.12 , 5.20]	*
illy (\$029) 2007 illy 2006a Parabiaghi (GiSAS) 2010 Parabiata (95% CI) Parabiata (9	20 5 10 35 Chi <sup>2</sup> = 2.18, 28 (P = 0.78 medium ter 9 9 8 35 (P = 0.73 medium ter 4 2 6 Chi <sup>2</sup> = 0.07, 09 (P = 0.93	134 40 97 <b>271</b> df = 2 3) m 134 <b>134</b> 40 <b>174</b> df = 1	1 8 33 (P = 0.34); 11 11 4 2 6 (P = 0.80);	31 103 275 $I^2 = 8\%$ 141 141 31 172 $I^2 = 0\%$	5.6% 28.6% 100.0% 100.0% 66.0% 34.0% 100.0%	3.88 [0.48, 31.49] 1.33 [0.55, 3.22] 1.07 [0.65, 1.77]  0.86 [0.37, 2.01] 0.86 [0.37, 2.01]  1.05 [0.27, 4.12] 0.78 [0.12, 5.20] 0.95 [0.31, 2.88]	*
illy (\$029) 2007 illy 2006a Parabiaghi (GiSAS) 2010 Parabiata (95% CI) Parabiata (9	$20$ $5$ $10$ $35$ $Chi^2 = 2.18$ , $28 (P = 0.78$ $medium ter$ $9$ $e$ $35 (P = 0.73$ $medium ter$ $4$ $2$ $6$ $Chi^2 = 0.07$ , $09 (P = 0.93$ $medium$ $1$	134 40 97 <b>271</b> df = 2 3) <b>m</b> 134 <b>134</b> 40 <b>174</b> df = 1 3)	1 8 33 (P = 0.34); 11 11 4 2 (P = 0.80);	$31$ $103$ $275$ $I^2 = 8\%$ $141$ $141$ $31$ $172$ $I^2 = 0\%$	5.6% 28.6% 100.0% 100.0% 66.0% 34.0% 100.0%	3.88 [0.48, 31.49] 1.33 [0.55, 3.22] 1.07 [0.65, 1.77]  0.86 [0.37, 2.01] 0.86 [0.37, 2.01]  1.05 [0.27, 4.12] 0.78 [0.12, 5.20] 0.95 [0.31, 2.88]	
illy (\$029) 2007 illy 2006a Parabiaghi (GiSAS) 2010 Parabiata (95% CI) Parabiata (9	20 5 10 35 Chi <sup>2</sup> = 2.18, 28 (P = 0.78 medium ter 9 9 8 35 (P = 0.73 medium ter 4 2 6 Chi <sup>2</sup> = 0.07, 09 (P = 0.93	134 40 97 <b>271</b> df = 2 3) m 134 <b>134</b> 40 <b>174</b> df = 1	1 8 33 (P = 0.34); 11 11 4 2 6 (P = 0.80);	31 103 275 $I^2 = 8\%$ 141 141 31 172 $I^2 = 0\%$	5.6% 28.6% 100.0% 100.0% 66.0% 34.0% 100.0%	3.88 [0.48, 31.49] 1.33 [0.55, 3.22] 1.07 [0.65, 1.77]  0.86 [0.37, 2.01] 0.86 [0.37, 2.01]  1.05 [0.27, 4.12] 0.78 [0.12, 5.20] 0.95 [0.31, 2.88]	




Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 85: Leaving the study early: 3b. Various reasons - medium term

	Haloper	ridol	Olanza	pine		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
4.86.1 Loss to follow up	- long tern	•					
Lilly (HGGN) 2000	7	97	14	150	100.0%	0.82 [0.34 , 1.96]	_
• •	1		14				
Subtotal (95% CI)	_	97		159	100.0%	0.82 [0.34, 1.96]	•
Total events:	7		14				
Heterogeneity: Not application							
Test for overall effect: Z =	0.45 (P = 0	).65)					
4.86.2 lack of efficacy - l	ong term						
Beasley (E003) 1997	3	14	6	48	4.9%	1.71 [0.49 , 5.99]	
Beasley (HGAD) 1996a	2	10	10	45		0.90 [0.23 , 3.49]	<u> </u>
Crespo-Facorro 2006	10	56	7	55		1.40 [0.58 , 3.42]	
•							
Jones 1998 (P022)	1	23	1	21	1.0%		
Lilly (HGGN) 2000	16	97	20	159	20.8%		
Tollefson (HGAJ) 1997	35	203	88	648	59.5%	1.27 [0.89 , 1.82]	-
Subtotal (95% CI)		403		976	100.0%	1.29 [0.98, 1.70]	<b>•</b>
Total events:	67		132				•
Heterogeneity: Tau <sup>2</sup> = 0.0			5 (P = 0.9	99); $I^2 = 0$	%		
Test for overall effect: Z =	1.79 (P = C	).07)					
4.86.3 patients decision	- long tern	n					
Jones 1998 (P022)	4	23	5	21	22.6%	0.73 [0.23 , 2.36]	
Lilly (HGGN) 2000	14	97	20	159	77.4%		
Subtotal (95% CI)		120		180		1.04 [0.59 , 1.81]	
Total events:	18		25			, [,]	<b>—</b>
Heterogeneity: Tau <sup>2</sup> = 0.0		11 df		51\· I2	0/		
Test for overall effect: Z =	-		I (F = 0.0	01), 1 = 0	70		
4.86.4 non-compliance -	_	56	2	55	27.8%	2.05.[0.94 10.21]	
Crespo-Facorro 2006	9	56		55			
Jones 1998 (P022)	0	23	1	21	5.6%		
Lilly (HGGN) 2000	16	97	23	159	66.7%	1.14 [0.63 , 2.05]	-
Subtotal (95% CI)		176		235	100.0%	1.38 [0.64, 2.96]	•
Total events:	25		27				
Heterogeneity: Tau² = 0.1 Test for overall effect: Z =	-		2 (P = 0.2	27); I <sup>2</sup> = 2	4%		
4.86.5 physician decisio							
Jones 1998 (P022)	2	23	0	21	26.1%	4.58 [0.23 , 90.30]	
, ,				21			_
Lilly (HGGN) 2000	2	97	3	159		1.09 [0.19 , 6.42]	
Subtotal (95% CI)		120		180	100.0%	1.59 [0.35 , 7.28]	
Total events:	4		3				
Heterogeneity: $Tau^2 = 0.0$ Test for overall effect: $Z =$	-		1 (P = 0.4	12); I <sup>2</sup> = 0	%		
4.86.6 sponsor decision	- long term	,					
Lilly (HGGN) 2000	0	97	1	159	100.0%	0.54 [0.02 , 13.23]	
Subtotal (95% CI)	J	97		159		0.54 [0.02 , 13.23]	
Total events:	0	91	1	199	100.0%	U.J4 [U.UZ , 13.Z3]	
			I				
Heterogeneity: Not application   Test for overall effect: Z =		).71)					
4.86.7 withdrawal, loss t				_		0.74 [0.04 4.04]	
Crespo-Facorro 2006	8	56			100.0%	0.71 [0.31 , 1.64]	
•		56		55	100.0%	0.71 [0.31, 1.64]	<b>*</b>
Subtotal (95% CI)	8		11				
Subtotal (95% CI) Total events:							
Subtotal (95% CI)							
Subtotal (95% CI) Total events:	able	0.43)					
Subtotal (95% CI) Total events: Heterogeneity: Not applic	able	0.43)					

Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 86: Leaving the study early: 3c. Various reasons - long term

	Ha	loperido	l	Ol	anzapine	•		Mean Difference	Mean Dit	fference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Randoi	m, 95% CI
4.87.1 medium term										
Kahn (EUFEST) 2005	0.5	1.5883	63	6.3	6.9629	30	6.4%	-5.80 [-8.32 , -3.28]		
San 2012	4.11	0.84	21	8.55	0.87	87	93.6%	-4.44 [-4.84 , -4.04]		
Subtotal (95% CI)			84			117	100.0%	-4.53 [-5.18, -3.88]	•	
Heterogeneity: Tau <sup>2</sup> = 0	0.08; Chi <sup>2</sup> =	1.09, df	= 1 (P = 0	.30); I <sup>2</sup> = 8	%				•	
Test for overall effect: Z	: = 13.62 (F	o < 0.0000	01)							
Total (95% CI)			84			117	100.0%	-4.53 [-5.18 , -3.88]	•	
Heterogeneity: Tau <sup>2</sup> = 0	0.08; Chi <sup>2</sup> =	1.09, df	= 1 (P = 0	.30); I <sup>2</sup> = 8	%				•	
Test for overall effect: Z	: = 13.62 (F	o.0000	01)						-10 -5	) 5 1
Test for subgroup differ	ences: Not	applicab	le						Olanzapine	Haloperidol .

Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 87: Leaving study early: 4a. Average time until discontinuation - medium term (months)



Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 89: Service use: 1a. Admission to hospital after randomisation

5.1.1 any dose of olanzapine Beasley (E003) 1997 Beasley (HGAD) 1996a Tollefson (HGAJ) 1997 Subtotal (95% CI) Total events: Heterogeneity: Tau² = 0.09; C Test for overall effect: Z = 0.96 5.1.2 1mg olanzapine Beasley (E003) 1997	38 29 189 256 :hi² = 14		867	350 198 1336 <b>1884</b>	30.0%	0.98 [0.76 , 1.27] 1.01 [0.73 , 1.40]	IV, Random, 95% CI
- · · · · · · · · · · · · · · · · · · ·	38 29 189 256 :hi² = 14	69 660 <b>810</b> .92, df = 2	82 618 867	198 1336	30.0%	•	
Beasley (HGAD) 1996a Tollefson (HGAJ) 1997 Subtotal (95% CI) Total events: Heterogeneity: Tau <sup>2</sup> = 0.09; C Test for overall effect: Z = 0.96 5.1.2 1mg olanzapine Beasley (E003) 1997	29 189 256 :hi <sup>2</sup> = 14	69 660 <b>810</b> .92, df = 2	82 618 867	198 1336	30.0%	•	
Tollefson (HGAJ) 1997 <b>Subtotal (95% CI)</b> Total events: Heterogeneity: Tau <sup>2</sup> = 0.09; C  Test for overall effect: Z = 0.96 <b>5.1.2 1mg olanzapine</b> Beasley (E003) 1997	189 256 hi² = 14	660 <b>810</b> .92, df = 2	618 867	1336		1.01 [0.73 , 1.40]	
Subtotal (95% CI) Total events: Heterogeneity: Tau <sup>2</sup> = 0.09; C Test for overall effect: Z = 0.96  5.1.2 1mg olanzapine Beasley (E003) 1997	256 hi² = 14	.92, df = 2	867		37.2%		
Total events: Heterogeneity: Tau <sup>2</sup> = 0.09; C Test for overall effect: Z = 0.96  5.1.2 1mg olanzapine Beasley (E003) 1997	hi <sup>2</sup> = 14	.92, df = 2	867	1884		0.62 [0.54, 0.71]	-
Heterogeneity: $Tau^2 = 0.09$ ; C Test for overall effect: $Z = 0.96$ <b>5.1.2 1mg olanzapine</b> Beasley (E003) 1997	hi <sup>2</sup> = 14				100.0%	0.84 [0.58, 1.20]	
Test for overall effect: Z = 0.96 <b>5.1.2 1mg olanzapine</b> Beasley (E003) 1997			2 / D 0 0				
Beasley (E003) 1997			2 (F = 0.0)	006); I <sup>2</sup> =	87%		
, , ,							
Subtotal (95% CI)	38	81	35	88	100.0%	1.18 [0.83 , 1.67]	
		81		88	100.0%	1.18 [0.83, 1.67]	
Total events:	38		35				
Heterogeneity: Not applicable							
Test for overall effect: Z = 0.94	4 (P = 0.	.35)					
5.1.3 5mg olanzapine							
Beasley (E003) 1997	38	81	40	87	64.6%	1.02 [0.74 , 1.41]	
Beasley (HGAD) 1996a	29	69	22	65	35.4%	1.24 [0.80 , 1.93]	
Subtotal (95% CI)		150		152	100.0%	1.09 [0.84, 1.42]	
Total events:	67		62				
Heterogeneity: $Tau^2 = 0.00$ ; C Test for overall effect: $Z = 0.67$			(P = 0.48)	); I <sup>2</sup> = 0%			
5.1.4 10 mg olanzapine							
Beasley (E003) 1997	38	81	43	86	61.8%	0.94 [0.69 , 1.28]	<del></del>
Beasley (HGAD) 1996a	29	69	27	64	38.2%	1.00 [0.67 , 1.48]	<del></del>
Subtotal (95% CI)		150		150	100.0%	0.96 [0.75 , 1.23]	
Total events:	67		70				J
Heterogeneity: $Tau^2 = 0.00$ ; C Test for overall effect: $Z = 0.32$			(P = 0.82)	$I^2 = 0\%$			
5.1.5 15mg olanzapine							
Beasley (E003) 1997	38	81	49	89	21.4%	0.85 [0.63 , 1.15]	
Beasley (HGAD) 1996a	29	69	33	69	13.8%	0.88 [0.61 , 1.27]	
Lieberman (HGDH) 2003	60	131	73	132	32.6%	0.83 [0.65 , 1.05]	
Lilly 2006a	27	40	22	31	19.6%	0.95 [0.70 , 1.30]	
Liu 2011i	15	25	19	25	12.6%	0.79 [0.54 , 1.16]	
Subtotal (95% CI)		346		346	100.0%	0.86 [0.75 , 0.98]	
Total events:	169		196			. ,	
Heterogeneity: $Tau^2 = 0.00$ ; C Test for overall effect: $Z = 2.18$	$hi^2 = 0.7$			$I^2 = 0\%$			

Comparison 5: COMPARISON HALOPERIDOL vs OLANZAPINE: OLANZAPINE DOSE STUDY, Outcome 1: Global state: Clinically important (short term)

## Analysis 4.2

Global state: 1b. Average endp	oint score (CGI-S, hig	gh=poor, :	skewed	l data)
Study	Intervention	Mean	SD	N
Avasthi 2001	Haloperidol	2.86	1.57	7
Avastni 2001	Olanzapine	3.19	0.98	16
Kahn (EUFEST) 2005	Haloperidol	3.0	3.05	103
Kann (EUFEST) 2005	Olanzapine	2.4	3.07	105
Lilly 2006a	Haloperidol	3.49	1.77	40
	Olanzapine	2.96	1.68	31

Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 2: Global state: 1b. Average endpoint score (CGI-S, high=poor, skewed data)

Mental state: 2c. Overall - average e	endpoint score (BPRS to	tal, high=p	oor, skev	ved data
Study	Intervention	Mean	SD	N
Avasthi 2001	Haloperidol	12.57	13.39	7
AVASTRI 2001	Olanzapine	9.5	7.06	16
B I (5002) 4007	Haloperidol	28.78	15.41	79
Beasley (E003) 1997	Olanzapine	25.95	16.2	85
Beasley (HGAD) 1996a	Haloperidol	28.99	15.86	68
Deastey (HGAD) 1996a	Olanzapine	27.43	17.28	65

UCC I (II a n a Kana) 1000	Haloperidol	26.86	13.71	14
HGCJ (Hong Kong) 1998	Olanzapine	12.75	8.81	16
HGCU (Taiwan) 1998	Haloperidol	20.32	12.21	28
	Olanzapine	15.83	11.33	24
1 ill., 2005-	Haloperidol	26.83	14.04	40
Lilly 2006a	Olanzapine	13.06	4.8	31
Tollefson (HGAJ) 1997	Haloperidol	26.16	13.34	636
	Olanzapine	22.16	13.36	1312

Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 10: Mental state: 2c. Overall -average endpoint score (BPRS total, high=poor, skewed data)

### Analysis 4.12

Mental state: 3b. Overall - average ch	ange score - short term (PANSS	total, high=po	or, skewed	d data)
Study	Intervention	mean	SD	N
Krakowski 2006	Haloperidol	0.58	15.2	36
Krakowski 2006	Olanzapine	4.83	9.7	37

Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 12: Mental state: 3b. Overall -average change score - short term (PANSS total, high=poor, skewed data)

### Analysis 4.14

Study	Intervention	Mean	SD	N
hort term				
A a.k.: 2001	Haloperidol	5.00	4.58	7
Avasthi 2001	Olanzapine	3.00	2.42	16
11661/11	Haloperidol	12.29	10.56	14
HGCJ (Hong Kong) 1998	Olanzapine	4.06	4.39	16
HGCU (Taiwan) 1998	Haloperidol	4.79	5.14	28
	Olanzapine	3.67	5.43	24
Linkarman (UCDU) 2002	Haloperidol	8.38	8.21	126
Lieberman (HGDH) 2003	Olanzapine	6.95	7.01	125
T. H. C /U.C. I.) 4007	Haloperidol	13.64	9.82	428
Tollefson (HGAJ) 1997	Olanzapine	10.65	8.3	1053
4. 11 2002	Haloperidol	7.91	5.39	9
de Hann 2003	Olanzapine	10.56	9.81	11
ong term change score	•	•		•
	Haloperidol	-1.7	7.9	92
Lilly (HGGN) 2000	Olanzapine	-2.9	8.3	153

Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 14: Mental state: 4b. Specific - average endpoint score - depression (MADRS, high=poor, skewed data)

### Analysis 4.15

Mental state: 4c. Specific - averag	e endpoint score - aggression - sho	ort term (MOAS, h	nigh=poor,	skewed data)
Study	Intervention	Mean	SE	N
Total score				
Krakowski 2006	Haloperidol	40.9	24	3-48
Krakowski 2006	Olanzapine	32.7	29	6-51
Mean change total score				
Krakowski 2006	Haloperidol	38.2	50.7	34
Krakowski 2006	Olanzapine	33.3	32.2	36
Change in Physical agression	score	-		
Krakowski 2006	Haloperidol	141.9	0.20	28
Krakowski 2006	Olanzapine	-13.4	0.06	31
Physical aggression score				
Krakowski 2006	Haloperidol	20.7	6	0-20
Krakowski 2006	Olanzapine	14.1	12	0-20
Aggression against property				
Krakowski 2006	Haloperidol	4.7	0	0-6
Krakowski 2006	Olanzapine	2.7	0	0-4
Verbal aggression score				
Krakowski 2006	Haloperidol	15.6	7.5	2-25
Krakowski 2006	Olanzapine	16.0	11	4-23

Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 15: Mental state: 4c. Specific - average endpoint score - aggression - short term (MOAS, high=poor, skewed data)

Mental state: 4d. Specific - average end	point score - depression (variou	s scales, high=	poor, ske	wed dat
Study	Intervention	Mean	SD	N
medium term (CDSS)				
	Haloperidol	0.9	1.9	24
Crespo-Facorro 2006	Olanzapine	0.7	2.0	37
Kahn (EUFEST) 2005	Haloperidol	1.9	2.03	103
	Olanzapine	1.8	2.05	105

long term (CDSS)				
C	Haloperidol	1.29	2.89	28
Crespo-Facorro 2006	Olanzapine	0.55	1.54	23
short term (HAM-DRS)				
Buchanan 2003	Haloperidol	9.8	8.2	34
	Olanzapine	9.4	6.2	29
Lindan 2007	Haloperidol	5.74	4.0	19
Lindenmayer 2007	Olanzapine	4.50	3.23	16
medium term (HAM-DRS)			•	
Crespo-Facorro 2006	Haloperidol	4.8	4.4	24
	Olanzapine	3.9	5.5	37

Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 16: Mental state: 4d. Specific - average endpoint score - depression (various scales, high=poor, skewed data)

### Analysis 4.21

Study	Intervention	Mean	SD	N
3PRS - short term				
Paralles (5002) 4007	Haloperidol	6.23	2.97	79
Beasley (E003) 1997	Olanzapine	5.26	3.27	85
- I (wash) sasa	Haloperidol	4.87	3.44	68
Beasley (HGAD) 1996a	Olanzapine	4.42	3.56	65
T. H. C (U.S. I) 1007	Haloperidol	5.55	3.22	636
Tollefson (HGAJ) 1997	Olanzapine	4.62	3.0	1312
PANSS-N - short term	•	•		
Avasthi 2001	Haloperidol	16.86	8.71	7
	Olanzapine	15.62	7.93	16
SANS - short term	•	•		
	Haloperidol	27.43	19.48	7
Avasthi 2001	Olanzapine	21.87	19.47	16
- 1 (	Haloperidol	11.22	4.8	68
Beasley (HGAD) 1996a	Olanzapine	9.32	5.39	65
SANS - medium term	•	•		
	Haloperidol	4.8	5.3	24
Crespo-Facorro 2006	Olanzapine	3.5	3.8	37
SANS - long term	· ·	U		
	Haloperidol	4.39	4.47	28
Crespo-Facorro 2006	Olanzapine	4.31	4.96	23

Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 21: Mental state: 5e. Specific - negative symptoms - average endpoint score (various scales, high=poor, skewed data)

### Analysis 4.22

Mental state: 5f. Specific - negative symptoms -	average change scores - long term (	PANSS-N, high=	poor, ske	ewed data)
Study	Intervention	mean	SD	N
Liller (HCCNI) 2000	Haloperidol	-1.5	4.8	94
Lilly (HGGN) 2000	Olanzapine	-2.5	5.3	153

Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 22: Mental state: 5f. Specific - negative symptoms - average change scores - long term (PANSS-N, high=poor, skewed data)

Study	Interventions	Mean	SD	N
hort term (BPRS)	<b>,</b>	· ·		
B I (5000) 1007	Haloperidol	7.91	4.74	79
Beasley (E003) 1997	Olanzapine	7.87	4.89	85
Beasley (HGAD) 1996a	Haloperidol	8.59	5.32	68
	Olanzapine	9.12	6.21	65
Paralla mana 2000	Haloperidol	10.1	5.3	34
Buchanan 2003	Olanzapine	9.8	5.3	29
Tollefson (HGAJ) 1997	Haloperidol	7.61	4.54	636
	Olanzapine	6.83	4.66	1312
hort term (PANSS-P)	·		•	•
	Haloperidol	10.86	8.49	7
Avasthi 2001	Olanzapine	11.44	4.11	16
Barak 2002	Haloperidol	17.3	6.1	10
Barak 2002	Olanzapine	15.4	7.8	10
nedium term (SAPS)	·		•	•
C F 3000	Haloperidol	1.7	2.5	24
Crespo-Facorro 2006	Olanzapine	1.0	2.0	37
ong term (SAPS)	•	•	•	•
C F 3006	Haloperidol	1.93	2.93	28
Crespo-Facorro 2006	Olanzapine	3.41	5.36	23

Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 26: Mental state: 6d. Specific - positive symptoms - average endpoint score (various scales, high=poor, skewed data)

### Analysis 4.27

Study	Intervention	Mean	SD	N
ort term				
Dhar 2010	Haloperidol	-16.5	6.6	20
Dnar 2010	Olanzapine	-20.6	13.2	20
Krakowski 2006	Haloperidol	-0.50	5.3	36
Krakowski 2006	Olanzapine	1.41	3.6	37
ng term				
1:11 (11CCN) 2000	Haloperidol	-3.1	5.8	94
Lilly (HGGN) 2000	Olanzapine	-4.3	4.9	153

Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 27: Mental state: 6e. Specific - positive symptoms - average change score (PANSS-P, high=poor, skewed data)

### Analysis 4.33

Functioning: 1b. General - average endpoint score - medium term (GAF, high=good, skewed data)				
Study	Interventions	Mean	SD	N
Kahn (EUFEST) 2005	Haloperidol	64.3	35.52	103
	Olanzapine	68.3	35.86	105

Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 33: Functioning: 1b. General -average endpoint score - medium term (GAF, high=good, skewed data)

### Analysis 4.37

Study	Interventions	Mean	SD	N
omposite score		•		
K-h (EUEEET) 2005	Haloperidol	0.36	0.76	52
Kahn (EUFEST) 2005	Olanzapine	0.46	0.55	74
lobal Cognitive Index				
Krakowski 2006	Haloperidol	-0.17	0.49	22
Krakowski 2006	Olanzapine	0.34	0.72	30
1 in damma 2007	Haloperidol	-0.09	0.25	19
Lindenmayer 2007	Olanzapine	0.13	0.47	16
urdue Pegboard Test				
Kahn (EUFEST) 2005	Haloperidol	0.32	0.9	59
Kann (EUFEST) 2005	Olanzapine	0.25	0.76	81
ey Auditory Verbal Learning Test				
V-b /FUEFCT\ 2005	Haloperidol	0.38	0.87	56
Kahn (EUFEST) 2005	Olanzapine	0.51	0.68	58
rail Making Test part A				
Kahn (EUFEST) 2005	Haloperidol	0.23	0.82	59
Kann (EUFEST) 2005	Olanzapine	0.28	0.73	81
rail Making Test part B				
K-k/FUEFET\ 2005	Haloperidol	0.13	0.42	55
Kahn (EUFEST) 2005	Olanzapine	0.33	0.6	81
IAIS III digit symbol				
K-h- (FUEEET) 2025	Haloperidol	0.22	8.0	58
Kahn (EUFEST) 2005	Olanzapine	0.39	0.71	80

Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 37: Functioning: 2d. Specific cognition - average change scores - medium term (various domains, high=good, skewed data)

Study	Intervention	Mean	SD	N
akathisia - short term				
Avasthi 2001	Haloperidol	0.29	0.49	7
Avastni 2001	Olanzapine	0.0	0.0	16
Paralau (5002) 1007	Haloperidol	0.91	1.24	79
Beasley (E003) 1997	Olanzapine	0.38	0.79	85
Daniel and (UCAD) 1000	Haloperidol	0.87	1.12	68
Beasley (HGAD) 1996a	Olanzapine	0.42	0.66	65
Bernardo (HGDD) 2001	Haloperidol	0.8	1.0	13
Bernardo (HGDD) 2001	Olanzapine	0.4	1.1	14
total score - medium term				
Current Francisco 2006	Haloperidol	0.58	1.02	24
Crespo-Facorro 2006	Olanzapine	0.0	0.0	37
total score - long term				
Craspa Facarra 2006	Haloperidol	0.25	0.7	28
Crespo-Facorro 2006	Olanzapine	0.0	0.0	23

L:IIv (HCCN) 2000	Haloperidol	0.41	1.26	93
Lilly (HGGN) 2000	Olanzapine	-0.18	0.92	153

Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 48: Adverse effects/events: 3g. Specific - extrapyramidal - average endpoint score (BAS, high=poor, skewed data)

### Analysis 4.49

Study	Intervention	Mean	SD	N
oarkinsonism - short term	<u>.</u>			
A	Haloperidol	0.86	1.86	7
Avasthi 2001	Olanzapine	0.75	1.39	16
Paralau (5003) 1007	Haloperidol	5.59	7.93	79
Beasley (E003) 1997	Olanzapine	1.8	3.10	85
Panalau (UCAP) 1005a	Haloperidol	3.34	4.39	67
Beasley (HGAD) 1996a	Olanzapine	1.35	2.44	63
Barrarda (UCBB) 2001	Haloperidol	4.5	3.4	13
Bernardo (HGDD) 2001	Olanzapine	0.2	1.7	14
total - short term				
Bushaman 2002	Haloperidol	3.1	3.6	33
Buchanan 2003	Olanzapine	1.5	1.9	29
Lindenmayer 2007	Haloperidol	0.89	1.15	19
	Olanzapine	1	1.37	16
Tamakina 2017	Haloperidol	6.6	4.37	30
Taraskina 2017	Olanzapine	0.85	1.5	30
total - medium term				
C F 2006	Haloperidol	0.75	1.59	24
Crespo-Facorro 2006	Olanzapine	0.24	0.76	37
1:11 (5020) 2007	Haloperidol	2.4	3.6	119
Lilly (S029) 2007	Olanzapine	1.9	3.6	126
total - long term				
C F 2006	Haloperidol	0.68	1.12	28
Crespo-Facorro 2006	Olanzapine	0.48	1.41	23
total- endpoint change- long term		•	•	
Lilly (HCCN) 2000	Haloperidol	-0.22	3.65	94
Lilly (HGGN) 2000	Olanzapine	-0.73	2.92	153

Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 49: Adverse effects/events: 3h. Specific - extrapyramidal - average endpoint score (SAS, high=poor, skewed data)

## Analysis 4.50

Study	Intervention	Mean	SD	N
dyskinesia				
B I (5002) 1007	Haloperidol	1.90	3.64	78
Beasley (E003) 1997	Olanzapine	1.38	2.8	85
- I (110-11)	Haloperidol	2.49	3.93	68
Beasley (HGAD) 1996a	Olanzapine	2.09	3.53	65
otal	•		•	
111	Haloperidol	0.53	1.47	19
Lindenmayer 2007	Olanzapine	0.94	2.57	16
NMS total - endpoint change - long term	·			
L:U., (U.C.C.N.) 2000	Haloperidol	1.13	4.36	93
Lilly (HGGN) 2000	Olanzapine	0.09	2.91	152

Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 50: Adverse effects/events: 3i. Specific - extrapyramidal - average endpoint score - short term (AIMS, high=poor, skewed data)

Study	Intervention	Mean	SD	N
akathisia		•	- I	
Jahianaha 2001	Haloperidol	0.50	0.9	80
Ishigooka 2001	Olanzapine	0.20	0.5	81
dyskinesia	·			
Libbarratio page	Haloperidol	0.20	0.50	80
Ishigooka 2001	Olanzapine	0.10	0.40	81
dystonia	·			
Jahianaha 2001	Haloperidol	0.10	0.40	80
Ishigooka 2001	Olanzapine	0.10	0.30	81
overall severity				
Jahinnaka 2001	Haloperidol	1.00	0.90	80
Ishigooka 2001	Olanzapine	0.70	0.70	81
parkinsonism				
lahisaaka 2001	Haloperidol	2.60	3.30	80
Ishigooka 2001	Olanzapine	1.70	2.50	81

Ishigooka 2001	Haloperidol	3.3	3.9	80
Ishigooka 2001	Olanzapine	2.0	3.0	81

Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 51: Adverse effects/events: 3j. Specific - extrapyramidal - average endpoint score - short term (DIEPSS, high=poor, skewed data)

### Analysis 4.52

Adverse effects/events: 3k. Specific - extr	apyramidal - average endpoint score	(ESRS, high score	=poor, skev	ved data
Study	Intervention	Mean	SD	N
SRS total - short term				
Tamakina 2017	Haloperidol	22.6	14.9	30
Taraskina 2017	Olanzapine	3.2	5.2	30
arkinsonism - short term	·		•	
Boulay 2002	Haloperidol	6.80	6.73	13
Boutay 2002	Olanzapine	7.79	7.75	14
Dhar 2010	Haloperidol	2.4	2.3	20
Dnar 2010	Olanzapine	0.8	2.5	20
arkinsonism, dyskinesia, dystonia	subjective) - short term			
Ph	Haloperidol	2.0	1.7	20
Dhar 2010	Olanzapine	0.4	1.4	20
arkinsonism - long term	•	•	•	•
	Haloperidol	2.57	2.61	23
Jones 1998 (P022)	Olanzapine	1.19	1.86	21

Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 52: Adverse effects/events: 3k. Specific - extrapyramidal - average endpoint score (ESRS, high score=poor, skewed data)

### Analysis 4.58

Adverse effects/events: 4g. Specific - metabolic - weight - wa	aist circumference change data- med	lium term (high=	poor, skewe	d data)
Study	Intervention	Mean	SD	N
Cultural out No. CC. (12012)	Haloperidol	-0.26	2.84	27
Gründer (NeSSy) 2012	Olanzapine	1.87	5.61	21

Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 58: Adverse effects/events: 4g. Specific - metabolic - weight - waist circumference change data- medium term (high=poor, skewed data)

### Analysis 4.59

Study	Intervention	Mean	SD	N
MI - short term	<b>'</b>	•		
Cuitin day (Na CCu) 2012	Haloperidol	0.49	1.56	27
Gründer (NeSSy) 2012	Olanzapine	0.86	1.72	21
Krakowski 2006	Haloperidol	-0.60	1.4	28
Krakowski 2006	Olanzapine	1.31	1.6	31
MI - medium term				
Crespo-Facorro 2006	Haloperidol	3.74	2.6	52
Crespo-Facorro 2006	Olanzapine	3.97	2.79	54
eight gain (kg) - short term				
Krakowski 2006	Haloperidol	-2.0	4.7	28
	Olanzapine	3.59	4.2	31
eight gain (kg) - medium term				
6	Haloperidol	10.65	7.66	52
Crespo-Facorro 2006	Olanzapine	11.22	7.99	54
1.11 (C.000) 2.007	Haloperidol	0.4	6.4	120
Lilly (S029) 2007	Olanzapine	1.8	6.6	131
Panaca 2011	Haloperidol	5.9	5.5	16
Raposo 2011	Olanzapine	7.0	7.7	18
eight gain (kg) - lomg term		•		•
Lille, (UCCN) 2002	Haloperidol	-2.34	4.80	94
Lilly (HGGN) 2000	Olanzapine	3.0	7.87	152

Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 59: Adverse effects/events: 4h. Specific - metabolic - weight - average change various measures (skewed data)

Study	Intervention	mean	SD	N
:holesterol - short term	·			•
C.::d/NCC\ 2012	Haloperidol	0.76	0.80	27
Gründer (NeSSy) 2012	Olanzapine	-0.04	1.16	21
Krakowski 2006	Haloperidol	-6.7	24.6	28
	Olanzapine	-1.2	34.5	31
:holesterol - medium term				
6 F	Haloperidol	19.3	37.3	52
Crespo-Facorro 2006	Olanzapine	23.6	35.1	54
holesterol - long term	·			•
Lilly (HGGN) 2000	Haloperidol	-3.72	24.41	71

	Olanzapine	8.97	31.41	111
glucose (mg/dl) - short term				
Krakowski 2006	Haloperidol	-0.8	7.18	26
Krakowski 2006	Olanzapine	-0.1	18.8	29
glucose (mg/dl) - medium term		<u>.</u>		
C	Haloperidol	3.3	11.8	52
Crespo-Facorro 2006	Olanzapine	2.7	16.2	54
glucose (mg/dl) - long term	<u>.</u>	<u>.</u>		
(	Haloperidol	0.6	57.26	71
Lilly (HGGN) 2000	Olanzapine	40.44	51.46	111
HDL - medium term	•		•	•
	Haloperidol	-2.2	10.8	52
Crespo-Facorro 2006	Olanzapine	-2.6	12	54
	Haloperidol	0.12	0.37	27
Gründer (NeSSy) 2012	Olanzapine	0.05	0.21	21
insulin (mU/ml) - medium term	•	•	•	
	Haloperidol	3.0	6.4	52
Crespo-Facorro 2006	Olanzapine	3.4	16.6	54
LDL - medium term	•	•	•	
	Haloperidol	14.4	25.4	52
Crespo-Facorro 2006	Olanzapine	15.7	28.3	54
	Haloperidol	0.52	0.93	27
Gründer (NeSSy) 2012	Olanzapine	0.13	1.02	21
triglyceride - short term	•	•	•	
	Haloperidol	0.05	0.86	27
Gründer (NeSSy) 2012	Olanzapine	-0.26	0.89	21
Kinda waldana	Haloperidol	-6.8	65.7	28
Krakowski 2006	Olanzapine	10.7	56.2	30
triglyceride - medium term	•	•		•
6 E	Haloperidol	40.3	70.1	52
Crespo-Facorro 2006	Olanzapine	28.9	56.8	54
triglyceride - long term	•	•	•	
	Haloperidol	-22.27	117.38	40
Lilly (HGGN) 2000	Olanzapine	31.58	131.61	96
prolactine - long term	· · · · · · · · · · · · · · · · · · ·	1		
	Haloperidol	-2.37	25.89	81
Lilly (HGGN) 2000	Olanzapine	-9.73	23.15	136

Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 63: Adverse effects/events: 5d. Specific - metabolic - metabolism-related serum levels - average change (high=poor, skewed data)

### Analysis 4.76

Adverse effects/events: 11. Specific - renal - average creatinine change - short term (skewed data)					
Study	Intervention	Mean	SD	N	
Gründer (NeSSy) 2012	Haloperidol	6.41	6.79	27	
Grunder (Nessy) 2012	Olanzapine	-0.65	9.20	21	

Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 76: Adverse effects/events: 11. Specific - renal - average creatinine change - short term (skewed data)

## Analysis 4.82

Quality of life: 2d. Specific - average endpoint score - short term (QLS total, high score=good, skewed data)						
Study		Intervention	Mean	SD	N	
Avasthi 2001	Haloperidol	49.14	33.88	7		
	Olanzapine	51.19	23.38	16		

Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 82: Quality of life: 2d. Specific - average endpoint score - short term (QLS total, high score=good, skewed data)

### Analysis 4.88

Leaving study early: 4b. Average time until discontinuation - long term (months, skewed data)					
Study	Intervention	Mean	SD	N	
Crosmo Fossavio 2006	Haloperidol	15.4	13.44	56	
Crespo-Facorro 2006	Olanzapine	23.8	13.68	55	

Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 88: Leaving study early: 4b. Average time until discontinuation - long term (months, skewed data)

Service use: 1b. Hos	spitalisation (skew	ved data)			
Study	Intervention	median	SD	N	
prior psychiatric hospitalisation (number of patients					
Krakowski 2006	Haloperidol	8.5	4.4	28	
	Olanzapine	12.1	10.1	31	
median length of	hospitalisation	1			
Krakowski 2006	Haloperidol	36	no data	28	
	Olanzapine	48	no data	31	

Comparison 4: COMPARISON HALOPERIDOL vs OLANZAPINE: SECONDARY OUTCOMES, Outcome 90: Service use: 1b. Hospitalisation (skewed data)